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Abstract
Preeclampsia is a common and well-recognised complication of human pregnancy. 
It remains one of the main causes of maternal and fetal mortality and morbidity 
worldwide and no single cause has been identified, though there are many known 
risk factors. It is a multi-system disorder that affects the vascular endothelium and 
appears to originate from the placenta. No treatment exists, save the delivery of the 
fetus and placenta. There is no single diagnostic test for preeclampsia and it remains 
a clinical diagnosis only. A reliable diagnostic or predictive test could lead to new 
treatments and this would be of great clinical benefit as it would allow both more 
effective antenatal surveillance of high-risk pregnancies and also facilitate further 
research into the aetiology and treatment of preeclampsia.
Previously published work has indicated a potential link between preeclampsia and 
IPGs. The nature of Inositol Phosphoglycans (IPGs) and their involvement (actual 
and theorised) in several pathologies is described. Pilot clinical data is presented to 
evaluate the utility of an ELISA assay for IPG-P in the screening and diagnosis of 
preeclampsia. The assay demonstrates a correlation between IPG-P levels in 
maternal urine and amniotic fluid in normal women but not in preeclampsia. The 
levels in preeclamptic women suggest a correlation with clinical severity of the 
disease. A hypothesis is presented suggesting disruption of maternal-fetal 
equilibrium in the preeclamptic disease state.
Total IPG-P bioactivity assays of serum samples show no difference between 
preeclamptic and normal women, and it may therefore play no role in the condition. 
Alternatively, there is the possibility that a sub-fraction or an unidentified, abnormal 
IPG-P form is part of the process.
Additionally, the ELISA assay demonstrates increased urinary IPG-P levels in 
normotensive labouring women. A second hypothesis is presented to suggest 
potential links between the onset of normal labour and the pathophysiology of 
preeclampsia. Finally, proposals for further work are discussed.
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Chapter 1
Introduction
1
1.1 Inositol Phosphoglycans
The name 'Inositol Phosphoglycan' (IPG) refers to a diverse family of molecules 
implicated as second messengers related to the cell membrane (Rademacher et al. 
1994; Gaulton and Pratt 1994). IPGs were first purified from bovine liver cell 
membranes in 1986 and identified to mimic some of the actions of insulin (Saltiel 
and Cuatrecasas 1986). They have been shown to be present in many tissues in 
mammals including muscle (Katz et al. 1996), adipose tissue, liver (Caro et al. 1997), 
placenta (Kunjara et al. 2000a) and T Lymphocytes (Gaulton et al. 1988). They are 
also found in other diverse groups of organisms from Trypanosomes (Misek and 
Saltiel 1992) to mycobacteria. IPGs may be involved in the pathophysiology of 
diabetes (Shashkin et al. 1997), preeclampsia (Kunjara et al. 2000a) and polycystic 
ovarian syndrome (PCOS) (Nestler 1998). Early evidence suggested the existence of 
a family of IPGs due to the multiple different effects seen (Huang et al. 1993). They 
were broadly divided into two groups, listed below with examples of differential 
functions:
1. ‘P-Type’ -  Activate Pyruvate Dehydrogenase (Lilley et al. 1992); activate 
glycogen synthase phosphatase (Jones and Varela-Nieto 1998)
2. ‘A-Type’ -  Inhibit cAMP-dependent Protein Kinase (Thompson et al. 
1984; Rademacher et al. 1994); inhibit adenylate cyclase (Malchoff et al. 
1987)
These groups are derived from the products of the extraction procedure by acid- 
elution at different pH from anion-exchange resin columns (Chapter 2, Laboratory 
Methods for a more detailed description of this process). The title IPG-‘P’ type is 
given to the fraction eluted from the column at pH 2.0 and the title IPG-‘A’ type 
given to the fraction eluted at pH 1.3. Recently Lamer published the first structural 
information regarding the ‘P-Type’ IPG (IPG-P) (Lamer et al. 2003) (Section 1.1.1).
1.1.1 IPG Structure
The structure of membrane glycosyl phosphatidyl inositol (GPI), from which IPG-A 
may be derived (Figure l.2) is highly variable (Low and Saltiel 1988). Early work 
centred on function and relatively scant structural information was known (Gaulton
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and Pratt 1994). Indeed, initial identification of a putative insulin mediator was as a 
small peptide (Cheng and Lamer 1985). Mato and colleagues described the partial 
structure of an insulin-sensitive glycophospholipid, derived from H35 hepatoma cells 
and rat liver membranes, containing a phosphatidyl-chiro-inositol moiety, 
glycosidically linked to a non-N-acetylated glucosamine (Mato et al. 1987a; Mato et 
al. 1987b). The release of the active compound following treatment of the 
membranes with bacterial (S aureus) phosphatidylinositol specific phospholipase C 
(PI-PLC), implies the presence of inositol phosphate. Around the same time, Saltiel 
and colleagues identified active compounds also generated by PI-PLC hydrolysis (or 
insulin stimulation) o f intact hepatic plasma membranes capable of altering the 
activity of cAMP phosphodiesterase (a cytosolic enzyme). Radio-labelling indicated 
equal quantities of inositol and glucosamine (Saltiel et al. 1986). Subsequently, 
evidence was published identifying mediators containing galactosamine and D-chiro- 
inositol (Lamer et al. 1988) and myo-inositol in the A-type plus glucosamine 
(Rademacher et al. 1994)
Recently, Lamer et al have published detailed structural information for the first time 
of IPG-P isolated from beef liver (Lamer et al. 2003). The D-chiro-inositol- 
containing mediator, termed by this group INS-2, was determined to be a novel 
inositol glycan pseudo-disaccharide Mn2+ chelate (Figure 1.1). The D-chiro-inositol 
is present as pinitol.
Figure 1.1. Structures of putative insulin mediator 1 (INS2), D-chiro-inositol 2a, and 
D-pinitol 2b. (Reproduced from Lamer et al. 2003)
IN S -2 ,1
2a: D-chiro-inositol, R=H 
2b: D-pinitol, R = CH3
3
^  I
This confirms the presence of Mn in the P-type IPG. Only when this complexing 
was present did the chelate show PDH phosphatase activation (in vitro) in a dose 
dependent manner (Lamer et al. 2003). Zinc may be complexed with the A-type 
(Rademacher et al. 1994).
Despite the initial lack of clarity and extensive variability, the use of structurally 
defined synthetic analogues of IPGs has confirmed that these molecules can affect 
the activities of key enzymes that are implicated in insulin action (Zapata et al. 1994; 
Varela-Nieto et al. 1996). There is also evidence that IPGs are related to, but not 
derived from the GPI protein anchors (Parpal et al. 1995).
1.1.2 Biological Origins
Insulin was first identified to cause the hydrolysis of a membrane glycolipid (later to 
be named as IPG) in 1986 (Saltiel et al. 1986). As mentioned above, early structural 
analysis indicated the presence of a phosphatidylinositol linked to glucosamine and 
an unidentified glycan moiety (Mato et al. 1987b). Insulin binding to the target cell 
receptor tyrosine kinase leads to cleavage of a GPI by the action of 
phosphatidylinositol-specific phospholipase C/D to release an IPG and phosphatidic 
acid or Diacylglycerol (Lamer 1988; Suzuki et al. 1993). Subsequently, other growth 
factors have been identified to use this signalling pathway. Insulin-like growth 
factor-1 (IGF-1) and epidermal growth factor (EGF) (Farese et al. 1988), 
erythropoietin (Devemy et al. 1994), and Transforming Growth Factor p i (TGF-pi) 
(Vivien et al. 1994) have also been shown to regulate GPI hydrolysis. Interestingly, 
hormones involved in the female reproductive cycle and pregnancy are also known 
to utilise GPI signal transduction. Namely, follicle stimulating hormone (FSH) and 
human chorionic gonadotrophin (hCG) (Fanjul et al. 1993a) and also prolactin 
(Fanjul et al. 1993b). Thus IPGs are derived from membrane-associated Glycosyl 
phosphatidyl inositol (GPI) (Figure 1.2) and are cleaved from the cell membrane by 
GPI-specific Phospholipase D (GPI-PLD) (Rademacher et al. 1994). Heterogeneity 
of GPI hydrolysis may give rise to specific IPGs in specific cell environments (Jones 
and Varela-Nieto 1998). The IPG is released outside the cell (Caro et al. 1996) and
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internalised (Anderson 1993; Rademacher et al. 1994) across the cell membrane. 
This may be closely associated with caveolae (Section 1.1.4).
The GPI is anchored in the cell membrane by the diglyceride tail attached to the 
phosphatidyl-inositol, which connects to the glucosamine and the glycan moiety.
A different family of GPI’s also act as membrane anchors for many cell surface 
proteins such as the folate receptor (Rothberg et al. 1990; Smart et al. 1996), CD 14 
(Wang et al. 1995) and prion (Harmey et al. 1995).
M embrane 
GPI
TTTTTTTTTTm GPI-PLD
(T)-P ® - l
m m  ITTTTTuuu! m
‘Active* IPG
Figure 1. 2. Simple model of GPI cleavage and translocation into the cell.
GPI = Glycosyl phosphatidyl inositol. GPI-PLD = GPI-specific phospholipase 
D. I = Inositol, G = Glycan group, P = Phosphate, T = Threonine, S = Serine 
Activation of GPI-PLD is by G proteins. (Modified from Rademacher et al.
1994)
1.1.3 Actions of IPGs
In the main these are related to insulin signalling (Rademacher et al. 1994) including 
stimulation of lipogenesis, activation of acetyl-CoA carboxylase and inhibition of 
cAMP dependent protein kinase (Villalba et al. 1988; Kunjara et al. 1999). IPGs 
antagonized glucagon-dependent activation of glycogen phosphorylase in a dose- 
dependent manner, as well as the inactivating pyruvate kinase (Alvarez et al. 1987).
5
It is interesting to note at this point that one report has commented on the increased 
accumulation of triglycerides in endothelial cells exposed to preeclamptic women’s 
sera in vitro (Lorentzen et al. 1991). Further work showed increased lipolytic 
activity and a higher ratio of free fatty acids to albumin in the sera of preeclamptic 
women (Endresen et al. 1992). There is no specific data regarding IPG-P and effects 
on triglycerides in preeclampsia. In a small study of obese women with polycystic 
ovary syndrome, oral administration of D-chiro-inositol (that shown to be in IPG-P 
by Lamer et al) was shown to decrease plasma triglycerides (along with other 
insulin-mimetic effects) (Nestler et al. 1999). However, these women have pre­
existing insulin resistance and thus may not be representative of changes seen in 
preeclampsia.
IPGs decrease hyperglycaemia and facilitate glucose disposal (Lamer et al. 1998). 
They also stimulate various cell types including T-lymphocytes, mast cells and 
platelets (Rademacher et al. 1994; Kunjara et al. 1999).
1.1.4 Caveolae
Caveolae are specialised plasma membrane domains originally identified in the 
1950’s by their flask or ‘omega’ (Q) shaped morphology (Figure 1.3), with a 
diameter of ~50nm (Yamada 1955).
Classically, invagination of the caveolae occurs to form intracellular vesicles and 
they are thus involved in endocytosis, exocytosis and transcellular movement of 
molecules across endothelial cells (Anderson 1998). Caveolae have been identified 
in many cell types and are now defined biochemically by a marker protein, caveolin 
(specifically Caveolin-1), and a specific membrane lipid composition, rich in 
glycosphingolipids (GSLs), and cholesterol (Brown and Rose 1992). They have a 
high prevalence of receptor and signal transduction molecules and other GPI- 
anchored proteins which are dynamically associated with the caveolae and appear to 
actually interact with the caveolin-1 (Anderson 1993; Anderson 1998). See also 
Table 1.1 for some molecules enriched in caveolae.
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Figure 1. 3. The caveola cellularis.
(a) Mouse gall bladder epithelium. The inset, top left shows a mitochondrion, 
(M) a synaptic vesicle (s), and the caveola (c) (Reproduced from Yamada 
1955). (b) Thin-section electron microscopy image of fibroblast caveolae. 
Arrows point to endoplasmic reticulum near invaginated caveolae (Reproduced 
from Anderson 1998).
Table 1.1 Partial list of molecules enriched in caveolae (From Anderson 1998)
Lipid
Sphingomyelin 
Diacylglycerol (DAG)
Cholesterol 
Acylated Protein
eNOS (endothelial Nitric Oxide Synthase) 
Caveolin 
GPI-Anchored Protein 
Folate Receptor 
Alkaline Phosphatase 
Prion
Membrane Receptor
Insulin 
Endothelin 
Membrane Transporter
Ca2+ ATPase 
Second Messenger
Inositol Phosphoglycan (IPG)
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It is interesting to note in particular the presence of eNOS, Ca2+ ATPase, insulin and 
IPGs have been associated with caveolae (Anderson 1998). IPGs have been isolated 
in caveolae from insulin-stimulated cells (Parpal et al. 1995). Dorahy et al have 
presented some evidence that platelet membrane micro domains (possibly related to 
caveolae) may be involved in platelet activation (Dorahy et al. 1996).
'Potocytosis'
This is the process, found within caveolae, of concentration and movement of small 
molecules into the cell and endoplasmic reticulum (ER) or receiving/transmission of 
various kinds of cellular signals (Anderson et al. 1992). Anderson et al summarise 
how various molecules may be manoeuvred in this way, including Ca2+, insulin and 
interleukin-2, in part by IPG intermediates formed from GPI-anchored molecules. 
They go on to suggest that this process can be controlled or compartmentalised by 
virtue of its location within the caveolae. This helps to solve the problem of 
potential loss of the IPG to the extracellular space after it is cleaved from the external 
side of the membrane. Examples cited of different pathways of potocytosis can be 
seen in figure 1.4.
In summary, caveolae are dynamic membrane domains in constant flux, active in cell 
transport and signalling processes in which are found several molecules of particular 
interest to the topic of preeclampsia. Additionally, caveolae may also be susceptible 
to oxidative stress, specifically oxidised cholesterol, containing receptors that bind 
HDL, LDL and oxidised lipoproteins (Babitt et al. 1997).
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CAVEOLAE
VESICLE
ER
• 1  CAVEOLAE CAVEOLAE CAVEOLA!
RECEPTOR RECYCLES, RECEPTOR RECYCLES, RECEPTOR TRANSPORTED, RECEPTOR SEQUESTERED,
UGAND TRANSPORTED UGAND TRANSPORTED LIGAND TRANSPORTED LIGAND SEQUESTERED
TO CYTOPLASM TO ER
•  5-Methyltetrahydrofolate •  Cholesterol #  Albumin •  Alkaline Phosphatase
•  Iron • F a t ty  Acids •T ransthy re tin  •  Bradykmin Receptors
•  C alcium  *  C alcium  ^  V arious P la sm a  P ro te in s  •  CCK R e cep to ra
•  Viruses •  Endothelin
Figure 1. 4. Multiple pathways of potocytosis.
ER = endoplasmic reticulum. Molecules and receptors internalised by caveolae 
can have one of four fates. (A) The ligand is delivered to the cytoplasm while 
the receptor recycles back to the surface. (B) The ligand is delivered to the ER 
while the receptor recycles back to the surface. (C) The ligand is transported 
across the cell, and the receptor recycles, (D) Both the ligand and the receptor 
remain in a vesicular caveolae compartment. Examples of molecules that 
follow these routes are listed. (From Anderson 1998)
1.1.5 Diabetes
Much of the work on IPGs has focused on their role in type II diabetes. They were 
initially identified as insulin-mimetic factors (Saltiel and Cuatrecasas 1986) and have 
been identified as second messengers intimately involved in insulin metabolism 
(Rademacher et al. 1994). They are formed in response to insulin itself (Parpal et al.
1995). Recent work has revealed that levels of IPG-A and IPG-P are altered in 
relation to one another and correlated with body mass index (BMI) that this may be 
involved in the aetiology of diabetes itself (Kunjara et al. 1999).
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1.1.6 The Placenta and IPGs
In the 1970s and 1980s it was demonstrated that placentae from diabetic pregnancies 
and hydatidiform moles contained more glycogen than for normal pregnancy 
(Maeyama et al. 1977; Gabbe et al. 1972; Diamant et al. 1982). Arkwright and 
colleagues investigated placental oligosaccharide content, specifically in the 
syncytiotrophoblast (STB) as this was noted to be the site of ultrastructural changes 
seen in preeclamptic and diabetic pregnancies. They demonstrated ten-fold higher 
glycogen content and sixteen-fold higher glycogen synthase activity in preeclamptic 
and molar STB (Arkwright et al. 1993). In view of the raised glycogen seen in 
diabetic pregnancies without hypertension or proteinuria, it was hypothesised that 
this may be a secondary consequence of the underlying pathophysiology of 
preeclampsia. IPGs have been implicated as the signal transduction mechanism 
involved in insulin’s regulation of human placental steroid hormone formation 
(Nestler et al. 1991). IPGs are shown to activate glycogen synthase phosphatase 
(Jones and Varela-Nieto 1998). Investigation with anti-IPG monoclonal antibody has 
shown that there are higher levels of IPG-P in preeclamptic placenta compared to 
normal control placenta (Deborde et al 1999b). This seems to be localised in the 
microvillous brush border of the syncytiotrophoblast (Deborde et al 1999a). Thus 
there is evidence that in preeclampsia, placental glycogen metabolism is abnormal, 
and that both glycogen and IPG-P are abnormally raised in the syncytiotrophoblast. 
It will be discussed later how this may be relevant to the pathophysiology of the 
condition.
1.1.7 The Detection of IPGs in Urine
As is noted above, IPGs are found in the placental microvillous border (on the 
maternal side of the placenta) and are increased in preeclampsia. Likewise, placental 
fragmentation and shedding is increased in the preeclamptic condition (Knight et al. 
1998). Potentially, therefore, large quantities of IPG-P are released into the maternal 
circulation. This would be abnormal as IPGs usually act at the autocrine (cell-to- 
cell) level. Increased urinary excretion of IPGs might therefore be expected as they 
are cleared from the maternal circulation. No data yet exists on maternal serum IPG 
levels in preeclampsia or normal pregnancy. However, data does exist on urinary 
IPG levels. Kunjara et al revealed that excretion of P-Type IPGs in the urine is
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increased 2 to 3 fold in preeclampsia (Kunjara et al. 2000a). This paper used specific 
bioassay procedures to show IPG activity. The IPG-P bioassay involves the 
activation of pyruvate dehydrogenase (PDH) complex. The IPG-A bioassay involves 
the inhibition of Protein Kinase A. There is also evidence in this work of close 
correlation with traditional markers of disease severity in preeclampsia, namely 
proteinuria, plasma aspartate transaminase and platelet count (Kunjara et al. 2000a). 
Unpublished data shows that a P-type inositol phosphoglycan can also be identified 
in the urine of preeclamptic women using a polyclonal-based Enzyme Linked 
Immunosorbent Assay (ELISA)(Rodaris Pharmaceuticals, Oxford, England). It may 
be that this is an abnormal form of IPG-P with an extra lipid group on the inositol. 
Due to this consequent amphiphilic structure, the IPG forms micelles in the urine, 
which adhere to the solid phase of the ELISA assay (Also Appendix 1). Further 
unpublished data from a series of 38 matched pairs of preeclamptic and normal 
controls shows that this test seems to have no false positives and a 100% positive 
predictive value for preeclampsia. In a series of over 180 women that the test became 
positive up to 50-60 days before the clinical diagnosis and could thus be used to 
predict the onset of preeclampsia before symptoms and signs appeared (Rodaris 
Pharmaceuticals; unpublished observations).
Validation of the Polyclonal-Based ELISA and IPG 
extraction/bioassay procedure
This will be discussed fully in Chapter 2 -  Laboratory Methods
1.1.8 The IPG Polyclonal-based ELISA vs. the ‘Bioassay’
IPG Extraction and Bioassay
The IPG extraction process used in this work is based on heat denaturation of 
protein, charcoal adsorption of nucleotides and anion exchange resin 
chromatography, yielding both ‘P-type’ (pH2.0 eluate) and ‘A-type’ (pH 1.3 eluate) 
fractions of IPG separately and was first described by Lamer and colleagues in 1988 
(Lamer et al. 1988), from the method of Cheng et al (Cheng et al 1984). The 
bioassay then relies on activation of the Pyruvate Dehydrogenase (PDH) complex for 
the ‘P-type’ fraction and inhibition of Protein Kinase A (PKA) for the ‘A-type’
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fraction. For IPG extraction from serum (from diabetic subjects), Shashkin et al have 
shown no crossover activity of these two fractions (Shashkin et al. 1997). Kunjara 
and colleagues showed a 2-fold increase in bioactivity of P-IPG in urine of pregnant 
women compared to non-pregnant controls and a further 3-fold increase in 
preeclamptic urine (Kunjara et al. 2000a). For extraction from urine, larger volumes 
are required (at least 50ml) than for serum (1ml). For this reason, I decided it was not 
feasible to perform bioextraction for urine samples in this study. As second and third 
trimester amniotic fluid is composed largely of fetal urine, it was treated in the same 
way as urine samples accordingly. No data have yet been published on serum IPG 
levels in preeclampsia using this same bioassay.
Polyclonal-based ELISA for IPG-P
The Polyclonal serum used for the ELISA was developed by Rodaris 
Pharmaceuticals Ltd, Oxford, UK using 150ml of urine from a severely ill 
preeclamptic woman. Unfortunately, it has not been possible to obtain clinical data 
of this index patient. The then best purification procedure was used for the 
extraction, but the antigen has never been fully characterised. It is indicated from 
Rodaris’ data that the ELISA assay shows strong positivity when used on urine of 
preeclamptic women, with up to a fifty-fold difference in signal (Section 2.1.1). 
Thus there is an order of magnitude difference between the ELISA and the bioassay 
in terms of how they distinguish between the normal and preeclamptic states. It is 
possible that this may be because the ELISA relies partly on the physical properties 
of the IPG-P (Appendix 1) and the bioassay on the biological activity. Equally, there 
is no reason why PDH-complex bioactive material (IPG-P) and the IPG measured in 
the diagnostic have to be one and the same. Although the ELISA is to be assessed as 
a clinical tool questions remain regarding its preparation, which will need to be 
answered in future, work.
Unpublished data from Rodaris Pharmaceuticals show no difference between 
preeclamptic and normal sera when assayed with the ELISA. Thus for the purposes 
of this research, the polyclonal-based ELISA assay was used for urine samples and 
the bioassay for the serum samples. See Chapter 2 -  Laboratory Methods for further 
details of the assay protocols.
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1.2 Preeclampsia
1.2.1 History and Epidemiology
De Sauvages first differentiated eclampsia from epilepsy in 1793 although 
preeclampsia had previously been recognised by others such as the ancient Greeks 
and Galen (Chesley 1984). It is a common and well-recognised complication of 
human pregnancy (Roberts and Redman 1993), occurring in 3-10% of all 
pregnancies (NHBPEP 1990; Williams and de Swiet 1997). It remains one of the 
main causes of maternal and fetal mortality and morbidity in Great Britain 
(Department of Health. 2001), the USA (Kaunitz et al. 1985), Scandinavia 
(Augensen and Bergsjo 1984) and the Developing World (Duley 1992) despite 
continued and widespread research. Direct maternal deaths due to hypertensive 
disorders of pregnancy in the United Kingdom have decreased to 15 over the last 
triennium (Department of Health. 2001), a rate of 7.1 per million maternities. Direct 
maternal deaths are those resulting from conditions or complications or their 
management that are unique to pregnancy, and preeclampsia remains the second 
leading cause of deaths in this category, behind thromboembolic disease. Worldwide, 
10% of the total maternal deaths are due to preeclampsia/eclampsia (Duley 1992) - 
50,000 women each year.
Table 1. 2 Some Risk Factors for Preeclampsia
Risk Reference
Primiparity/primipatemity (Discussed below)
Multiple pregnancy (Long and Oats 1987)
Obesity (Sibai etal. 1995)
Pre-existing Vascular pathology -
Type I Diabetes (Siddiqi et al. 1991)
Hypertension
Family history (Chesley et al. 1968)
Non-smoker (Klonoff-Cohen et al. 1993)
Molar Pregnancy (Discussed in Chesley 1984)
Extremes of age
Barrier contraception (Klonoff-Cohen et al. 1989)
Donor Gametes (Serhal and Craft 1989; Abdalla et al. 
1998)
High Altitude (Palmer etal. 1999)
The precise aetiology of preeclampsia remains obscure. It is unique in that it only 
occurs in human gestation and only in pregnancy (Williams and de Swiet 1997). It is
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a multi-system disorder (Roberts and Redman 1993) that affects vascular 
endothelium membranes and appears to originate from the placenta. There are many 
risk factors such as nulliparity and those with multiple pregnancy (Table 1.2). Many 
theories exist as to the cause of preeclampsia, which will be discussed in more detail 
below. Because the pathophysiology remains poorly understood, no diagnostic test 
or treatments exist (Higgins and Brennecke 1998) . Great potential clinical benefit 
seems likely if a diagnostic test and, subsequently, a treatment can be provided.
1.2.2 Aetiology and Pathophysiology
As stated above, the aetiology and pathophysiology of preeclampsia is complex and 
multifactorial and it has been dubbed 'The Disease of Theories' (Chesley 1984). 
Despite this however, it is generally agreed that the signs of preeclampsia are thought 
to arise from maternal endothelial dysfunction caused by circulating factors of 
placental origin (Kertesz et al. 1999).
1.2.3 The Normal Placenta
Before understanding the pathology behind preeclampsia, it is necessary first to
describe the process of normal 
placentation. The placenta is the fetal 
lifeline, the source of oxygen and 
nutrients and waste removal. It 
develops from embryonic
trophoblastic cells, which invade the 
decidual lining of the uterus in the first 
few weeks of the pregnancy. The 
extra-villous trophoblast migrates 
along the uterine spiral arterioles, 
breaking down the muscularis.
Wilkins.
Consequently, these vessels lose their narrow architecture and become the wide- 
bored, low-resistance vessels that allow adequate maternal-fetal exchange. This
••v.   ; •  - r
Figure 1. 5. Diagram of normal placenta 
illustrating dilated spiral arteries. 
(Reproduced from van Beek and Peeters 
1998) Copyright © 1998 Williams and
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process is completed by the middle of the second trimester of the pregnancy. Normal 
placentation involves trophoblast migration along firstly the decidual and secondly 
the myometrial portions of the spiral arteries. It is usually said that it is this second 
phase of placental invasion that fails or is inadequate in preeclampsia (see below and 
Figures 1.6 and 1.7). Classically this is thought to occur at 14-16 weeks’ gestation 
(Clark 1994).
1.2.4 The Placenta and Preeclampsia
Evidence that the placenta is key in the aetiology of preeclampsia is compelling. It 
has been known for some time that placental histology is grossly abnormal in 
preeclamptic pregnancies. Robertson, Brosens and Dixon described the abnormal 
placental histology seen in preeclampsia three decades ago (Brosens et al. 1972; 
Robertson et al. 1975). The endovascular trophoblastic invasion is restricted to the
decidual portion of the spiral arteries (rather than continuing into the myometrial
portion) and consequent ‘acute atherosis’ is likely to develop in the myometrial
portion. Meekins and colleagues examined a series of placental
bed biopsies (21 normal, 24
preeclamptic taken at caesarean
section, identifying defective 
endovascular trophoblast invasion in 
preeclampsia (Meekins et al. 1994).
There is failure of the migration of the 
extra-villous trophoblast, resulting in 
persisting spiral arteriole architecture 
and consequent inadequate blood 
supply and fetal compromise.
Preeclampsia occurs in hydatidiform
molar pregnancies when only
'placental' (trophoblast) tissue is 
present (Berkowitz and Goldstein
1996).
Figure 1. 6. Diagram of preeclamptic 
placenta illustrating narrow spiral arteries 
leading to the high-resistance flow seen in 
the disorder (Reproduced from van Beek 
and Peeters 1998). Copyright © 1998 
Williams and Wilkins.
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Interestingly, 90% of complete moles contain entirely paternal DNA (Kajii and 
Ohama 1977). Also, preeclampsia improves when and only when the placenta is 
removed at delivery.
PRE-ECLAMPSIA NORMAL
INNER 1/3 '
M YOM ETRIUM
P l a c e n t a l  b e d
J  TROPHOBLAST INVASION 
1 | MUSCtTLO-HLASnC STRUCTURE
Figure 1. 7. Diagram comparing normal and preeclamptic placentation.
1 -  Spiral artery. 2 -  Myometrial spiral artery. 3- Basal arteriole, 4 -  Radial 
artery (Adapted from Robertson et al. 1975).
It has been demonstrated with both morphological studies (Jaameri et al. 1965) and 
monoclonal antibody (JMB2) labelling (Chua et al. 1991) that shedding of placental 
(trophoblast) tissue into the maternal circulation occurs in normal and preeclamptic 
pregnancy. Trophoblast cells were first found in the lungs at post mortems of 
women who had died following eclampsia (Schmorl 1893) and more recently 
following preeclampsia (Attwood and Park 1961). It is probable that most of these 
fragments do not reach the maternal arterial circulation due to their size and 
consequent entrapment in the pulmonary circulation. It has been confirmed that the 
quantity of trophoblast fragment shedding is increased in preeclamptic pregnancy 
compared to normal controls though it is not related to disease severity (Chua et al. 
1991; Knight et al. 1998; Johansen et al. 1999). Additionally, it has been shown that
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these membrane fragments impair maternal vascular endothelial function in vitro 
(Cockell et al. 1997). This group used isolated maternal resistance arteries perfused 
with syncytiotrophoblast microvillous (STBM) membrane vesicles to show 
consequently reduced vasodilatation to acetylcholine. Smarason and colleagues also 
showed that STBM from both normal and preeclamptic placentae impaired 
endothelial cell growth in vitro but speculated that a quantitative (not qualitative) 
difference in shedding may be the crucial causative factor for preeclampsia 
(Smarason et al. 1993).
The release of free fetal DNA in normal and preeclamptic pregnancies is further 
discussed in Section 1.4.5.
It is speculated then that the increased shedding of trophoblast in preeclampsia is due 
to the abnormal placentation seen in the disorder. However, no correlation was seen 
with other markers of the severity of the preeclampsia (Johansen et al. 1999) and thus 
it is not known whether a subsequent connection with the maternal disease exists. 
Might it be possible that the IPGs, being concentrated on the microvillous brush 
border of the syncytiotrophoblast are transported into the maternal circulation with 
the fragments, to exert a local effect on the maternal endothelium at a site distant to 
the uterus?
1.2.5 Preeclampsia, Diabetes and Insulin Metabolism
Type I Diabetes is an independent risk factor for preeclampsia (Siddiqi et al. 1991) 
and an increased incidence of preeclampsia is seen with poor control of diabetes in 
early pregnancy (Hanson and Persson 1998). It has been mentioned previously that 
preeclamptic placenta, like placentae from diabetic pregnancies shows increased 
deposition of glycogen. (Arkwright et al. 1993)
Plasma glucose levels are not raised in preeclamptic pregnancies as compared to 
normal pregnancy. However, there is evidence that there may be insulin resistance 
(Kaaja et al. 1999) or frank hyperinsulinaemia in these women (Bauman et al. 1988; 
Martinez et al. 1996). Bauman’s study did not control for maternal body mass index. 
The latter investigation was a well-controlled study with properly matched, but small 
series (10 each) of normal and preeclamptic women (Martinez et al. 1996).
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Hyperinsulinaemia was demonstrated in both the fasting and post-glucose load states. 
The sympathomimetic effect of insulin may then contribute to the rise in blood 
pressure. Obesity is a common cause of insulin resistance and is an independent risk 
factor for preeclampsia (Sibai et al. 1995). It is also possible that diabetes is a risk 
factor due to the pre-existing vascular disease. I have also mentioned that glycogen 
deposits are greater in both the diabetic and preeclamptic placenta, although different 
mechanisms have been proposed (Arkwright et al. 1993).
1.2.6 Amniotic Fluid (AF) and Preeclampsia
AF at the most basic level is composed largely of fetal urine from 16-18 weeks of 
pregnancy onwards (Cunningham et al 1997). It is intimately involved with 
placental function, being the site of exchange for fluid, nutrients and metabolites 
between mother and fetus. It is well known that a reduction in placental function can 
lead to a reduction in the AF volume, presumably due to reduced fetal renal 
perfusion and therefore fetal renal output. This is usually measured as the ‘Amniotic 
Fluid Index’ (AFI), a function of the deepest pools of liquor measured on ultrasound 
scan.
Table 1. 3 Amniotic Fluid Factor Changes In Preeclampsia
Factor Change Sample 
Size (PE)
Reference
Prostacyclin Decreased 27 (Ylikorkala et al. 1981)*
Thromboxane No Change 27 (Ylikorkala et al. 1981)*
6 -Keto-PGFla, TXB2 No Change 19 (Moodley et al. 1984)
Fetal fibronectin Increased 20 (Kupferminc et al. 1995)
Soluble VEGF Receptor-1** Increased 33 (Vuorela et al. 2000)
Interleukin-6 Increased, 15 (Nakabayashi et al. 1998)
Decreased or 9 (Silver etal. 1993)
No Change (Heikkinen et al. 2001)
Oxytocinase Activity Decreased 80 (Roy et al. 1993)
cGMP Decreased 20 (Rizzo et al. 1996)
PE = Preeclampsia, PG = Prostaglandin, TX = Thromboxane, VEGF = Vascular 
Endothelial Growth Factor, cGMP = Cyclic Guanosine Monophosphate
*No definition of 'preeclampsia* given; ** sFK1______________________________________________________________
It must be remembered that increased levels of a marker could be due to a decreased 
AFI and the liquor being correspondingly concentrated. Some authors have
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expressed results of AF per micromol of creatinine (For example Di Iorio et al.
1998).
Amniocentesis is commonly used to aspirate fluid for the analysis of fetal cells (for 
karyotyping), bilirubin measurement (management of fetal haemolysis) and other 
reasons. Being relatively easy to acquire therefore it has been an obvious target for 
research into preeclampsia and its pathophysiology.
Bjorkhem et al found amniotic total cortisol levels to increase with gestation (most 
significantly after 40 weeks) and, independently, in preeclampsia (Bjorkhem et al. 
1978). The free cortisol changed much less so. Historically it was suggested that 
cortisol might have a role to play in the onset of labour, though this now thought to 
be only true in some mammals other than humans. Other groups have also looked at 
other markers (Table 1.3).
Of course, the presence of a substance in amniotic fluid may be the result of one or a 
combination of several pathways. For example, guanylate cyclase activity is present 
in the placenta and membranes (Rizzo et al. 1996) and any change in the AF levels 
may be a result of changes in either or both of these locations. Any substance that is 
physiologically present in the maternal system may potentially be transported across 
the placenta. Alternatively fetal production may be the main source. The difficulty 
with preeclampsia remains the lack of reliable and comparable animal models, as 
novel metabolic pathways may be present in the disease state.
1.2.7 Preeclampsia and Other Hormonal Links
A small study with age and gestation-matched women, using commercial RIA and 
ELISA showed raised testosterone (but not other androgens) in preeclampsia 
(Acromite et al. 1999) -  The authors suggested a link to inhibin as this increases 
androgen production from ovarian theca cells in non-pregnant subjects with 
polycystic ovarian syndrome (Pigny et al. 1997), in which abnormal insulin 
metabolism is also found (Hopkinson et al. 1998). Inhibin, human chorionic 
gonadotrophin and alpha feto-protein are also raised in preeclampsia and this is 
discussed in Chapter 1.4.4.
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1.2.8 Aetiological Theories
Once it is accepted that the placenta is central to the problem, it is helpful to define 
several separate, though partially overlapping areas, which need to be considered 
when discussing the aetiology of preeclampsia.
Immunological -  From Primipaternity to HLA-G
Normal pregnancy is an immunologically intriguing event. It is known to be a 
stimulation of the immune system towards the tolerance pathway, rather than 
immune-suppression. It has been suggested that preeclampsia is a manifestation of a 
malfunction in this process.
It has long been recognised that women in their first pregnancy are at greater risk of 
preeclampsia compared to multiparous women, Mauriceau commenting in 1694 that 
primigravidae were more likely to develop convulsions than multiparae (Chesley 
1984). It has been postulated that this is due to the maternal immunological 
sensitisation to paternal DNA either pre-conception (for example in the form of 
sperm antigens) or as the paternal component of fetal DNA in the trophoblast. 
Klonoff-Cohen et al noted the apparent increased risk of preeclampsia in women 
who used barrier contraception, resulting in fewer episodes of sperm exposure 
(Klonoff-Cohen et al. 1989). A dose-response gradient was observed. More recently, 
a Dutch group showed a reduced risk of preeclampsia related to oral sex and 
swallowing of sperm (Koelman et al. 2000). These effects may both potentially be 
secondary to induction of allogenic tolerance to paternal HLA.
Alternatively the actual duration of sexual cohabitation may affect the preeclampsia 
risk (Robillard and Hulsey 1996). A controversial explanation has been offered by 
the same authors in reference to genomic imprinting of the sperm (Robillard et al.
1999). Specifically, the higher incidence of preeclampsia in short-term relationships 
may be because “...males would imprint their sperm more aggressively when they do 
not expect to have another offspring with that female (or i f  a mother already has 
existing children by another father).”
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Robillard has furthermore expounded a new theory of 'Primipaternity’ as being more 
relevant (Robillard et al. 1998; Robillard et al. 1999). The theory focuses on the risk 
for preeclampsia being associated not with the mother's first pregnancy but with the 
first pregnancy with any given partner. Namely, multigravidae share the risk with 
primigravidae in case of a subsequent conception with a new partner (Robillard et al.
1998).
More recently, Skjaerven et al. using retrospective data for a large cohort of women 
(over 750 000) from the Medical Birth Registration of Norway concluded that the 
protective effect of previous pregnancy against preeclampsia is transient (Skjaerven 
et al. 2002). Their data indicated that the risk of preeclampsia following a pregnancy 
increased with time, returning to that of a primigravida after 10 years. After 
adjustment for inter-birth interval, a change of partner was not associated with an 
increased risk of preeclampsia. This would seem to contradict the primipaternity 
theory. The group offers no explanation for this in immunological terms. 
Presumably, a mechanism might be similar to that of a primary inoculation with 
Hepatitis antigen - requiring a booster after 6 months to maintain a persistent 
immune response. A major problem with this study however is that retrospective use 
of birth records for paternity data is confounded by a potential 30% false paternity 
rate. One must therefore call the validity of the data into question. It was recognised 
by the authors that the data might also be confounded by the lack of data on non­
smoking status and obesity (both associated with preeclampsia).
Logically, if immune tolerance plays a part in the causation of preeclampsia, the 
presence of immunologically foreign material should increase the incidence of the 
disorder. Fertility treatment involving donated gametes is such a situation. A large 
retrospective analysis of 232 ovum donation pregnancies, (leading to 140 deliveries) 
has shown increased incidence of non-proteinuric hypertension (11%) and 
preeclampsia (11%) (Abdalla et al. 1998). A smaller series from Italian ovum 
donation program suggests that there is no increased risk of preeclampsia, quoting 
13% (6 of 44 clinical pregnancies) (Antinori et al. 1995). However, there is no 
definition given of what is meant by ‘gestational hypertension’, a misleading 
terminology. Secondly, the rate of this hypertension should be expressed as a 
percentage of the live-birth rate, namely 6 of 34 deliveries -  18%. This is
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significantly higher than in spontaneous gestations. Similar preeclampsia rates were 
found in a more recent retrospective study of 72 women with donated gametes (Salha 
et al. 1999) though much higher rates (38%) have been reported in oocyte donation 
cases (Serhal and Craft 1989). A further paper by Makhseed and colleagues also 
shows increased rates of ‘PIIT in multiple pregnancies following IVF and ICSI 
treatment (Makhseed et al. 1998). However, this paper is also flawed in that neither 
does it define the term ‘pregnancy induced hypertension’ nor was it primarily 
designed to look at this as an outcome measure. A history of infertility or in vitro 
fertilisation alone do not increase the risk of preeclampsia (Ros et al. 1998; Skupski 
et al. 1996).
It is all very well to have epidemiological evidence, but is this backed up by evidence 
of an immunological process?
Human Lymphocyte Antigen-G (HLA-G) is a non-classical class I gene of the major 
histocompatibility complex (MHC) with restricted tissue distribution, including 
expression on trophoblast in maternal spiral arteries (Geraghty et al. 1987). 
Involvement of this gene would be consistent with the fetal-paternal DNA 
component described by Lie et al below. It is possible that reduced or absent HLA-G 
expression exists in preeclamptic cases (Goldman-Wohl et al. 2000) and differences 
in HLA-G genotype between control and preeclamptic samples are an important 
component in the susceptibility to or development of preeclampsia (O'Brien et al. 
2000).
Genetic Component
There is a strong familial association with a history of preeclampsia in first-degree 
relatives with a four- to eight-fold increased risk for women with a previously 
affected sister or mother (Williams and de Swiet 1997). Various models of 
inheritance have been proposed based on population data, including a single 
recessive or dominant maternal gene (Amgrimsson et al. 1990) or homozygosity for 
a single recessive gene shared by mother and fetus (Liston and Kilpatrick 1991). 
However the precise nature of the genetic link is not known. One study using 
retrospective data and patient interviews shows a familial predisposition in daughters 
of eclamptics/preeclamptics (Amgrimsson et al. 1990).
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Table 1. 4. Single gene candidate studies
Blood Pressure
eNOS
T235 Angiotensinogen Variant
Thrombogenesis
Factor V Leiden 
Prothrombin 
MTHFR 
Placentation
Adhesion molecules 
TNFa
No link
Possible link (variable between 
different populations) ’
Many mixed results
No proven link4,5
(Lade et al. 1999) (Ward et al. 1993) (Morgan et al. 1999) (Lachmeijer et al. 
2001)5(Livingston et al. 2001)
Retrospective analysis of birth records seems to reveal a low male/female sex ratio in 
the daughters compared to the daughters-in law of preeclampsia/eclampsia sufferers 
(Amgrimsson et al. 1993). Various candidate gene studies have been carried out 
looking at vascular and placental factors, some of which are summarised in Table 
1.4.
There is also a single gene for GPI-PLD (which is involved in the production of IPG) 
in humans on chromosome 6p22 (Schofield and Rademacher 2000). Although no 
data exists as to prevalence of different alleles in preeclamptic and normal placentae, 
linkage studies have not demonstrated a connection with chromosome 6p22 . 
Opinion is moving away from a single gene theory, with most inclined to believe in 
the involvement of a fetal paternal genetic component (i.e. separate to that from 
maternal DNA). For example, a woman’s risk of preeclampsia a given pregnancy is 
increased if her partner has already fathered a preeclamptic pregnancy with another 
woman (Lie et al. 1998). The most likely situation may be one of a genetic 
predisposition/susceptibility to the disease process itself.
Placental
As already mentioned, the placenta is inextricably involved in the aetiology of 
preeclampsia. Poor utero-placental perfusion is usually found in preeclampsia and 
this is accompanied by changes in Doppler waveforms on ultrasound scan (Bower et 
al. 1993b) showing high resistance. Abnormal placentation leads to placental
22
ischaemia (Williams and de Swiet 1997) but it is not clear what the origins of the 
initial abnormality are.
Placental growth factor (P1GF), is an angiogenic factor whose levels are down- 
regulated by lowered oxygen tension (Ahmed et al. 2000). It is a marker of placental 
function and is decreased in the serum of preeclamptic women from the second 
trimester (Torry et al. 1998; Levine et al. 2004b) This can even be shown in high-risk 
women before the onset of clinical disease (Chappell et al. 2002). 
Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF), a placental growth- 
enhancing agent was reduced in the serum of preeclamptic subjects (Gratacos et al.
1998). The authors acknowledged that this might not represent the situation at the 
maternal-fetal interface however.
Vascular/Endothelial -  Inflammatory response and Platelets
It is thought that the maternal syndrome of preeclampsia is an endothelial disorder 
(Roberts and Redman 1993; Williams and de Swiet 1997). Women with pre-existing 
microvascular disease (e.g. diabetics) or hypertension are more at risk (Roberts and 
Redman 1993).
It has been shown that there are increased cytokine levels (Conrad and Benyo 1997; 
Roberts et al. 1989a) as well as endothelial cell damage (Roberts et al. 1989b). 
Platelet activation (Greer et al. 1988; Redman 1990) has also been demonstrated. 
Vascular endothelial growth factor (VEGF), an angiogenic growth factor, is 
expressed in placental tissue (Jackson et al. 1994). Recently, Maynard et al 
demonstrated that soluble fms-like tyrosine kinase 1 (sFltl), a potent VEGF and 
P1GF antagonist is increased in maternal serum in preeclampsia and that it produces a 
preeclampsia-like syndrome in a rat model (Maynard et al. 2003). Further work by 
the same group demonstrated that it is also increased before the onset of clinical 
symptoms and that P1GF levels are correspondingly decreased (Levine et al. 2004a). 
Brockelsby indicated that VEGF levels may be increased in preeclampsia and that it 
parallels some of the effects of preeclamptic plasma in vitro (Brockelsby et al. 2000). 
This study measured plasma (not serum) VEGF levels and used both total and free 
(not bound to sFlt-1 receptors) levels - both important factors to consider when 
investigating VEGF. It is also an in vitro study and as Jelkmann notes in his review 
of VEGF, platelets and leukocytes both release VEGF during blood clotting
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(Jelkmann 2001). In fact, free circulating levels of VEGF may actually be decreased 
in preeclampsia (Maynard et al. 2003) and this was hypothesised to be due to 
scavenging of the free component by sFltl.
Table 1. 5. Summary of Vascular Factors Altered in Preeclampsia
Raised Decreased
Plasma P-Selectin 1 Endothelial Prostacyclin3
Total VEGF 2 Nitric Oxide (bioavailability) 3
Thromboxane 4 Free VEGF7
TNFa5
ICAM-1 and VCAM-1 6
1. (Bosio et al. 2001) 2. (Brockelsby et al. 2000) 3. (Dekker and Sibai 1998) 4. (Friedman 1988) 5. 
(Conrad and Benyo 1997) 6. (Krauss et al. 1997) 7. (Maynard et al. 2003)
A longitudinal study of 70 women showed levels of plasma P-Selectin, an adhesion 
cell molecule were raised by 10-14 weeks in women who later developed 
preeclampsia (Bosio et al. 2001). The data is from a subset of non-matched women 
(preeclampsia, gestational hypertension and non-hypertensive pregnant controls) but 
shows quite significant rises in plasma P-Selectin from the first trimester, supporting 
the inflammatory model.
Pro-thrombotic Tendency
Pregnancy is a hypercoagulable state and this is increased in preeclampsia. There is 
increased thromboxane and platelet activity in preeclampsia (Friedman 1988). 
Although a major randomised trial failed to show benefit from aspirin, an anti­
platelet agent (CLASP 1994), detection of this increased activation in the first 
trimester (CD63 expression) has been suggested as a way of predicting preeclampsia 
(Konijnenberg et al. 1997). Prostacyclin (PGI2), which is mainly produced by 
endothelial cells, is a potent vasodilator and inhibitor of platelet aggregation. A 
Scottish group showed sera from preeclamptic women lowered PGI2 in peripheral 
blood mononuclear cells (Chen et al. 1993). It has been shown that cell adhesion 
molecules may be raised early in pregnancy in those women who will subsequently 
develop preeclampsia (Krauss et al. 1997).
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Oxygen Free Radicals -  Oxidative Stress and Vitamin C
‘Oxidative stress’, a pathological state in which pro-oxidants dominate over anti­
oxidants, has been implicated in the pathophysiology of both preeclampsia and 
atherosclerosis (Chappell et al. 1999b; Roberts and Hubei 1999), as well as other 
disease states. Reduced levels of antioxidants are present in preeclamptic women 
(Mikhail et al. 1994). Free radicals have emerged as likely promoters of maternal 
vascular endothelial damage (Dekker and Sibai 1998) and reactive oxygen species 
induce endothelial activation through many pathways (Davidge 1998). A trial of 238 
women with ‘high-risk’ pregnancies (as determined by uterine artery Doppler or 
previous history of preeclampsia) suggested that prophylaxis with the antioxidant 
vitamins C and E may be effective for these selected cases (Chappell et al. 1999b). 
More recently, the same group have shown decreased ascorbic acid levels in 
preeclamptic pregnancies, as early as the second trimester (Chappell et al. 2002).
1.2.8 Summary
It is likely that the aetiology of preeclampsia is multifactorial, a series of events in a 
susceptible mother. One summary of this overall aetiological process has been 
presented by Williams and de Swiet (Williams and de Swiet 1997):
'It seems that susceptible women develop placental ischaemia triggering 
maternal endothelial cell dysfunction. This then leads to vasoconstriction, 
plasma volume contraction, maternal organ hypoperfusion and thus 
further impairment o f placental blood flow. ’
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Figure 1. 8. Possible pathophysiology of preeclampsia
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1.3 The Possible Role of IPG-P in Preeclampsia and 
Labour
1.3.1 Maternal Endothelial Activation
For some years the theory of maternal endothelial activation has been popular as 
explaining a unifying process behind the clinical syndrome of preeclampsia (Roberts 
et al. 1989b; Redman et al. 1999). The factor(s) responsible for this activation 
remain elusive, with many potential candidates being proposed. Is it possible that 
IPG is in some way involved as a signal or trigger in this process?
As Redman observed thirteen years ago, it is peculiar that secondary manifestations 
of the preeclamptic disorder such as hypertension and proteinuria remain absolute 
requirements for diagnosis (Redman 1990).
1.3.2 Differing Levels in Normal vs. Preeclampsia
When measuring blood-borne factors in normal and preeclamptic groups one must 
remember differences exist in the basic physiology of the two states. Two factors in 
particular, present in preeclampsia, have the potential to cause bias. Firstly, reduced 
renal clearance secondly to renal involvement in the disorder. Plasma urate levels 
increase with worsening preeclampsia and are a good example of renal involvement 
and are often used in the monitoring of the preeclamptic woman. Secondly, 
haemoconcentration due to a reduced plasma volume compartment may confound 
apparently different levels of a measured factor.
1.3.3 Calcium
A significant increase in the response of intracellular free calcium to arginine 
vasopressin in maternal platelets predates the onset of preeclampsia (Zemel et al.
1990). Other authors have noted that platelet membrane-bound and free-intracellular 
calcium levels are increased in hypertension (Cooper et al. 1989) and preeclampsia 
(Haller et al. 1989) respectively.
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IPGs have been implicated reducing calcium entry to rat hepatocytes by inhibiting 
calcium oscillations (Sanchez-Bueno et al. 1997).
A recent investigation indicated that plasma calcium concentrations may be 
decreased in preeclampsia compared to pregnant and non-pregnant controls (Kosch 
et al. 2000). The same paper demonstrated increased membrane calcium in 
erythrocytes, suggesting altered membrane ion transport. The authors did comment 
that only the free plasma calcium was measured and so it would be possible for 
protein binding to be altered in the preeclamptic state. It should be noted that some 
other authors have not found the plasma levels to be decreased.
There may also be a reduced calcium/creatinine ratio in urine of preeclamptic women 
(Rodriguez et al. 1988).
Caveolae, which have been identified as a key location for IPGs (as discussed in the 
Introduction), are also involved in calcium storage and entry (Anderson 1998). Is it 
possible that there is a link between abnormal IPG metabolism in caveolae and the 
observed changes in calcium seen in preeclamptic women?
Other factors altered in preeclampsia and affecting ion transport have also been 
identified, such as sodium pump inhibitors (Lopatin et al. 1999).
1.3.4 Zinc
Zinc has been described as an in vivo insulin mimetic in some of its functions (Ilouz 
et al. 2002). Zinc has been proposed as an important component of IPGs although 
the exact role has not been determined.
1.3.5 Preeclampsia, Lipid Metabolism and Plasma Leptin
Preeclampsia and obesity share certain metabolic characteristics, namely 
dyslipoproteinemia, insulin resistance and glucose intolerance (McCarthy et al.
1999). Obesity is also an independent risk factor for preeclampsia and pregnancy 
induced hypertension (Sibai et al. 1995). It was discussed in Chapter 1 that IPGs are 
ubiquitous in insulin metabolism. It is also known that human Placental Lactogen (a 
hormone with a lipolytic component) is increased in preeclampsia (Murai et al.
1997).
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Leptin is the product of the Lep gene (the so-called human obesity gene). It is a 
circulating hormone produced by adipose tissue in the non-pregnant state, which 
responds rapidly to the availability of nutrients. Maternal leptin levels are raised in 
normal pregnancy by a factor of 3 or 4 compared with non-pregnant controls and 
correlate with maternal body mass index (Geary et al. 1999) and inversely with 
placental weight (Schubring et al. 1996). Umbilical cord levels also correlate with 
birth weight (Schubring et al. 1996; Geary et al. 1999). These two findings 
suggested a possible role for leptin as a regulator o f maternal weight and fetal intra­
uterine growth.
Plasma leptin levels are raised in preeclampsia (McCarthy et al. 1999; Ramsay et al 
2003) and may possibly be used as part of a screening tool in the second trimester 
(Chappell et al. 2002). McCarthy and colleagues showed raised maternal plasma 
leptin levels in comparison to controls in a group of preeclamptic women in the third 
trimester. Subjects were matched for BMI and fetal gestational age. At the same 
time, there was a correlation in the preeclamptic cases between maternal and cord 
levels of Leptin. Unfortunately the cord bloods were mixed arterial and venous 
samples. More recently, Ramsay et al also showed raised fasting leptin, VLDL-C 
and triglyceride levels, as well as certain inflammatory markers (VCAM-1 and IL6), 
compared to women with intrauterine growth restriction (IUGR). Chappell’s group 
showed elevated leptin and lowered placental growth factor in women identified as 
high risk for preeclampsia by personal history or abnormal second trimester uterine 
artery Doppler waveforms. It is possible that Leptin may be a significant factor in 
preeclamptic metabolism.
IPG-A has been demonstrated to inhibit leptin release from rat adipocytes in vitro 
contrasting with the action of insulin (stimulation) and IPG-P (no effect) (Kunjara et 
al. 2000b). If IPG-A levels were shown to be lower in preeclampsia, this would 
result in a correspondingly diminished inhibitory effect.
1.3.6 Nitric Oxide
Nitric oxide is synthesised from L-arginine by the enzyme nitric oxide synthase, 
which is found in endothelial cells, platelets and the placenta. The latter is an 
important source of nitric oxide (NO) during pregnancy (Norris et al. 1999).
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Unfortunately, the evidence as to the status of Nitric Oxide in preeclampsia is 
contradictory and confusing. It was shown recently in a small series of age-matched 
preeclamptic and normal controls that NO was higher in the uteroplacental, 
fetoplacental and peripheral circulations in the preeclamptic cases (Norris et al.
1999). Some of the other conflicting results are summarised in Table 1.6 below.
Table 1. 6. Summary of Nitric Oxide (NO) Study Results
Sample and Location Sample Size 
PE C
Change in NO/ 
NO Synthase
Authors & Date
Nitric Oxide
Mat. Peripheral, Uterine 15 15 Increased (Norris et al. 1999)
Vein Increased
Mat. Peripheral 23 393 Increased (Nobunaga et al. 1996)
Mat. Peripheral 20 32 Increased (Smarason et al. 1997)
Mat. Peripheral 26 26 Decreased (Seligman et al. 1994)
Mat. Peripheral, 14 20 Unchanged (Davidge et al. 1996)
Urine Decreased
NO Synthase
Placenta 16 29 Decreased (Brennecke et al.
1997)
Placenta 6 17 Decreased (Morris et al. 1995)
PE = Preeclampsia, C = Control (pregnant and non-pregnant), Mat. = Maternal
Both sides of the apparent conflict have been explained in seemingly convincing 
ways. Namely if the NO levels/activity is increased, this is seen as either a 
compensatory mechanism for the effects of the preeclampsia or a reflection of 
decreased renal elimination. In either case, the increased NO may be a cause for 
endothelial cell injury. If it is decreased, this is seen as part of the disease process 
itself, causing the subsequent pathophysiological changes, principally the high- 
resistance blood flow patterns seen.
It is difficult to explain the different results as all the authors use similar collection 
and processing methods for the samples. Dietary differences are known to alter 
nitric oxide metabolite levels in the short-term and only Nobunaga et al control for 
this by taking fasting samples. However, the same group is the only one not to have 
made an attempt at matching preeclamptic and control subjects to some degree. The 
decreased urinary levels observed by Davidge et al would correspond to the raised
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peripheral levels being as a result of reduced excretion. Magnesium sulphate may 
also affect NO metabolism.
Reduced activity of placental nitric oxide synthase would seem to be a possible cause 
of the high resistance fetoplacental circulation seen in preeclampsia (Morris et al. 
1995; Brennecke et al. 1997). This would correspond to low measured maternal 
levels, though the local situation in the placenta is of course under local control and 
thus potentially isolated from the mother’s periphery.
The situation is made more interesting by Cyclic Guanosine Monophosphate (cGMP) 
which can be used as a surrogate marker for nitric oxide production as NO stimulates 
guanylate cyclase. Reduced levels of amniotic fluid cGMP (Rizzo et al. 1996) have 
been discussed already in Chapter 6 but increased levels have also been reported
So where is this leading us? Caveolae have already been discussed in relation to IPG 
signalling. Various techniques have been employed to show that the majority of cell 
surface endothelial nitric oxide synthase (eNOS) is located in caveolae and Anderson 
has written that ‘this suggests that caveolae are the site of NO production.’ 
(Anderson 1998). Anderson goes on to suggest that caveolae are the location for 
signal integration between some of these signalling molecules, which, it must be 
remembered, is what IPGs function as at the most basic level.
Is it possible that abnormal IPG levels are affecting eNOS activation and thus 
causing the raised NO levels observed by some authors?
1.3.7 Are IPGs the missing ‘Factor-X’?
There is a significant body of evidence to support the existence of a so-called 
‘Factor-X’ (Walker et al. 1994) released from the placenta into the maternal 
circulation, leading to the maternal symptoms seen in preeclampsia (van Beek and 
Peeters 1998).
Studies to show the direct effects of preeclamptic serum on several features of 
preeclampsia are summarised in Table 1.7, and compared on the right to evidence of 
some of the effects of IPGs.
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Table 1. 7. Effects of Preeclamptic Serum Factor(s) and IPGs
EFFECT OF SERUM FACTOR(S) KNOWN EFFECTS OF IPGs
Cytotoxic to human endothelial cells
(Rodgers et al. 1988)
Mitogenic to fibroblasts Fibroblast proliferation
(Musci et al. 1988) (Vasta et al. 1992)
Stimulating synthesis of platelet-derived
growth factor (PDGF)
(Taylor et al. 1991b)
Selectively activating endothelial cell
procoagulant products
(Taylor et al. 1991a)
(Activated platelets in preeclampsia) Human platelet activation
(Harlow et al. 2002) (Bruni et al. 1991)
(Progesterone levels may be raised in Insulin-dependent progesterone
preeclampsia) synthesis
(Zamudio et al. 1994) (Romero et al. 1993)
It can be seen therefore that there is some overlap with known properties of IPGs.
Different groups have suggested a proteinaceous cytotoxic factor as the culprit 
(Tsukimori et al. 1992b; Tsukimori et al. 1992a). Smarason and colleagues 
demonstrated a factor cytotoxic to human umbilical vein endothelial cells (HUVECs) 
that was present in plasma from preeclamptic women but was absent from their sera 
(Smarason et al. 1996), in contrast to the data from Rodgers et al and Tsukimori et al. 
However the latter two groups used a different methodology (release of 51Cr from 
HUVECs) to Smarason’s group (uptake of 3H-Thymidine -  taken up during 
spontaneous proliferation), which may explain this. Of course, this is all work in 
vitro and there is also the possibility that more than one factor is being released.
An alternative explanation would be that an alteration in maternal metabolism 
represents the ‘Factor-X’ rather than it being a distinct molecule released from the 
placenta.
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1.4 Current Screening and Diagnosis of Preeclampsia
1.4.1 Methods of Diagnosis and Classification
The clinical syndrome of preeclampsia is classically defined as one of hypertension 
and proteinuria with or without oedema. However, classifications of hypertension in 
pregnancy are multiple and indeed there is much confusion in the available literature 
with overlap of terminology (such as 'Pregnancy Induced Hypertension')(Chappell et 
al. 1999a). Recently the International Society for the Study of Hypertension in 
Pregnancy (ISSHP) produced a statement to clarify the situation (Brown et al. 2001). 
For the purposes of this project, the definitions used in this statement will be used 
universally to avoid confusion.
The ISSHP considered several published reports:
1. Australian Society for the Study of Hypertension in Pregnancy (ASSHP), 
2000 (Brown et al. 2000)
2. National High Blood Pressure Education Program (NHBPEP), 2000 
(NHBPEP 2000)
3. Previous ISSHP report, 1998 (Davey and MacGillivray 1988)
4. World Health Organisation (WHO), 1987 (World Health Organisation 
Group 1987)
5. Canadian Hypertension Society, 1997 (Helewa et al. 1997)
Following from this, Table 1.8 below summarises the definitions used and using 
these definitions, the consensus for defining the hypertensive disorders of pregnancy 
is then shown in Table 1.9.
Table 1. 8. Definitions of hypertensive disease in pregnancy used here.
• Hypertension in A systolic blood pressure (BP) of > 140 mmHg
Pregnancy and/or a diastolic BP > 90 mmHg (Korotkoff 5 f)
• Proteinuria Ideally measured in a 24-hour collection as >
300mg/day. Dipstick testing - if the only test 
available, 1 + (30mg/dl) is often, but not always 
associated with > 300mg/day proteinuria.
fNote on Blood Pressure readings: Korotkoff 5 (disappearance) should be used and K 4 
(muffling) only utilised when K5 is absent. K4 shows significant inter-observer variability.
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Table 1. 9. ISSHP Classification of hypertensive disorders of pregnancy
Chronic Hypertension
Preeclampsia/Eclampsia
• Preeclampsia superimposed 
on chronic hypertension
• Gestational hypertension
Known hypertension before pregnancy or 
rise in blood pressure to > 140/90 mmHg 
before 20 weeks’ amenorrhoea.
De novo hypertension accompanied by 
proteinuria (both as defined in Table 1.8) 
occurring after 20 weeks’ gestation and 
returning to normal post-partum.
Eclampsia is the occurrence of seizures in a 
patient with preeclampsia.
The combination of chronic hypertension 
and de novo proteinuria. *
Rise in blood pressure detected for the first 
time after 20 weeks gestation, without 
proteinuria. May be changed to "transient" 
when pressure normalises post-partum._____
'A sudden increase in the magnitude of hypertension, the appearance of 
thrombocytopenia and/or abnormal levels of transaminases are labelled as highly likely 
of superimposed preeclampsia (NHBPEP 2000)____________________________________
It is interesting to note that even within the current consensus there lies a certain 
degree of debate on the difference between so-called 'Clinical' (broader) and 
’Research’ (more restrictive) definitions of preeclampsia. The ISSHP statement 
recommended a research effort to investigate if the research criteria need to be 
broadened to approach the clinical criteria defined by the ASSHP.
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1.4.2 Methods of Screening
It could be imagined that a disorder seemingly so difficult to even classify would be 
somewhat enigmatic in its origins. Indeed, preeclampsia was first called the ‘Disease 
of Theories’ by Zweifel in 1916 (Quoted in Dekker and Sibai 1991) and whilst a 
more accurate picture of the subsequent pathophysiology is emerging, no definite 
evidence of the initial trigger exists.
There are more than 100 separate ‘tests’ for the screening or prediction of 
preeclampsia (Dekker and Sibai 1991) and yet no single predictive or diagnostic test 
exists (Grunewald 1997). In addition to this, the only definitive treatment that exists 
is to remove the placenta, leading to more than 40% of preterm iatrogenic deliveries 
(Meis et al. 1998).
The Screening Test
Before discussing individual pathologies and the screening tests that are available, it 
is first necessary to define the nature of the screening test itself. Many tests are used 
to predict if a patient has, or will develop preeclampsia. These range from simple 
blood tests such as urate levels (Chesley & Williams 1945) and platelet count to 
invasive tests. Initially it is necessary to look at the criteria for a valid screening test 
as set down by the WHO (Wilson and Jungner 1968), (Table 1.10). These criteria can 
be applied to each screening test as it is proposed and, of course, very few if any will 
meet the ‘gold standard’.
There are four broad categories of screening tests used at this time, which are 
illustrated with examples in the table below (Table 1.11). For the purposes of this 
introduction, screening as it exists for preeclampsia falls in to the first category.
Table 1. 10. Criteria for an ideal screening test (Modified from Wilson and 
Jungner1968)
• The condition should be an important health problem
• There should be an acceptable treatment for patients with recognised disease
• Facilities for diagnosis and treatment should be available
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• There should be a recognisable latent or early symptomatic stage
• There should be a suitable test or examination
• The test should be acceptable to that population
• The natural history of the condition, including development from latent to 
declared disease should be adequately understood
• There should be an agreed policy concerning whom to treat as patients
• The cost of case-finding (including diagnosis and treatment of patients
diagnosed) should be economically balanced in relation to possible expenditure 
on medical care as a whole
• Case finding should be a continuous process and not a “once and for all” 
project
Table 1.11.  Categories of screening tests
Reason Example
1. Screening to detect early disease, Breast Cancer, Cervical Intraepithelial
which can then be treated. neoplasia
2. Screening as individual may be a Hepatitis B (blood donors, health care
risk to others workers)
3. Screening because special care may Screening children for hearing
be beneficial impairment following premature
delivery/ Serum screening for Down’s
and neural tube defects
4. Screening to modify risk factors Smoking, raised plasma lipids
At the present time, there is no cure for preeclampsia other than delivery of the infant 
and placenta. Additionally, there is no antenatal diagnostic test, other than clinical 
criteria. Placental histology can be used to confirm diagnosis but obviously only in 
the postnatal period. These factors therefore may restrict the clinical usefulness of 
any screening test. However, earlier identification of a pregnant woman with 
preeclampsia can be used to focus management of her care to allow earlier detection 
of clinical signs and symptoms. If an effective treatment is established, then a
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screening test could potentially allow initiation of this treatment before completion of 
placentation. This will be discussed again later on.
Screening for preeclampsia also falls into the second category in table 1.11 above as 
treating the mother also benefits the fetus.
The 2 By 2 Table
In any population, a screening test is trying to identify two groups of individuals: 
those with the condition (or risk factor) being screened for and those without. The 
test itself will split the population into those who screen positive and those who 
screen negative. It is the efficiency with which any given test does this that tells us 
how good a test it is. An example of a 2 by 2 table is given below:
D isease
T es t Yes No
Positive a c
Negative b d
a) True Positives -  Those with disease correctly identified as positive
b) False Negatives -  Those with the disease incorrectly screened as negative
c) False Positives -  Those without disease incorrectly screened as positive
d) True Negatives -  Those without the disease correctly screened as negative
Statistically this may then be utilised to form a picture of the effectiveness of the 
screening. The five main formulae used are:
• SENSITIVITY = a/(a+b)%
The percentage of those with the disease who were correctly identified as 
positive by the screening test
• SPECIFICITY = d/(c +d)%
The percentage of those without the disease who were correctly 
identified as negative by the screening test
• POSITIVE PREDICTIVE VALUE = a/(a+c)%
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The proportion of those with a positive test who actually had the disease
• NEGATIVE PREDICTIVE VALUE = d/(b+d)%
The proportion of those with a negative test who actually did not have the 
disease
• PREVALENCE = (a+b)/(a+b+c+d)
The proportion of those in the screened population who actually have the 
disease
• LIKELIHOOD RATIO:
The likelihood that a given test result would be expected in a patient with 
a disease compared to the likelihood that the same result would be 
expected in a patient without that disease.
Likelihood ratios tell us how much we should shift our suspicion for a 
particular test result. Because tests can be positive or negative, there are 
at least two likelihood ratios for each test. The “positive likelihood ratio” 
(LR+) tells us how much to increase the probability of disease if the test 
is positive, while the “negative likelihood ratio” (LR-) tells us how much 
to decrease it if the test is negative. The formula for calculating the 
likelihood ratio is:
Probability o f an individual with the condition having the test result 
LR = Probability o f an individual w ithout the condition having the test result
Thus, the positive and negative likelihood ratios are respectively:
Probability o f an individual with the condition having a positive test 
LR+ = Probability o f an individual without the condition having a positive test
Probability o f an individual with the condition having a negative test 
LR- = Probability o f an individual w ithout the condition having a negative test
One can also define the LR+ and LR- in terms of sensitivity and 
specificity:
LR+ = sensitivity / (1-specificity)
LR- = (1-sensitivity) / specificity
Any given screening test will have a fixed sensitivity and specificity (independent of 
prevalence) and the ideal would obviously be 100% for both. However, this is not 
practically possible and often, such as in the case of serum screening for neural tube
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defects with serum AFP (Alpha feto-protein) levels, a trade-off between the two is 
achieved. That is to say, as one increases the sensitivity, the specificity will drop and 
vice versa. The positive and negative predictive values are dependent partially on 
the prevalence of the disease or risk factor in the screened population and will rise in 
proportion to this. The likelihood ratio is independent of disease prevalence within a 
population and thus has particular value in assessing clinical usefulness of a 
screening test.
It can be seen, therefore, that there are obvious benefits to screening for preeclampsia 
and this why so much research has been devoted to the area. The diagnosis of both 
conditions can be difficult and much often hangs on getting it right. There is also a 
great incentive for an accurate diagnostic test for preeclampsia for these reasons.
1.4.3 Assays Used in Diagnosis and Management of Preeciampsia
Some tests available are routinely used in management of preeclampsia and function 
as diagnostic or clinical tools rather than screening tests. The most common 
examples would be:
a) Platelet count
Lowered platelet count may be a sign of worsening disease or even HELLP 
Syndrome (Haemolysis, Elevated Liver Enzymes and Low Platelets). There is some 
evidence to suggest that the rate of a drop in the platelet count may be an indicator of 
the severity of the disorder.
b) Serum Urate Levels
Hyperuricemia has been used as a marker of preeclamptic disease for several decades 
and is associated with the severity of preeclampsia and with fetal outcome (Liedholm 
et al. 1984). Traditionally the high uric acid concentration in preeclampsia has been 
attributed solely to renal dysfunction. It has been suggested by Many and colleagues 
(Many et al. 1996) that other factors are involved. Purines (xanthine and 
hypoxanthine) act as a substrate for xanthine dehydrogenase/oxidase to produce uric 
acid. Uric acid production is coupled with formation of reactive oxygen species when
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the enzyme is in the oxidase form. Several factors can increase the holoenzyme 
activity and the conversion of xanthine dehydrogenase/oxidase to its oxidase form. 
These factors include
1. Hypoxia-reperfusion
2. Cytokines
3. Increased substrate availability.
Preeclampsia is characterized by hyperuricemia and signs of increased formation of 
reactive oxygen species (such as free radicals) and decreased levels of antioxidants, 
producing elevated oxidative stress.
Preeclampsia is also characterized by shallow implantation, producing a relatively 
hypoxic maternal-fetal interface, and increased turnover of trophoblast tissue, which 
can result in higher xanthine and hypoxanthine concentrations and higher levels of 
circulating cytokines. These mechanisms can lead to increased production of uric 
acid and free radicals and contribute to the hyperuricemia and increased oxidative 
stress present in preeclampsia (although xanthine oxidase activity has not been 
demonstrated in the placenta). It is also noted that the antioxidant properties of urate 
may have a protective role in preeclampsia.
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1.4.4 Currently Used Screening for Preeclampsia
As mentioned before, certain risk factors for preeclampsia provide an indication of 
increased risk at the time of pregnancy booking. Examples include raised diastolic 
(>80 mmHg) or systolic (>130 mmHg) blood pressure or the presence of 
anticardiolipin antibodies or lupus anticoagulant. There are then specific screening 
tools, examples of which are discussed below.
a) Uterine Artery Doppler Ultrasound
Doppler ultrasound is currently the most widely used early-pregnancy screening 
technique for preeclampsia and growth 
restriction. It is known that an 
increase in impedance to blood flow in 
the uterine artery occurs in preeclamptic pregnancies (Campbell et al. 1983). This is 
due to failure of invasion of trophoblast into the maternal spiral arteries. Campbell 
first identified the use of Doppler ultrasound as a potential screening test for high- 
risk pregnancies over 17 years ago (Campbell et al. 1986).
An elegant paper by Bower et al revealed the power of Doppler ultrasound as a 
screening tool using strict diagnostic criteria for preeclampsia and including early 
diastolic notching in the definition of an abnormal flow velocity waveform (FVW) in 
the uterine artery (Bower et al. 1993b). Strong positive predictive and negative 
predictive values were achieved when screening for ‘moderate to severe’ 
preeclampsia in particular. Subsequent further research by the same group used the 
criteria to screen for high-risk women by Doppler ultrasound at 18-22 and 24 weeks 
(Bower et al. 1996). This study showed the potential for Aspirin (an anti-platelet 
agent) to prevent some cases of severe preeclampsia in women identified as high risk 
by the presence of persistent uterine artery notching. In so doing, this study seemed 
to demonstrate a therapeutic effect of low-dose aspirin (in selected, ‘high-risk’ 
women) where the CLASP trial (CLASP 1994) (with an unselected population) did 
not. More recently, Doppler ultrasound has been used in combination with other 
tests to improve the positive predictive value. A preliminary study on a large group 
of women (689 women, with a preeclampsia rate of 5.5%) indicated that a 
combination of Doppler at 20 weeks’ gestation and second trimester (15-19 weeks)
RI = Systolic Peak -  End-diastolic trough 
Systolic Peak
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serum Inhibin levels could be used (Aquilina et al. 2001). They showed a Positive 
Predictive Value (PPV) of 38.5% (Sensitivity 71.4%, Specificity 93.4). This is as 
powerful and at a significantly earlier stage in the pregnancy than previous screening 
- Doppler alone at 24-26 weeks (Bower et al. 1993a)- but does rely on a dual-stage 
test. This confers some complexity and additional expense.
b) Beta Human Chorionic Gonadotrophin (phCG)
Human Chorionic Gonadotrophin is a placental hormone with alpha and beta sub­
units. There has been interest in serum phCG as a potential screening test and 
various groups have investigated levels in the first (Haddad et al. 1999), second 
(Sorensen et al. 1993; Wenstrom et al. 1994; Ashour et al. 1997) and third (Said et al. 
1984) trimesters. Said et al found significantly higher maternal serum phCG levels in 
41 primigravid patients with ‘proteinuric preeclampsia’ compared with those in 41 
primigravid normotensive women matched for age and gestation (although an 
archaic definition of ‘proteinuric preeclampsia’ was used with 0.25g/litre of urine). 
The more recent studies by Sorensen et al and Ashour et al (the larger series of the 
two) both used a retrospective examination of samples taken for serum screening 
purposes. Using a cut-off of 2.0 MoM (Multiples of the median) both groups 
concluded that second trimester phCG levels could be used to screen for women at 
high risk of pregnancy related hypertension. Both groups found higher risk ratios 
relating to proteinuric (compared to non-proteinuric) hypertension as would be 
expected. Sorensen’s apparently more impressive results may be due to the inclusion 
process and the smaller sample size. As with any screening program this could then 
lead to closer surveillance of the high-risk group with potential therapeutic 
intervention.
The problem with second trimester intervention for the prevention of preeclampsia is 
that success may be limited as placental invasion and vessel formation is complete by 
16 weeks. Thus a screening/diagnostic test would be of more clinical use. 
Unfortunately, the study by Haddad et al failed to show a significant difference in 
serum phCG levels in the first trimester (samples taken in 236 singleton IVF 
pregnancies between day 13 and 35 post-conception). Preeclampsia (ISSHP research 
definition used) was a primary outcome measure but is possible that the sample size 
was too small to detect differences at this early stage.
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c) Inhibin/ Activin
Inhibins are heterodimeric proteins consisting of apA (inhibin A) and aPB (inhibin 
B) subunits. Activins are homodimers with the subunits linked by disulphide 
bridges. Like phCG these hormones are derived from the trophoblast, with both 
inhibin and activin subunits being expressed in human placenta (Vale et al 1994). 
Inhibin A has been established in screening programmes for Down’s Syndrome 
(Wald et al. 1999; Gilbert et al. 2001). Interestingly, it has also been shown that 
maternal serum alpha-fetoprotein (AFP), another component of this screening test is 
raised in preeclamptic pregnancies too (Waller et al. 1996). In some institutions a 
high AFP observed at the time of routine serum screening, in the absence of a 
karyotypic abnormality, is now used as an indication to perform further screening 
(for poor pregnancy outcome) by the use of Doppler ultrasound as described above.
It was demonstrated convincingly in a small retrospective study in the second half of 
pregnancy that serum inhibin A is raised in preeclampsia compared to age and 
gestation-matched control subjects (Muttukrishna et al. 1997). A further 
retrospective study of early second trimester Inhibin A levels, with preeclamptic 
subjects identified by lab records of proteinuria, indicated the predictive potential of 
the marker (Cuckle et al. 1998). A cross-sectional study found both Inhibin A and 
Activin A were raised in preeclamptic subjects and Activin A alone was raised in 
gestational hypertension (Silver et al. 1999). All three studies use the same, highly 
specific two-site immuno-assay (Serotec, Oxford, UK).
Inhibin B on the other hand may fall in preeclamptic pregnancies compared to 
normal (Petraglia et al. 1997). This group showed that Inhibin B levels rise with 
gestation but that it is not the predominant form of inhibin in the maternal 
circulation.
1.4.5 Historic and Potential Future Screening Tests
Two historic tests exist that are applicable in a practical way only in a research 
setting.
a) Angiotensin Sensitivity Test
Abdul-Karim and Assali first identified refractoriness to pressors in pregnant women 
in the 1960s (Abdul-Karim and Assali 1961). Subsequently, it was determined that
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this was lost in those women who develop preeclampsia (Talledo 1966). This 
increased sensitivity to angiotensin II may arise several weeks before the onset of 
preeclampsia (Oney and Kaulhausen 1982). Kyle and colleagues have shown this to 
be ineffective as a screening test (Kyle et al. 1995) and it is also too complicated and 
time-consuming to be used in clinical practice (Dekker and Sibai 1991).
b) Supine Pressor Test:
Physiologically related to the angiotensin sensitivity test, in that it assesses the 
pressor response in pregnancy, this test was first described nearly thirty years ago 
(Gant et al. 1973). The method is less invasive than infusing angiotensin II, merely 
involving the measurement of blood pressure in the right arm of the patient lying on 
the left side, then supine. Although initially promising, Gant et al describe a very 
high prevalence (44.7%) of preeclampsia for an unselected group of primigravidae 
(Gant et al. 1973). Subsequent authors have failed to reproduce these results and 
again this test is of little clinical use.
Furthermore, assays for several markers have been proposed which may become 
useful in the future as part of a screening tool for preeclampsia prior to the onset of 
clinical symptoms or signs.
c) Free Fetal DNA
As well as the discovery of trophoblast tissue in the maternal circulation (Chua et al.
1991), several groups have identified free fetal DNA in maternal plasma. A group 
from London has demonstrated fetal DNA to be present throughout pregnancy from 
the first few weeks.(Thomas et al. 1995) The principle is one of demonstrating Y- 
chromosome DNA (from a male pregnancy) by means of PCR (polymerase chain 
reaction) amplification. Bianchi et al examined a series of peripheral venous samples 
taken from women undergoing prenatal cytogenetic diagnosis (amniocentesis and 
chorionic villous sampling) (Bianchi et al. 1997). Using PCR quantitation from a 
16ml blood sample, detection of male DNA was possible in 99.3% of male 
pregnancies. More interestingly, there is an elevation of fetal cell DNA equivalents 
with pregnancies of abnormal karyotype (specifically, Trisomy 21). This difference 
has been shown significantly but to a lesser degree, using real time PCR techniques 
by Lo et al.(Lo et al. 1999a) Quantitative analysis shows an increase with 
gestation.(Lo et al. 1998) More relevant to the subject matter of this thesis is data
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from the same group indicating a similar rise (Lo et al. 1998; Lo et al. 1999b) in the 
circulating fetal DNA in preeclamptic pregnancies. This study used gestation- 
matched groups of preeclamptic and non-hypertensive women (32 and 33 weeks 
mean respectively) with investigator blinding for analysis, once again by real time 
PCR.
d) First trimester Biochemical Markers
Leptin, a circulating hormone produced by adipose tissue in the non-pregnant state, 
may be raised in preeclampsia. It was shown in a group of preeclamptic women in 
the third trimester that maternal plasma leptin levels were raised in comparison to 
controls matched for BMI and fetal gestational age (McCarthy et al. 1999). At the 
same time, there was a correlation in the preeclamptic cases between maternal and 
cord levels of Leptin. Unfortunately the cord bloods were mixed arterial and venous 
samples. It is possible that Leptin may be a significant factor in preeclamptic 
metabolism. See also Chapter 1.3.5 regarding leptin.
e) Immunological Markers
1. Interleukin-2 (IL-2)
A small prospective study of non-matched preeclamptic and normal 
pregnant controls indicated raised IL-2 activity in peripheral blood 
mononuclear cells (Chen et al. 1995). The group suggested that IL-2 
may play a role in induce reactive oxygen species in preeclampsia. More 
recently, it was shown by a separate group that elevated IL-2 receptor 
levels were present in the first trimester in women who subsequently 
developed preeclampsia (Eneroth et al. 1998). This particular study was 
small (10 preeclamptic and 10 normal controls matched for age and 
parity).
2. Interleukin-6 (IL-6)
IL-6 was initially thought to be decreased in the amniotic fluid of 
preeclamptic pregnancies (Silver et al. 1993). Other authors have 
subsequently shown that the opposite may be true (Nakabayashi et al. 
1998). Neither the source nor the function of amniotic fluid IL-6 is 
known, though Silver et al suggest increased levels observed in preterm 
delivery may be due to an infective process.
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0  Other Candidates -  More Factors Altered in Preeclampsia:
It has been demonstrated that magnesium levels rise with gestation in normal 
pregnancy but that total magnesium levels decrease early in preeclamptic 
pregnancies relative to the normal range (Standley et al. 1997). The authors 
comment that previously this has been related to the development of insulin 
resistance. Other altered factors include increased intra-cellular calcium levels 
(Haller et al. 1989), a low urinary kallikrein : creatinine ratio (Millar et al. 1996) and 
urinary N-acetyl glucosamine.
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1.5 Summary and the Aim of this Thesis
Preeclampsia is a common and well-recognised complication of human pregnancy. 
It remains one of the main causes of maternal and fetal mortality and morbidity 
despite continued and widespread research. The cause remains an enigma although 
recent advances indicate that we are getting closer to an answer. It is unique in that it 
only occurs in human gestation. It is a multi-system disorder that affects endothelial 
membranes and appears to originate from the placenta. Many theories exist as to the 
cause of preeclampsia, from immunological through genetic. No treatment exists, 
save the delivery of the fetus and placenta. Great potential clinical benefit seems 
likely if a diagnostic test and, subsequently, a treatment can be provided.
The nature of IPGs and their involvement (actual and theorised) in several 
pathologies has been described above. Previously published work has indicated a 
potential link between preeclampsia and Inositol Phosphoglycans. The aim of this 
project was to further clarify the role of IPGs in specific relation to normal and 
preeclamptic pregnancy and labour. It was hoped that the work would cast further 
light on the role of IPGs in the pathophysiology of preeclampsia. In the future this 
may lead to a diagnostic test and potential treatment for the condition. Over the time 
of the project, specific clinical studies have been carried out with this in mind (Table 
1. 12)
At present there is no single diagnostic test for preeclampsia that can be used in a 
clinical setting. Early risk assessment has been proposed to identify women at high- 
risk of morbidity using a combination of clinical features and/or standard lab assays 
(urate, creatinine, proteinuria and liver enzymes) (Martin, Jr. et al. 1999; Chappell et 
al. 2002).
1.5.1 Preeclampsia
The aim was to further reveal the role of P-Type IPGs in the pathophysiology and 
pathogenesis of the disease process. This involved both a longitudinal and a cross- 
sectional study looking at women both before and after the onset of the clinical 
symptoms. Assessment was with a polyclonal-based ELISA assay, and also
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previously validated extraction and bioactivity assays. Specimens collected were 
urine, cord blood, amniotic fluid, placenta and maternal blood from the peripheral 
circulation and also from the uterine vein.
1.5.2 Labour
The aim was to formally establish any change in urinary IPG-P levels in non- 
preeclamptic subjects before and after the onset of labour. This involved a 
prospective study of non-preeclamptic subjects recruited in the third trimester of 
pregnancy and followed to the time of delivery. Urine samples and clinical data 
were collected at recruitment and in labour. Assessment of samples was with a 
polyclonal-based ELISA assay.
Table 1. 12. Summary of Clinical Studies
Title Aim
The role o f IPGs in Preeclampsia Longitudinal study to detect early 
pregnancy changes in urinary IPGs in 
subsequently preeclamptic women.
The Presence o f IPGs in Normal To detect any increase in urinary IPG
Labour levels in normal labour in the absence 
of raised blood pressure
The Presence o f IPGs in To ascertain levels if IPGs in various
Preeclamptic tissue body fluids in known preeclamptics at 
caesarean section
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Chapter 2
Laboratory Methods
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2.1 Urine Samples
Polyclonal-Based Enzyme-Linked Immunosorbent Assay (ELISA) 
for detection of IPG-P
2.1.1 Development of the ELISA
The Polyclonal serum used for the ELISA was developed by Rodaris 
Pharmaceuticals Ltd, Oxford, UK and kindly donated for the purposes of this 
research. IPG-P was prepared from 150ml of urine from a single preeclamptic 
woman. This was dissolved in 500ml of water, to form a stock solution. 75pl of this 
stock was mixed with 175pl water and 750pl Freund’s Complete Adjuvant (FCA). 
Two rabbits received a l ml inoculation each in 5 sites.
Boosts (stock solution in Freund’s Incomplete Adjuvant) were given on days 30 and 
62 with 75% of antigen used in the initial immunisation (Figure 2.1). 
Exsanguination was carried out on day 70. Pre- and test bleeds were screened 
against human placental IPG-P extract. No data were provided on the purity of this 
extract but unpublished data from Rodaris indicated no correlation of the ELISA 
positivity with urine protein content. Sera from rabbits inoculated with FCA alone 
showed no reactivity.
Figure 2. 1. Screening of Sera against IPG-P*
2 0
■ m —  Rabbit 1 
Rabbit 2 Plac-P IPG 
BlockRM 
Rb sera 1/500 
Anti Rb IgG 
TMB
Boost
Boost
Immunise
o.o
7020 30
Day post immunisation
40 60
*Data from Rodaris validation document
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Data From Rodaris Product Profile
The polyclonal was evaluated with a total of 32 urines-16 patients with severe pre­
eclampsia and 16 gestation-matched controls. The data with this kit show 100% 
(16/16) specificity and 100% sensitivity (16/16) with clear separation between 
patients and controls (Figure 2.2). A capture ELISA, using the polyclonal rabbit anti 
IPG-P showed significant difference between preeclamptic and normal pregnant 
controls (Figure 2.3).
Figure 2. 2. ELISA assay of 16 matched pairs of urines.
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Figure 2. 3. Capture ELISA Normal and Preeclamptic Women (displayed as 
a percentage of a positive control*)
Assay of 27 PET and 47 pregnant controls
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* Polyclonal-based ELISA for IPG-P raised from the urine of a preeclamptic 
woman. Data from Rodaris validation document
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A serial dilution of one of the positive pre-eclamptic urines with the polyclonal 
serum showed that IPG could still be detected at a 5,000-fold dilution (Figure 2.4). 
This indicates that positive samples can still be detected at high dilutions.
Figure 2.4. Serial dilution of representative pre-eclamptic urine with 
prototype ELISA kit. Data from Rodaris Pharmaceuticals Ltd.
o(/>X
<  0.5 -
0.0
100010 100
Urine dilution factor
2.1.2 Application of the ELISA -  ELISA Protocol Used 
Materials
Nunc Maxisorb® ELISA plates purchased from Fisher Scientific Ltd (Loughborough, 
UK). Hydrolysed gelatine, phosphate buffered saline (PBS) tablets, 3,3’, 5-5’- 
Tetramethyl-Benzidine (TMB) and Polyoxyethylene-Sorbitan Monolaurate (Tween 
20) purchased from Sigma (Poole, Dorset, UK). Goat anti-rabbit IgG Horseradish 
Peroxidase (HRPO) conjugate purchased from Harlan Sera-Lab (Loughborough, 
UK). Rabbit IgG anti-IPG-P polyclonal serum kindly donated by Rodaris 
Pharmaceuticals (Oxford, UK). Hydrochloric acid purchased from BDH Laboratory 
supplies (Poole, Dorset, UK).
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Protocol
Urine samples to be tested were defrosted immediately prior to assay. 1% gelatin 
solution was used as the capture and also the blocking agent. A solution of 1% 
hydrolysed gelatine in phosphate buffered saline (PBS) was made. A Maxisorb plate 
was blocked with 200pl of the blocking reagent in each plate well. The plate was 
stored in a sealed plastic container lined with a damp tissue to maintain humidity and 
incubated at 37°C for 20 min.
Blocking reagent was flicked out and the plate was blotted dry on tissue paper. 
Urine For each patient sample, two solutions were made:
1. ‘Non-heated’ - a 2pl aliquot of the sample was diluted to 1 in 100 by 
adding urine to 198pl blocking solution.
2. ‘Heated’ - A 200pl aliquot was heated in a water bath at 85°C for 5 
minutes. 2pl aliquot of this was then also diluted to 1 in 100 by adding 
198pl blocking solution.
Samples were assayed on the ELISA plate in triplicate (50pl in each of 3 plate 
wells). A plate blank of blocking solution and a positive control urine sample (from 
the same preeclamptic woman for all the plates) at 1 in 5000 dilution (in blocker) 
were also assayed in triplicate on each plate. The plate with the diluted urine samples 
was incubated for 40 min at 37°C. After the incubation, the liquid was flicked out. 
The plate was washed 3 times with 0.05% PBS/Tween 20 solution and was blotted 
dry on tissue paper. Figure 2.5 illustrates a sample plate template.
Polyclonal rabbit IgG anti-IPG was diluted 1/10,000 in blocking solution (by adding 
lp l of polyclonal to 10ml of the 1% gelatine/PBS). 50pl of this polyclonal solution 
is then added per well and incubated at 37°C for 30 min. Once again, the plate was 
washed 3 times with 0.05% PBS/Tween 20 solution and was blotted dry on tissue 
paper.
Goat anti-rabbit IgG-HRPO was diluted 1/6000 as for the polyclonal above. 50pl of 
this solution was added to each plate well and the plate was incubated at 37°C for 20 
min. The plate was washed 5 times with 0.05% PBS/Tween 20 solution and was 
blotted dry on tissue paper. TMB solution was pre-warmed to room temperature and
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50fj.l of this was then added to each well. This was incubated at room temperature 
for 10 minutes.
The colour reaction was stopped with the addition of 50pl of 1M HC1 per well. This 
resulted in a blue to yellow colour change, additionally increased the sensitivity of 
the plate reading. Any bubbles in the wells were burst with a fine needle and the base 
of the plate was wiped with a dry tissue. Absorbance was read at 450nm using a 
standard ELISA plate reader ThermoMax Optical Plate Reader (Molecular Devices, 
Wokingham, UK). See Fig 2.6 (b) for image of sample ELISA plate prior to plate 
reading
Figure 2. 5. Sample ELISA Plate Template 
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Figure 2. 6. ELISA plates (a) after incubation with TMB, (b) after addition of HCL 
and (c) in situ on plate reader.
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2.1.3 Standardisation and error minimisation for the ELISA assay.
1. I assayed all the ELISA plates myself using the same lab equipment.
2. The positive control urine sample used was the same for all ELISA plates.
3. Results were recorded as the optical density at 450nm (OD450) with the 
mean for the plate blank subtracted. The results were then expressed as a 
percentage of the positive control for the plate. See below for an example 
of this.
4. All samples were assayed in triplicate
2.1.4 Example of ELISA Data and Formatting
Sample Mean OD SD Well OD
Plate Blank 0 .0981 0.003 B2 0.101
B3 0.095
B4 0.099
Plate Positive Control 0 .4402 0.034 B5 0.453
B6 0.402
B7 0.466
254 0.154 0.013 C2 0.141
C3 0.166
C4 0.155
255 0.796 0.041 C5 0.841
C6 0.759
C7 0.789
Subtract the plate blank mean value (1 above) from all mean OD values, including 
the plate positive control. The result for each sample mean is expressed as a 
percentage of the plate positive control mean (2 above). A cut-off of 80% or greater 
has been defined as a ‘positive’ result according to the Rodaris validation document.
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E.g.
For sample 254
Sample mean 0.154 -- x
Subtract plate blank mean 0.098 -- b
0.056
Express this figure as a percentage of the mean plate positive control (after 
also subtracting the blank from this value) — z
0.056 (0.440-0.098)%
= 16% i.e. A ‘Negative’ Result
For sample 255
Sample mean 0.796
Subtract plate blank mean 0.098
0.698
Express this figure as a percentage of the plate positive control (after also 
subtracting the blank)
0.698 -  (0.440-0.098)%
= 204% i.e. A ‘Positive’ Result
To summarise, the formula for calculating the results is:
r —
X - b
R =
L c -
x  1 0 0 %
Where R is the final result for a given urine sample
x is the mean from triplicate wells for the sample
b is the mean of the plate blank wells
c is the mean of the positive control wells
This method of expressing the data will be used for all the clinical studies on the 
following chapters.
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2.1.5 Standardising Urine Samples
Creatinine Correction and Creatinine Assay
The standard correction/standardisation for 24-hour urine collection is the creatinine 
content of the sample. Creatinine is a nitrogenous waste product and 24-hour 
production is proportional to body 
muscle mass. The molecular mass is 
113.1 (Figure 2.7).
It was possible to use this as an 
independent correction factor for the 
samples as the Coomassie Blue 
protein stain does not pick up 
creatinine in the samples due to the 
lack of free amino groups on the 
molecule.
Samples were therefore assayed for creatinine content using a standard lab assay 
(Roche Integra) at the Chemical Pathology Department, University College London 
Hospitals NHS Trust (Windeyer Building). All samples were anonymised prior to 
hospital lab analysis.
Protein Assay
Samples were assayed by using Bio-Rad Protein Assay (purchased from Bio-Rad 
Laboratories Ltd, Hemel Hempstead, UK), which is based on the shift in the 
absorbance maximum for Coomassie Brilliant Blue G-250 from 465nm to 595nm 
when binding to protein (stoichiometrically, based on charged groups, for most 
proteins and polypeptides with MW >5000).
An Albumin Standard solution of an initial 2mg/ml was used (purchased from Micro 
BCA Protein Assay Reagent Kit, Perbio Science UK, Tattenhall, Cheshire, UK) to
HN =C/
Figure 2. 7. Creatinine
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make the required dilutions for the standard curve. Dilutions of 1, 5, 10, 15, 20 and 
25 pg/ml were made and 1ml aliquots of each dilution were stored at -20°C until use. 
Urine samples were defrosted and assayed at a 1 in 10 dilution to read in the linear 
portion of the absorbency spectrum. 80 pi of urine sample, 720 pi of distilled H20 
and 200 pi (1ml total volume) of the Protein Assay solution were well mixed in 
Eppendorf tubes. 100 pi of this solution was pipetted in triplicate into the ELISA 
plate wells. Each plate was assayed with triplicate blank wells (H2O and Protein 
Assay Solution only) and each of the dilutions for the standard curve plus 25 urine 
samples. The plates were read on the same ELISA plate reader as for the urine 
ELISAs at absorbencies of 565 and 650nm (due to limitations of the reader).
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2.2 Serum Samples
2.2.1 Collection and Processing of Blood Samples
Blood samples were collected from preeclamptic and normal women recruited at 
King Edward VIII Hospital, Durban, South Africa (Chapter 6 , IPGs in Established 
Preeclampsia). Local Research Ethics Committee approval had been given for the 
study. As described in chapter 6, the samples were from 
1 .Peripheral (antecubital) vein
2 .Uterine broad ligament vein
3.Umbilical artery
4.Umbilical vein
Blood samples were taken by syringe using a 21G (green) needle and transferred to 
plain Vacutainer tubes (Beckton-Dickinson, Oxford, England) and processed within 
3 hours of sampling time. Samples were spun in an Eppendorf 5804R centrifuge 
(Eppendorf, Hamburg, Germany) for 5 minutes at 5000rpm («4200g) at room 
temperature. Serum was then stored at -20°C at the King Edward VII Hospital until 
transport to the UK.
2.2.2 Transport of Samples
Sample tubes were taken on dry ice via overnight air flight and delivered to 
University College London. Total transit time was 24 hours and samples remained at 
or below -20°C at all times. Samples then remained frozen at University College 
London until analysis.
2.2.3 IPG Extraction Protocol
The method for the IPG extraction has been adapted from Shashkin et al (Shashkin et 
al. 1997), as originally described by Lamer, (Lamer et al. 1988), Asplin (Asplin et al. 
1993) and others, originally from the method of Cheng et al (Cheng et al 1984). In 
summary, the method uses separation of the IPG fractions from human serum using 
anion (Cheng et al 1984) exchange columns and elution with HC1.
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2.2.4 Anion Exchange Resin
The basis of the extraction is an anion exchange resin. The AG (analytical grade) 
resin is a strongly basic anion exchanger. It is capable of exchanging anions of 
acidic, basic and neutral salts on the basic side if its pi. The formate form of the 
resin is used in the extraction. Relative selectivities of the AG 1 resin are shown in 
Table 1.
Table 2 .1 . Relative Selectivity of Various Counterions*
Counterion Relative Selectivity
OH' TO
c r  22.0
HP04' 5.0
Formate 4.6
*From Product Information, supplied by Bio-Rad
The separation relies on the phosphate groups on the IPGs to be attracted to the resin. 
It can then be eluted off by use of increasing concentrations of Cf in hydrochloric 
acid.
2.2.5 Materials
Formic Acid and Hydrochloric Acid were purchased from BDH Laboratory supplies 
(Poole, Dorset, UK). 2-mercaptoethanol, Ethylenediamine Tetraacetic Acid (EDTA, 
Tetrasodium Salt), charcoal and ammonia solution were purchased from Sigma 
(Poole, Dorset, UK). Anion exchange resin (AG 1-X8, hydroxide form) and 
Polyprep chromatography columns were purchased from Bio-Rad Laboratories 
(Hemel Hempstead, UK). Nalgene® Polycarbonate centrifuge tubes were purchased 
from Nalge Company (Rochester, New York, USA).
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2.2.6 Conversion of Resin
The AG1-X8 resin in hydroxide form was converted to the formate form. This was 
achieved by passing 2N Formic acid through the resin column to a pH of 2.0. 
Distilled water was then passed through the column until a pH of 4.0 was achieved.
2.2.7 Extraction Process
lml serum was mixed with 3 ml extraction solution (Formic Acid 50 mmol/1, 2- 
mercaptoethanol 1 mmol/1, EDTA 1 mmol/1 (final concentrations). The samples were 
heated at 100°C for 5 min in an oven and then cooled on ice. Following this, 20mg 
of charcoal was added to each sample. After 10 minutes the samples were 
centrifuged at 40000 x g for 30 minutes. (Beckman UltraCentrifuge, Model J2-21, 
18,000 rpm, rotor type JA20).
The supernatants were neutralised with NH4OH to pH6.0 and centrifugation repeated 
for a further 30 minutes. Anion exchange resin (formate form, 1.6ml) was added to 
each supernatant. The slurry was kept on ice in a fridge cabinet for approximately 
20h with agitation. Each sample was then poured into a PolyPrep column.
Stepwise elution was then carried out with 3 bed volumes (i.e.4.8ml) of distilled 
water, 5 bed volumes (8ml) of HC1 pH 2.0 (10 mmol/1) -  (Eluate A) and 5 bed 
volumes (8ml) of HC1 pH 1.3 (50 mmol/1) (Eluate B). Eluate A was neutralised with 
NH4OH to pH4.0.
Both eluates A & B were frozen with liquid nitrogen and lyophilised, reconstituted 
with 500pl distilled H2O and re-lyophilised in Eppendorf tubes. Extracts were then 
frozen at -20°C until time of the bioassay. At the time of the bioassay, samples were 
reconstituted as described below.
After the extraction of a proportion of the samples, it was decided to reduce the 
extraction volume by half due to the small quantity of some of the available samples. 
Thus, for these samples, 0.5ml serum was mixed with 1.5 ml extraction solution and 
the samples were heated at 100°C for 5 min in an oven and then cooled on ice. 
Following this, lOmg of charcoal was added to each sample. Centrifugation and 
neutralisation were the same, but only 0 .8ml of the anion exchange resin was added. 
Similarly, on day 2 of the extraction, in the columns stepwise elution was carried out
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with 3 bed volumes (i.e.2.4ml) of distilled water, 5 bed volumes (4ml) of HC1 pH 2.0 
(10 mmol/1) -  (Eluate A) and 5 bed volumes (4ml) of HC1 pH 1.3 (50 mmol/1) 
(Eluate B). Eluate A was again neutralised with NH4OH to pH4.0.
Freezing and lyophilisation were as above.
A. pH 2.0 fraction activates PDH phosphatase = pH 2.0 IPG-P N crossover
Amniotic fluid samples were collected at caesarean section from preeclamptic and 
normal women recruited at King Edward VIII Hospital, Durban, South Africa (see 
Chapter 6 , IPGs in Established Preeclampsia). 5ml samples were collected as 
detailed in the study protocol with a syringe and frozen within 3 hours of collection. 
Transport of the samples was as for serum and assay with the ELISA was performed 
as for the urine samples.
The extraction procedure as described here, using heat denaturation and charcoal 
treatment at acid pH, followed by anion-exchange column chromatography and acid 
elution was first described in 1988 (Lamer et al. 1988), from the method of Cheng 
and colleagues (Cheng et al 1984). It is based on heat denaturation of protein, 
charcoal adsorption of nucleotides and anion exchange resin chromatography, 
yielding both fractions of IPG separately.
This extraction method has been used by Caro et al (Caro et al. 1997) to characterise 
the different IPG fractions. In this paper, the pH2.0 fraction from the extraction was 
shown to stimulate PDH phosphatase and the pH 1.3 fraction stimulated lipogenesis. 
There was no cross-over reactivity shown (Caro et al. 1997). In the same work, 
human liver-extracted IPG A and P type were shown to be structurally different and 
to have distinct insulin-like effects.
B. pH 1.3 fraction inhibits PKA = pH 1.3 IPG-A
No crossover 
activity seen
2.3 Amniotic Fluid Samples
2.4 Validation of Extraction Procedure
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2.5 IPG Bioassay
2.5.1 IPG-P
The bioassay of the IPG-P type fraction involves the activation of Pyruvate 
Dehydrogenase complex (PDC), as first described in 1992 (Lilley et al. 1992) and 
subsequently applied by Caro et al (Caro et al. 1997). The method described is 
similar to that described by Caro et al, modified to allow multiple simultaneous 
assays to be read in a multiwell plate reader.
The PDC and the Pyruvate Dehydrogenase (PDH) phosphatase were kindly donated 
by Dr S Kunjara (Rodaris Pharmaceuticals, Oxford, UK) having been prepared as 
described (Lilley et al. 1992) and stored at -80°C until use. The assay for the PDH 
phosphatase, in the presence or absence of insulin mediator, was based upon the 
initial rate of the activation of the inactivated phosphorylated PDH complex.
The initial activity of the PDC was 25 units/ml (where 1 unit of enzyme produces 
lpmol NADH/min). After inactivation with ATP, this value was reduced to 1% of 
the total activity.
A two-stage assay was used to quantitate the phosphatase activity. All samples were 
assayed blind and in duplicate on adjacent plate wells. Standards and water blanks 
were used on each plate.
A sample of inactivated PDC was pre-incubated at 30°C with 1 mg/ml fat-free bovine 
serum albumin (BSA) containing 10 mM MgCk, 0.1 mM CaCh, 1 mM dithiothreitol 
and 20 mM potassium phosphate buffer, pH 7.0 for 3 min.
At this time, IPG-P extracts were reconstituted in 24 pi distilled H2O to form stock 
solutions. 2 pi of each solution (equivalent to 83pi of serum) was added to the centre 
of a 96-well plate (Nunc Maxisorb® ELISA plate, Fisher Scientific Ltd 
Loughborough, UK). 25 pi of the PDC mixture was then added to each well. The 
reaction was initiated by the addition of 2 pi of PDH phosphatase and incubated for 
3mins. At the end of this time 14 pi of chilled 0.3M NaF was added to each well to 
stop the reaction.
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The activated PDH was determined at the second stage spectrophotometrically by 
measuring the rate of production of NADH. 200 pi of reaction mixture containing 
50 mM potassium phosphate buffer at pH 8.0, 2.5 mM of the oxidised form of 
NAD+, 0.2 mM thiamine pyrophosphate (TPP) 0.13 mM coenzyme A, and 0.32 mM 
dithiothreitol was added. This was followed by 20 pi 2 mM sodium pyruvate for 
each plate. The production of NADH was followed using an absorbance at 340 nm 
for 7 minutes. One unit of IPG PDH activity is the amount required to increase the 
basal rate by 50%.
2.5.2 IPG-A
Due to time constraints the IPG-A activity was not carried out at this time.
2.6 Validation of IPG-P Bioassay Procedure
The assay of IPG-P activation of the pyruvate dehydrogenase complex has been 
established for a number of years as referenced above. The Pyruvate Dehydrogenase 
(PDH) complex is a mitochondrial multi-enzyme complex with 3 active site regions, 
which converts pyruvate to Acetyl-CoA and as such is key in glucose metabolism. 
Multiple factors affect its activity through kinase (inactivating) and phosphatase 
(activating) enzymes, which may be tissue-specific. It has been shown that IPG-P 
stimulates PDH phosphatase in certain tissues (Gottschalk and Jarett 1988; Macaulay 
and Larkins 1990) and thus this has been used as a measure of IPG-P activity. Figure
2.8 illustrates the role of IPG-P in modulation of the PDH complex.
Although not commercially prepared, the PDC preparation was standardized as 
described in Chapter 2.5.1 above so initial activity of the preparation was always 
identical.
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Figure 2. 8. Control of the pyruvate dehydrogenase (PDH) complex. IPG-P binds 
and lowers Ca2+ binding coefficient (KD), leading to increased Ca2+ binding which 
activates the phosphatase enzyme. NB kinases and phosphatases seem to be tissue- 
specific
2.7 Western Blot
The Western Blot of 4 urine samples was carried out at the end of the research period 
to determine what protein fractions might be being detected by the polyclonal serum 
used in the ELISA assays of the urine samples. It was decided that this might shed 
some light on the quality of the preparation used in the inoculation of the rabbits in 
the preparation of the polyclonal serum. This is discussed more fully in Chapter 7.
2.7.1 Selection of Urine Samples
Due to limitations of equipment available at the time of the experiment (the number 
of lanes that could be created with the comb for the gel) 4 urine samples could be 
assayed. I randomly selected two urine samples from women with non-hypertensive 
pregnancy outcome (the subject identities of which were not known to me at the 
time), one with a positive ELISA result, and one negative. One sample was selected 
from a woman with clinically diagnosed preeclampsia and one sample from a subject 
with hypertension but no proteinuria on dipstick. All samples had previously been
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assayed using the ELISA assay and protein assay as described above. The samples 
and results of these two assays are summarised in table 2.2 below:
Table 2. 2. Samples selected for Western Blot
Sample Unique Clinical ELISA Protein Assay
Number Pregnancy
Outcome
Result (pg/ml at OD 
565)
321 Preeclampsia 313 630
© 432
Non-proteinuric
hypertension 212 82
© 262 Normal 208 367
0 264 Normal 14 228
2.7.2 Preparation of Urine Samples
For the purposes of the Western Blot, it is ideal to have each urine sample with a 
similar quantity of protein at the time of the experiment. The ideal value is 25-50 pg 
protein in 50 pi of sample. Thus aliquots of each urine sample were spun in 
10,000MW Vivaspin concentrator tubes (Purchased from Vivascience AG, Hanover, 
Germany) at 3000rpm in a Sorvall RT7 Centrifuge for 5 -  15 minutes until the 
correct volume (50 pi) was reached. The aliquots were removed and an equal 
volume of loading buffer (Laemmli -  Sigma, Poole, Dorset, UK) to each one. The 
100 pi samples were then frozen at -20°C for 48 hours until the rest of the 
experiment.
At the time of the experiment, the samples were defrosted and heated at 100°C with 
the added buffer for 3 minutes.
2.7.3 Gel Polymerisation
The gel was prepared with the Protogel System (Purchased from National 
Diagnostics, Atlanta, Georgia, USA). The following reagents were mixed to make 
100ml of gel: Protogel (26.7ml) Protogel Buffer (26.0ml) deionised H2O (46.2ml), 
Tetramethyl-Ethylene Diamine (TEMED, Purchased from Sigma, Poole, Dorset, 
UK) (100 pi) and Ammonium Persulphate (1ml). The gel was injected between the 
spaced glass plates and overlaid with isobutanol to facilitate polymerisation. The 
overlay was poured off and the stacking gel prepared in a similar way.
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The following reagents were mixed to make 20ml of the stacking gel: Protogel 
(2.6ml), Protogel Stacking Buffer (5.0ml), deionised H2 O (12.2ml), TEMED (20 pi), 
Ammonium Persulphate (0.1ml). The Teflon comb was inserted into the stacking gel 
and it was allowed to set. After setting, the comb was removed and the wells washed 
with buffer to remove unpolymerised acrylamide.
The two times four 100 pi samples loaded, along with a protein standard mixture for 
molecular weights 30,000-200,000 (Sigma, Poole, Dorset, UK) as shown below:
Figure 2. 9. Western Gel Set-up
©
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2.7.4 Electrophoresis
The electrophoresis apparatus was assembled and attached to power supply at 100V 
(8 V/cm). After running the gel for 90 minutes, this was increased to 200V (15 
V/cm) and run until the bromophenol reached the bottom of the gel. When the glass 
plates had been removed, the gel was divided along the dotted line depicted in Figure
2.9 above.
2.7.5 Staining and Destaining of Gel
Side ‘A’ of the gel was stained with Coomassie brilliant Blue (0.25g) in 100 ml 
Methanol: H2 O: Acetic Acid mixture (proportions of 45:45:10 respectively) 
overnight at room temperature on an agitator plate. Destaining in the above solution 
without the dye was carried out the next day and the gel was dried with a vacuum 
drier.
©
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2.7.6 Electro-blotting of Gel
The electro-transfer apparatus 
was set up as in Figure 2.10, 
using a Hybond® ECL nitro­
cellulose membrane (Purchased 
from Amersham Biosciences) 
and run overnight (with on a 
stirrer plate) at 4°C at 120 mA 
current.
Figure 2.10. Electro-transfer apparatus
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2.7.7 ECL Western Blot
This was carried out after electro-transfer, using the standard protocol for the ECL 
Western Blotting Detection System (Amersham Biosciences, Little Chalfont, 
Buckinghamshire, UK).
Membrane Blocking
The membrane was removed from the electrophoresis apparatus and blocked with 
100 ml 5% non-fat dried milk, 0.1% (w/v) PBS Tween for 1 hour and then rinsed 
twice in PBS-Tween wash buffer.
Primary Antibody Incubation
The membrane was incubated in 1:6000 dilution of the IPG-P polyclonal serum 
(Rodaris Pharmaceuticals, Oxford, UK) for 1 hour at room temperature and rinsed 
with the wash buffer.
Secondary Antibody Incubation
The membrane was incubated with goat anti-rabbit HRP conjugate (Harlan Sera-Lab, 
Loughborough, UK), diluted 1 in 2000, for 1 hour at room temperature and rinsed for 
a third time in the wash buffer.
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2.7.8 Detection
Detection was with the ECL + Plus Western Blotting Detection System (Purchased 
from Amersham Biosciences). The membrane was used to expose radiograph film.
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Chapter 3
Urinary IPG-P in Normal Pregnancy
3.1 Introduction
At this point in time, no prospective data exist on the levels of IPG in normal 
pregnancy. Kunjara et al have used a PDH activation bioassay to show increased 
levels of IPG-P in preeclamptic urine (Kunjara et al. 2000a). This study looked at 
24-hour urine samples from only a small number of women (four). However, whilst 
this could be viewed as a current gold standard, in an outpatient clinic setting the 24- 
hour urine collection is not practical.
Furthermore at the commencement of this research project, no data was available on 
the clinical utility of the polyclonal-based ELISA assay, which had potential (on the 
basis of data provided by the company) to be a useful test in the diagnosis of 
preeclampsia. Thus it was decided not to use the bioassay for our urine samples for 
this prospective study, as the aim was to assess the clinical utility of the ELISA. 
Potentially it could become a simple bedside or outpatient clinic test and this 
prospective data would help to establish the future feasibility of this. Serial data 
from normal pregnancies was also lacking. Thus the aim of this portion of the 
research was to establish whether the ELISA assay could be used to:
• Establish a normal set of values for the ELISA over the course of normal 
pregnancy.
• Diagnose and/or predict preeclampsia in a group of subjects with Tow-risk’ 
pregnancies -  i.e. with no known pre-existing risk factors for preeclampsia 
(outlined in Chapter 1).
The study was set up with these two aims in mind. The standard protocol for the 
ELISA assay to be used in the study and supplied by Rodaris Pharmaceuticals has 
been discussed in Chapter 2.
Ideally, the data gathered would be for a group of Tow-risk’ women from early in 
pregnancy, through to term (greater than 37 completed weeks of gestation from the 
last menstrual period).
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3.2 Setting up the Longitudinal Studies
3.2.1 Aim
The aim of the longitudinal study was to collect pilot data by following a group of 
women from pre- or early pregnancy to collect serial urine samples for analysis with 
a novel ELISA assay for P-type inositol phosphoglycans. Subsequently, this data 
would be used to establish the profile of urinary IPG-P in women with a normal 
pregnancy. These data have never previously been established. It was planned to 
recruit as large a number as possible of women in the time available who might 
subsequently develop preeclampsia.
3.2.2 Recruitment Considerations
Due to the presence of only one investigator (myself) to carry out recruitment and 
follow-up of subjects as well as all the laboratory assays of the urine samples, it was 
decided to restrict recruitment to one site (University College London Hospitals NHS 
Trust). As this project was collecting pilot data, a formal power calculation was not 
performed as it was instead decided to try to recruit as many subjects as time and 
manpower would allow.
3.2.3 Chronology
Initially, the study was set up to allow recruitment from two areas. Firstly, pre­
pregnancy subjects from the Assisted Conception Unit (ACU) at University College 
London Hospitals NHS Trust (Group A) and secondly a control group form the Early 
Pregnancy Unit at the hospital (Group B). These subjects were to be matched for 
age, parity, smoking habits, ethnicity and number of fetuses. The aim was to recruit 
100 women pre-pregnancy in group A. Allowing for a quoted fecundity rate of 30%, 
this would yield 30 subject pregnancies to be followed. Correspondingly, 30 
subjects were then to be matched for group B. It was anticipated that a significant 
proportion of the ACU subjects would have multiple pregnancies.
Full Research Ethical Committee approval was given on 7th April 2000 to 
commence recruiting for the study.
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Unfortunately, it became clear as recruitment began that the numbers of subjects 
being recruited from the ACU would not achieve the planned targets. Additionally, 
it was noted that the time scale of the follow up was quite lengthy, following the 
initial recruitment.
For these two reasons, it was decided to table an amendment to the protocol 
(Amendment 1, 17th June 2000) to include recruitment of a ‘high risk’ group of 
women from two clinics at the hospital. A high-risk obstetrics clinic is run on the 
Tuesday a.m. and patients were to be recruited from here and also the multiple 
pregnancy ultrasound scanning clinic in the Fetal Medicine Unit. Inclusion criteria 
are outlined below in Table 3.1.
Table 3.1. Inclusion Criteria for High-Risk Subjects after Amendment 1.
Multiple pregnancy
Previous preeclampsia/eclampsia or IUGR*
Pre-existing Vascular pathology - 
Diabetes or Essential Hypertension 
Previous abruptio placentae 
Certain types of fertility treatment 
Sickle Cell Trait
Renal Disease**____________________________________________
■"Defined as fetal birthweight below 10th centile for gestation as per Chitty and colleagues 
(Chitty et al. 1994a; Chitty et al. 1994c; Chitty et al. 1994b)
♦♦Previous renal transplant or demonstrated renal impairment with serum creatinine 
>100mmol/l
The amendment was approved on July 19th 2000 and the new recruitment 
commenced on 5th September 2000.
Furthermore, it was apparent that recruitment from the Early Pregnancy Unit would 
be neither possible (due to the restricted space and time available) nor appropriate in 
some cases. Thus in order to boost numbers of normal, low risk subjects the location 
of recruitment was switched to the antenatal clinic setting, where subjects would first 
attend at between 10 and 13 weeks of gestation. Additionally, to maximise numbers, 
subjects were not matched at the recruitment stage and simply recruited as a cohort.
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3.3 The Study -  Setting and Methods
3.3.1 Setting
It was established that a broad range of data points was desirable, covering gestations 
from the first to the third trimesters for a number of women. The local hospital is 
University College London Hospitals NHS Trust. The Trust has a busy obstetric unit 
within the Elizabeth Garret Anderson and Obstetric Hospital with an antenatal clinic.
A link with the hospital had been previously established and the first step was to 
discuss with the Clinical Director about recruiting patients from the antenatal clinic. 
Basic approval was given at this point and a full ethical committee application was 
made.
3.3.2 Recruitment of Patients and Patient Numbers
I attended the antenatal clinic at the Elizabeth Garret Anderson and Obstetric 
Hospital. 40 ‘low risk’ women were recruited from the Monday a.m. clinic between 
November 2000 and September 2001. Low risk was defined as the absence of any 
inclusion criteria for the ‘high risk’ group for the other parts of the study (Table 3.2 
and Chapter 5, High Risk Subjects). The subjects were recruited at their booking 
visit and were both primigravidae and multigravidae.
Table 3.2. Exclusion Criteria for Low-Risk Subjects
Multiple pregnancy
Previous preeclampsia/eclampsia or IUGR*
Pre-existing Vascular pathology - 
Diabetes or Essential Hypertension 
Previous abruptio placentae 
Certain types of fertility treatment 
Sickle Cell Trait
Renal Disease**____________________________________________
♦Defined as fetal birthweight below 10th centile for gestation as per Chitty and colleagues 
(Chitty et al. 1994a; Chitty et al. 1994c; Chitty et al. 1994b)
♦♦Previous renal transplant or demonstrated renal impairment with serum creatinine 
>100mmol/l
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At recruitment, the study was discussed in full with the subjects and they were 
instructed to read the Patient Information Sheet (Appendix 2). After further 
discussion and if informed consent to participate was given, the subject was asked to 
sign a consent form (the same form was used for all the clinical studies) -  see 
Appendix 5.
The original aim at the time of submission of the study was to collect certain samples 
from all the subjects at the time of delivery (placenta, cord blood, uterine vein blood 
in the event of a caesarean section). It became clear as the study progressed that this 
would not be practical or desirable due to (a) limited freezer storage space and (b) 
lack of intent to analyse multiple blood or placental samples from non-preeclamptic 
women.
3.3.3 Collecting samples
The gold standard assay for protein analysis is currently the 24-hour urine collection. 
Although there is poor predictive value from urine dipstick testing, accuracy may be 
improved at higher thresholds (greater than 1+ proteinuria)(Waugh et al. 2004). For 
the purposes of the longitudinal study it was decided that dipstick testing was the 
most practical. A protein assay of each sample was carried out as defined in the 
Laboratory Methods (Chapter 2).
All patients were asked to provide a mid-stream urine sample (MSU) at the time of 
their clinic attendance. These samples were collected in MSU sample pots provided 
by the antenatal clinic solely for this purpose. I collected these samples after 
standard Albustix® (Bayer pic Diagnostics, Newbury, Berkshire, England) dipstick 
testing for protein, performed by the clinic staff or myself. Occasionally, if the initial 
sample provided was too small, or if the MSU sample needed to be sent for 
microbiological culture, the patient provided a second sample in an identical 
container.
3.3.4 Patient tracking and follow-up
Patients were anonymously logged in a record with details of initials and hospital 
number to allow tracking of future appointments via the hospital Patient Access 
System (PAS). A weekly check of the PAS system by myself for all the patients in
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the study established those attending for appointments. It was hoped at the outset 
that patients would be seen at routine times during their pregnancy as set out in the 
antenatal care plan. However, due to changes in hospital policy throughout the 
course of the study, subjects were often seen at variable and infrequent intervals in 
the antenatal clinic. At other times, the GP or Community Midwife saw subjects in a 
community setting.
3.3.5 Case report form completion
At the time of recruitment, basic demographic details were logged for each subject, 
including date of birth, medical and obstetric history, last menstrual period (and thus 
gestation) and expected date of delivery. At each subsequent visit where a urine 
sample was collected, a further sheet was filled out, with initials, date of birth and 
study number for identification purposes and also blood pressure (where taken) urine 
dipstick reading and any symptoms or signs of preeclampsia.
Following delivery I carried out a retrospective review of the case notes for each 
subject. I defined the hypertensive pregnancy outcome strictly by the previously 
described criteria (Tables 1.8 and 1.9). This did not necessarily agree with any 
clinically documented diagnosis in the notes. Accordingly then, a final data sheet 
was filled, with the details of the labour and delivery, and the outcome code as 
defined in the study protocol (Table 3.3 below).
Table 3. 3. Outcome Codes for Subjects
1. Preeclampsia (hypertension and proteinuria)
2. Pregnancy Induced Hypertension (PIH)(no proteinuria)
3. Preeclampsia superimposed on chronic hypertension
i.e. Hypertension present before 20 weeks of pregnancy
4. No hypertension
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3.3.6 Labelling, logging and Storage of samples
All samples were labelled with details as on the example of sample label details 
below.
Key to Label:
Date = Date of sample collection 
Study No. = Subjects were assigned a 
unique study number at the time of 
recruitment
Sample No. = nth sample for this 
subject
All samples were thus anonymous at this 
stage to preserve patient confidentiality. At the time the samples were brought for 
storage, a unique number was given to each one, allowing a sample log to be kept 
and ensuring that samples could be accurately identified and traced back to the 
source patient. 2ml aliquots of the samples were taken in apex tubes. These tubes 
were labelled solely with the unique sample number and thus were completely 
anonymised. This served a twofold purpose. Firstly, it added to the patient 
confidentiality and secondly, it provided operator blinding for the time the ELISA 
assay was carried out. The 2ml aliquots and remaining sample were frozen separately 
at -20°C within 4 hours of sample collection.
3.4 ELISA Assay
3.4.1 ELISA Protocol
This is described in some detail in Chapter 2, Laboratory Methods. The protocol 
does not need to be further discussed at this point save to say that the same operator 
assayed all samples (myself). Operator blinding was achieved by the method 
outlined in the paragraph above.
3.4.2 Result analysis
All samples were run in triplicate as discussed in Chapter 2, Lab Methods. The 
ELISA plate reader, reading at an optical density (OD) of 450nm expressed the 
ELISA results in the form of a mean and standard deviation of the mean (s.d.).
Initials  Study Number.
Date.............  Sample No. ..
Time of Collection.........
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3.4.3 Expression of Results
Results of the ELISA were expressed as a ratio of the plate positive control per mmol 
of creatinine (Units/mmol, where 1 Unit equals 1% of the plate positive control), as 
discussed in Chapter 2. For the subjects with serial labour samples, a single mean 
value was calculated to compare with the recruitment level for the same subject and 
paired t-test analysis was used to compare recruitment with labour samples using 
statistical software packages: Microcal Origin 5.0 (Microcal Software Inc., 
Northampton, MA, USA) and SPSS 11.5 (SPSS Inc., Chicago, IL, USA).
3.5 Results
40 low-risk women were recruited from the antenatal clinic in the ten months 
between 27th November 2000 and 3rd September 2001. 3 women were lost to 
follow up due to moving address and/or delivery at other centres. Clinical and 
demographic details for the subjects are summarised in Table 3.4 below. Mean age 
of the subjects was 32 years and mean BMI was 23.4. Median gestation at the time of 
recruitment (which was usually at the booking visit) was 11.9 weeks (range 9.1-19.6 
weeks).
Table 3. 4. Details for Recruitment Low-risk Subjects
Demographic
Mean (sd)
Age (y) 32 (±5.0)
BMI 23.4 (±3.5)
Ethnicity n (%)
Caucasian 39 (97.5)
Asian 1 (2.5)
Parity
Primiparous 29 (72.5)
Multiparous 11 (27.5)
BMI = Body Mass Index
4 (10%) of the women were smokers, 2 (5%) had a definite family history of 
preeclampsia in a first-degree relative (mother or sister). At the booking visit, mean 
blood pressure was 105 systolic over 65 diastolic (Mean Arterial Pressure, MAP = 
92).
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Delivery details for the 37 women followed through are summarised in table 3.5 
below. Median gestation of delivery was 40.9 weeks (range 37.1-42 weeks). A 
median of five urine samples was collected for each subject between recruitment and 
delivery. 62% (n=23) of the low-risk women laboured spontaneously and 46% (n = 
17) overall had a normal vaginal delivery, which was lower than expected. This may 
be due to small numbers but is in fact a higher vaginal delivery rate than for the high- 
risk groups (Table 5.7) and may in fact be a reflection on overall delivery 
demographics for an inner London teaching hospital. A further 21% had assisted 
vaginal delivery with the remainder delivering by elective or emergency caesarean 
section.
Table 3. 5. Details for Pregnancy, Labour and Delivery Low-risk Subjects
Pregnancy Median (Range)
Gestation at recruitment (weeks) 11.9 (9.1-19.6)
Gestation at delivery (weeks) 40.9 (37.1-42)
Samples per patient 5 (1-9)
Onset of Labour n (%)
Spontaneous 23 (62)
Induced 11 (30)
Caesarean Section 3 (8)
Delivery n (%)
Normal Vaginal 17 (46)
Assisted Vaginal
Ventouse 6 (16)
Forceps 2 (5)
Elective Caesarean Section 2 (5)
Emergency Caesarean Section 10 (28)
Primary outcomes for the subjects are summarised in Table 3.6 below and are based 
on the ISSHP classification as discussed in Chapter 1 (Brown et al. 2000). The 
overall preeclampsia rate for the low-risk women was 7.5% (n=3) with a further
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7.5% (n=3) developing non-proteinuric hypertension (Table 3.6). This is comparable 
with other studies regarding the population prevalence of the disorder.
Table 3. 6. Details of hypertensive outcome for low-risk subjects
n (%)
Preeclampsia (hypertension and proteinuria) 3 (7.5)
Pregnancy Induced Hypertension (no proteinuria) 3 (7.5)
Preeclampsia superimposed on chronic hypertension 0
No hypertension 31 (77.5)
Lost to Follow-up 3 (7.5)
3.5.1 Normal Range for ELISA assay results
ELISA results for all subjects with no hypertension in pregnancy are displayed in 
figures 3.1-3.3 below. Serial values are shown for each subject, grouped numerically 
by study number. There is a large range of ELISA signal seen for these subjects. The 
median number of samples per subject was 5 (range 1-9).
The pilot study design and resultant mix of single and serial samples from different 
study subjects does not make the creation of a true normal range possible. However, 
it is possible to take several messages from the individual plots below. Firstly, it can 
be seen that the majority of ELISA signal results from the samples lie below the 
nominal cut-off of 80% ppc (percent of the plate positive control) as established by 
the supplier of the ELISA protocol. Secondly however, it is noted that a certain 
number of ‘false positive’ ELISA results are seen at all gestations and for low- and 
high-risk subjects. Some can be possibly explained by the presence of a urine 
infection at the time of the sampling. For most of these false-positive results 
however, no obvious explanation exists.
A certain false positive rate is usually accepted with any screening test (often 5%) 
and with a serious condition such as preeclampsia this may be an acceptable 
consequence.
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Figure 3. 1. A-E Low-risk subjects. Individual serial ELISA-assay plots for all 
subjects with normotensive outcome, grouped by study number. ELISA values 
shown as a percentage of the plate positive control, as previously discussed. Dotted 
reference line shows cut off point for a ‘positive test’ (80% of plate positive control, 
ppc).
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Figure 3. 2. A-C High-risk subjects. Individual serial ELISA-assay plots for all 
subjects with normotensive outcome, grouped by study number. ELISA values 
shown as a percentage of the plate positive control, as previously discussed. Dotted 
reference line shows cut off point for a ‘positive test’ (80% of plate positive control, 
ppc).
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Figure 3. 3. A-C Multiple pregnancy subjects. Individual serial ELISA-assay plots 
for all subjects with normotensive outcome, grouped by study number. ELISA values 
shown as a percentage of the plate positive control, as previously discussed. Dotted 
reference line shows cut off point for a ‘positive test’ (80% of plate positive control, 
ppc).
co
O
00O
Q.
vPo'-
oo
_ i
LU
1200  
1 0 0 0  -  
8 0 0  -  
6 0 0  -
3 2 0  -  
2 8 0  -  
2 4 0  -  
200 
1 6 0  -  
1 2 0  -  
8 0  - - -  
4 0  -  
0
A - No R a i s e d  BP
■— T02 — T03  
—A— TD4 — TD5 
♦ — T06 — T08
1 0  20
Gestation (Weeks)
30
I
40
COO
</>o
CL
sP0s
<CO
_i
LU
B - No R a i s e d  BP7 0 0  -
6 0 0  -
5 0 0  J s
TQ9  — A —  T 1 0 
—▼— T 11 — + — T1 2 
— ♦ —  T 1 3  — X — T 1 5
3 2 0  -
2 8 0  -
2 4 0  -
2 0 0  -
1 6 0  -
1 2 0  -
80
4 0  -
0 5 10 15 20 25 30
Gestation (Weeks)
87
EL
ISA
 
% 
Po
s 
Co
nt
ro
l
360
C - No R a i s e d  BP
3 2 0  - — T16 T18 
T17 —▼— T20
2 8 0  -
2 4 0  -
2 0 0  -
1 6 0  -
1 2 0  -
8 0  -
4 0  -
10 150 5 20 25 3 0 3 5 4 0
Gestation (Weeks)
8 8
3.6 Conclusions/Discussion
This is the first collection of longitudinal data illustrating the use of this polyclonal- 
based ELISA in normal pregnancy for the detection of IPG-P. Corresponding in 
women subsequently developing hypertensive complications of pregnancy are shown 
in Chapter 5.
It is easy to see a certain number of false positive results for women with no 
subsequent preeclampsia. In some cases this can be explained by concurrent 
pathology affecting the composition of maternal urine -  such as a UTI (Figure 3.1 
B). Additionally, it can be seen in certain cases the rise in IPG-P ELISA signal at the 
time of labour (Chapter 3, Figure 3.3). This mirrors the data later seen in Chapter 4. 
Possible bias was introduced at recruitment due to lack of interpreter for some ethnic 
minority patients. Consequently, patients usually had English as their first language 
or else were fluent in English.
3.6.1 Practical Problems of Sample Collection
Ideally, urine samples would be collected for each subject at each visit during her 
pregnancy, whether in the community or at the hospital. However, certain conditions 
stipulated by Rodaris Pharmaceuticals for the collection of the samples made this 
impossible (or at the very least highly impractical and expensive for a single 
investigator). The urine samples had to be frozen at -20°C within 4 hours of 
collection and to remain frozen until analysis. This prevented the patients posting 
samples to the investigator if they were not attending the hospital and courier 
transport of the samples would have been prohibitively expensive.
Practically, this meant that I would have to attend each community appointment for 
each patient and physically transport the samples back immediately to be frozen. 
When following over 100 patients this was obviously not possible. In fact, I took 
this approach for part of the study and this will be discussed further in Chapter 5. 
Low-risk subjects often only attended the antenatal clinic for booking and in the last 
month of the pregnancy and due to the above limitations, sample collection was 
unfortunately often infrequent and irregular. This may have limited the value of the 
study and certainly complicates its analysis.
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Chapter 4
Urinary IPG-P in Labour and the 
Post-natal Period
90
4.1 Background & Introduction
The precise mechanism for the onset of labour remains obscure and in humans, 
unlike other species, its timing is quite variable (Slattery and Morrison 2002). Up to 
20% of women with a normal singleton pregnancy will not labour at term (40 weeks 
±2 weeks from date of last menstrual period) and in addition premature labour is a 
cause of a large percentage of maternal and neonatal morbidity and mortality 
(Slattery and Morrison 2002).
It is widely accepted that prostaglandins (PG) or other hormones such as oxytocin are 
involved in labour onset and are used in the artificial induction of labour. 
Prostaglandin gradients of PGE2 and PGF2« between uterine vein and peripheral 
artery are increased in labour (Davidson et al. 1987). Both uterotonic and 
uterorelaxant pathways have been characterized in mammalian and non-human 
primate systems but the precise sequence of events in humans is not established 
(Slattery and Morrison 2002). The non-human studies however all implicate 
modulation of intracellular calcium concentrations or calcium sensitisation as the key 
events in regulating myometrial contraction and relaxation. Placenta derived PGE2 
inhibits CTLL-2 T cells and may be involved in the immune response to the fetus 
during pregnancy suggesting that its primary role may not be in regulating labour 
onset per se (Kvirkvelia et al. 2002). However it has recently been shown that PGE 
may exist chemically bound to inositol cyclic phosphate, prostaglandylinositol cyclic 
phosphate (cPIP) which functions as a second messenger of insulin action similar to 
the inositol phosphoglycan (IPG) class insulin mediators (Shashkin et al. 2001). The 
latter class of insulin mediators have been shown to inhibit the calcium oscillations in 
liver cells (Sanchez-Bueno et al. 1997). Recent studies suggest that calcium 
signalling does not act as a simple on/off switch, but the transient oscillation number 
is used to differentially regulate and temporally coordinate different calcium- 
dependent processes (Ducibella et al. 2002).
Further, IPG-P has recently been demonstrated to interact with calcium sensitive 
transducers, such as in the pyruvate dehydrogenase phosphatase reaction to regulate 
the Km for calcium (Kunjara et al. 2002). IPGs or cPIP type molecules therefore
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would be able to mediate events, both increases in intracellular calcium or calcium 
sensitisation, which could initiate the onset of labour.
Previous work (unpublished data) indicated possible raised levels of urinary P-type 
inositol phosphoglycans (IPG-P) in labour and we hypothesized that a potential link 
might exist. A pilot study was initiated to further investigate urinary IPG-P in 
normal pregnant women in the 3rd trimester and during labour.
4.2 Methods
4.2.1 Recruitment
Recruitment of subjects was from a large central London teaching hospital antenatal 
clinic. The proposal was approved by the Joint UCL/UCLH Committees on the 
Ethics of Human Research. Subjects were consented to provide urine samples 
antenatally and agreed to provide further samples when in labour. Mid-stream urine 
samples were obtained from 37 iow-risk’ non-labouring women in the third 
trimester of pregnancy. Serial urine samples were then obtained after admission in 
labour. Two patients were excluded from the study due to the development of 
pregnancy-induced hypertension/preeclampsia subsequent to recruitment. 11 
patients were lost to follow-up due to delivery at other units (n=ll) in the London 
area. This prevented sample collection due to the strict stipulations regarding sample 
freezing times as previously described (Paragraph 3.6.1). 1 patient withdrew
consent. All urine samples were stored at -20°C until analysis. All samples were 
assayed using the polyclonal antibody-based ELISA for IPG-P (Rodaris 
Pharmaceuticals Ltd., Oxford, England) and also for total protein and creatinine 
content as described in Chapter 2 -  Lab Methods.
4.2.2 Expression of Results
Results of the ELISA were expressed as a ratio of the plate positive control per mmol 
of creatinine (Units/mmol, where 1 Unit equals 1% of the plate positive control). For 
the subjects with serial labour samples, a single mean value was calculated to 
compare with the recruitment level for the same subject and paired t-test analysis was
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used to compare recruitment with labour samples using a statistical software package 
(Microcal Origin).
4.3 Results
23 non-labour and 59 labour samples were obtained from 23 women with 
uncomplicated singleton pregnancies (median 2 labour samples for each subject). 
The mean gestation at recruitment was 35.8 weeks (range 34.1-38.7). 16 women 
were primigravidae, 7 were multigravidae. 17 women laboured spontaneously, 6 
women had induction of labour with prostaglandins (Prostin E2 Vaginal Gel, 
Pharmacia & Upjohn). Reasons for induction of labour were post-dates (n=2), 
premature rupture of membranes, low liquor volume, maternal request and systemic 
lupus erythematosus (1 each). 13 women (57%) achieved a normal vaginal delivery, 
7 women had ventouse extraction (30%) and the remaining three (13%) underwent 
caesarean section. The ELISA showed that urinary IPG-P levels in labour were 
significantly higher (median 9.64 Units/mmol) when compared to paired samples 
from the same women prior to labour (non-labouring group, median 2.31 
Units/mmol) p<0.00001, see Figure 4.1. There was no significant difference 
between the non-labour and labour samples for protein (p = 0.13) or creatinine (p =
0.09) content, Figure 4.2. No correlation was found between IPG levels and vaginal 
delivery rate or length of labour though larger numbers are needed to confirm this, as 
it was not a defined primary outcome measure of the study. No difference in 
outcome was seen between primigravidae and multigravidae, but this was not a 
defined outcome measure so the study is insufficiently powered to examine this 
properly. Figure 4.3 shows the urinary ELISA values for women (n=17) with 
spontaneous labour and suggests that the IPG values start to rise around 18-24 hours 
before birth consistent with Figure 4.2. Interestingly the data suggests that peak 
levels occur prior to delivery suggesting that the raised levels may not simply be the 
consequence of increased myometrial activity but more consistent with a possible 
role in either the priming or actual induction of labour. Figure 4.4 shows the values 
for 6 women undergoing induction of labour with vaginal prostaglandins. These 
women relative to the time of delivery also show raised levels occurring around 18-
24 hours prior to delivery. Clearly further studies are required to detail the exact 
timing of the rise in IPG levels.
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Figure 4. 1. Urinary samples were obtained from 17 women prior to spontaneous 
labour (all third trimester) and during labour. When more than one value was 
obtained during labour the mean value is reported. Values are expressed per mmol 
urinary creatinine.
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Figure 4. 2. Protein and Creatinine content for non-labour (recruitment) and labour 
samples. Bars represent mean ± 95% confidence intervals
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Correlation between time of labour samples and ELISA reactivity 
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Figure 4. 3. Urinary IPG values from the 17 women shown in Figure 4.1 who had 
spontaneous labour are shown between delivery and eighteen hours prior to delivery. 
Results are expressed as ELISA values relative to a standard urine sample.
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Figure 4. 4. Urinary IPG-P values from 6 women who required induction with 
vaginal prostaglandins given at the following times 25hr, 20hr, 7hr and 3.5hr. Two 
women received multiple doses (27hr, 21 hr) and (55hr, 38hr). Results are expressed 
as ELISA values relative to a standard urine sample.
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4.4 Conclusions/Discussion
It is thus demonstrated that urinary IPG-P levels are significantly higher in 
normotensive labouring women than in non-labouring women. Previous studies have 
demonstrated that the most likely source of these urinary IPGs in pregnancy is the 
placenta (Kunjara et al. 2000a).
Placental factors which are able to affect both the uterotonic pathways of the 
myometrium and also have a systemic effect on the mother in preparing her for the 
immediate partum and subsequent postpartum changes necessary to enter the 
lactation phase of neonatal development would make evolutionary sense. Despite the 
rapid rise in the P-type IPG during labour and removal of the placental source they 
persist into the circulation during the postpartum period for a considerable period, 
which may extend to weeks (Kunjara et al. 2000a).
Raised levels in labouring women compared to non-labour may indicate a role in the 
onset or progress of labour. IPGs release occurs outside the cell within the caveolae 
(Parpal et al. 1995) and consequently IPG may act in an autocrine manner by being 
transported back into the cell or released to have paracrine effects. 
Syncytiotrophoblast microvilli are classed as tubular caveolae and consequently IPG 
could be released directly into the maternal circulation from the placental surface. 
Alternatively any shedding of syncytiotrophoblast membrane fragments into 
maternal circulation during labour due to mechanical trauma (Attwood and Park 
1961) would result in IPG release or in this case also release of their lipidic 
precursors. It is clear from our data that a correlation exists between labour and 
urinary IPG-P levels and further research is needed to investigate any possible active 
role.
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Chapter 5
IPGs and the Prediction of Preeclampsia
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5.1 Introduction
5.1.1 Aim
The data presented in this chapter form a parallel set to those from Chapter 3. The 
aim was to try to recruit as large a number as possible of women in the time available 
who might subsequently develop preeclampsia. ‘High-risk’ groups of patients were 
therefore recruited. Subsequently, this data would be used to establish the profile of 
urinary IPG-P in women with a hypertensive pregnancy outcome. These 
longitudinal data have never previously been collected.
5.1.2 Recruitment Sites
The following three sites were identified as locations where women with a higher 
than average risk of developing preeclampsia might be found.
1. Assisted Conception Unit
2. High-risk Obstetric Antenatal Clinic
3. Multiple Pregnancy Ultrasound Clinic
As this project was collecting pilot data, a formal power calculation to calculate 
subject numbers was not performed as it was instead decided to try to recruit as many 
subjects as time and manpower would allow. As with the low-risk women in Chapter 
3, the sites were all favourable in respect to their location within the University 
College London Hospital location. Each group will now be discussed separately as 
regards the recruitment
5.1.3 Assisted Conception Unit
I saw this site as an advantageous recruitment location for two reasons. Firstly, pre­
pregnancy urine samples could be obtained from women who would become 
pregnant in the near future. This was combined with the favourable fecundity rate 
reported by the Unit (see results). Secondly, certain forms of assisted conception 
(principally those with donor gametes, but also multiple pregnancies) carry a 
reportedly higher incidence of preeclampsia (Serhal and Craft 1989; Abdalla et al. 
1998; Salha et al. 1999). The potential reasons for this have been discussed in 
Chapter 1.
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5.1.4 High Risk Obstetric Antenatal Clinic
Women identified as being ‘high-risk’ are referred for the booking visit in this clinic. 
Certain of these women had risk factors for preeclampsia, detailed in Table 5.1 
below. Women were identified from case notes as having one or more of the risk 
factors and the study was then discussed with them.
Table 5.1. Inclusion Criteria for High-Risk Subjects after Amendment 1.
Multiple pregnancy
Previous preeclampsia/eclampsia or IUGR*
Pre-existing Vascular pathology - 
Diabetes or Essential Hypertension 
Previous abruptio placentae 
Certain types of fertility treatment 
Sickle Cell Trait
Renal Disease**____________________________________________
♦Defined as fetal birthweight below 10th centile for gestation as per Chitty and colleagues 
(Chitty et al. 1994a; Chitty et al. 1994c; Chitty et al. 1994b)
♦♦Previous renal transplant or demonstrated renal impairment with serum creatinine 
>100mmol/l
5.1.5 Multiple Pregnancy Ultrasound Clinic
All women booking at University College London Hospital were offered a 
booking/dating ultrasound scan. Those identified as having a multiple pregnancy 
were subsequently scanned in the specialist multiple pregnancy ultrasound clinic in 
the Fetal Medicine Unit for their anomaly scan in the second trimester. It was at this 
point that I identified these women and discussed the study with them.
For each of these three groups of women, the study was discussed and full informed 
consent gained as per the Amendment 1 to the study protocol.
5.1.6 Sample Collection and Patient Tracking/Follow-Up
The process was as described for the low-risk subjects in Chapter 3.
5.1.7 CRF completion
At the time of recruitment, basic demographic details were logged for each subject, 
including date of birth, medical and obstetric history, last menstrual period (and thus
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gestation) and expected date of delivery. At each subsequent visit where a urine 
sample was collected, a further sheet was filled out, with initials, date of birth and 
study number for identification purposes and also blood pressure (where taken) urine 
dipstick reading and any symptoms or signs of preeclampsia.
At the time of delivery, a final sheet was filled, with the details of the labour and 
delivery, and the outcome code as defined in the study protocol (Chapter 3, Table 
3.3).
5.2 ELISA Assay
5.2.1 ELISA Protocol
This is described in some detail in Chapter 2, Laboratory Methods. The protocol 
does not need to be further discussed at this point save to say that the same operator 
assayed all samples (myself). Operator blinding was achieved by the method 
outlined in the paragraph above.
5.2.2 Result analysis
All samples were run in triplicate as discussed in Chapter 2, Lab Methods. The 
ELISA plate reader, reading at an optical density (OD) of 450nm expressed the 
ELISA results in the form of a mean and standard deviation of the mean (s.d.). 
These results were analysed following subtraction of the plate blank, as a percentage 
of the plate positive control (as discussed in Chapter 2).
5.3 Results
In total, 55 women were recruited in the antenatal period and 46 non-pregnant 
women were recruited from the Assisted Conception Unit (ACU). In the latter 
group, 25 pregnancies were recorded but 8 of these miscarried in the first trimester. 
Of the pregnancies that were ongoing beyond the 20th week, three were multiple and 
fourteen were singleton. One of the three multiple pregnancies was a triplet 
pregnancy with a fetal reduction in the early second trimester to a twin pregnancy 
carried out in the second trimester. This pregnancy continued to 38 weeks, when a
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vaginal delivery of both twins was achieved. The other two were also twin 
pregnancies. See Table 5.2 for details of mode of conception for the ACU subjects.
Table 5 .2 . Mode of conception for Assisted Conception Unit patients
Mode of Pregnancy_____________________________n
In-vitro Fertilisation (IVF) 7
IUI/Superovulation 1
Gamete Intra-Fallopian Transfer 1
Male Factor
Intra-Cytoplasmic Sperm Injection (ICSI) 4
ICSI/PESA 1
ICSI/TESA 1
IVF with Pre-Implantation Genetic Diagnosis (PGD) 1
Spontaneous 1
PESA = Percutaneous epididymal sperm aspiration, TESA = Testicular Sperm 
Aspiration
35 women were recruited from the high-risk antenatal clinic and 20 from the multiple 
pregnancy clinic. Three of these women were lost to follow up due to mid-trimester 
miscarriage (n=l) or change of address (n=2). Clinical and demographic details for 
the subjects are summarised in Table 5.3. The mean age of the high-risk antenatal 
subjects was 35.6 years and mean Body Mass Index (BMI) was 27.7. Both values 
were significantly higher than for the low risk women (p = 0.002 and 0.007 
respectively). No difference was seen for the values of the women with multiple 
pregnancies (Mean age 33.9y, BMI 23.6).
A breakdown of the risk factors for preeclampsia for those women recruited in the 
high-risk clinic can be seen in table 5.4. The most common inclusion criteria were a 
history of thrombophilia (n=l 1) and/or a previous history of preeclampsia (n=9) or a 
combination of one of these plus (an)other risk factor(s). Often, an adverse event in 
a previous pregnancy led to investigation and diagnosis of an underlying 
predisposing factor. All the women seen in antenatal clinic with thrombophilia were 
commenced on low-dose aspirin (75mg) plus low-molecular weight heparin 
(LMWH) daily by the clinical team or by the subject’s own general practitioner. 
Several of the other subjects had also been (or were subsequently) commenced on 
low dose aspirin only (Table 5.4).
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Table 5.3. Details for Recruitment High-risk Subjects
ACU High-Risk 
Antenatal
Multiple
(n == 17*) (n = 32) (n =20)
Mean (±2s.d) Mean (±2s.d) Mean (±2s.d)
Age (y) 35.6 (6.6) 33.9 (9.2)
BMI 27.7 (12.2) 23.6 (7.4)
Ethnicity n (%) n (%) n (%)
Caucasian 14 (82) 22 (67) 18 (90)
Affo-Caribbean - - 4 (12) - -
Black African 2 (12) 2 (6) 1 (5)
Asian - - 1 (3) 1 (5)
Indian Sub-Continent 1 (6) 1 (3) - -
Other - 3 (9) - -
Parity
Primiparous 17 (100) 13 (40) 13 (65)
Multiparous 0 (0) 20 (60) 7 (35)
ACU = Assisted Conception Unit. *Numbers shown for pregnancies achieving >20 weeks
Table 5. 4. Risk Factors for preeclampsia at recruitment
Risk Factor ___________________________
Thrombophilia**
Previous Severe Preeclampsia/Eclampsia
Essential Hypertension
Previous Abruptio Placentae at <37 weeks**
IVF, Gamete donation
Previous cerebro-vascular accident
Sickle Trait
Diabetes
Other
Previous abruption + history of essential hypertension 
Essential Hypertension + family history of preeclampsia 
Factor V Leiden + previous HELLP syndromeJ 
Increased hCG at Serum Screening
n
11
9
2
2
*e.g. Anti-phospholipid syndrome (APS), Factor V Leiden, Prothrombin gene mutation 
heterozygote, Positive Lupus Anticoagulant, Anti-phospholipid antibodies, anticardiolipin 
antibody
*Of which all treated with low dose aspirin ± LMWH (Low Molecular Weight Heparin) 
^Treated with low dose aspirin
No delivery details were available for a further four subjects in the high-risk group 
and one of the multiple pregnancies. Details of the onset of labour can be seen in 
Table 5.5 below (cf. for low risk women, Chapter 3, Table 3.5). Chi Squared 
analysis indicates that the high-risk antenatal group were significantly more likely to 
have a caesarean section than the low risk group, (%2= 7.93, p<0.05) though this was 
not the case for the multiple pregnancy group.
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Table 5. 5. Details for Onset of Labour High-risk Subjects
ACU High-Risk Multiple
Antenatal
(n=  17*) (n = 29) (n = 19)
n (%) n (%) n (%)
Onset of Labour
Spontaneous 8 (47) 7 (24) 5 (26)
Induction 1 (6) 10 (34) 3 (16)
ELSCS 4 (24) 8 (28) 11 (58)
EmLSCS 0 4 (14) 0
Not Known 4 (24)
ACU = Assisted Conception Unit. ELSCS = Elective Lower Segment Caesarean Section, 
EmLSCS = Emergency Caesarean Section (before labour). *Numbers shown for pregnancies 
achieving >20 weeks_____________________________________________________________
Overall, in these high-risk women, there were 6 cases of preeclampsia, an overall 
rate of 7.6%. However, the rate varied between the 3 recruitment sites. The highest 
rate being in those women recruited from the antenatal clinic at 15% (n=5), with 5% 
(n=l) in those with multiple pregnancies. This was lower than expected and indeed 
lower than that in those women with no identified risk factor at booking (7 .5%, n=3). 
No cases of preeclampsia were identified in the women from the Assisted 
Conception Unit (Table 5.6). However, Chi Squared analysis of the distribution of 
hypertensive outcomes revealed no significant difference between the low risk 
women and any of the high-risk groups (%2 value = 6.24, p>0.1) but this may be due 
to the small numbers.
Booking blood pressure was significantly higher in the high-risk group compared to 
the low risk group (p=0.002 for Mean Arterial Pressure, MAP, using Student’s T 
Test), but not in the multiple pregnancy group. These women also had a 
significantly higher age (p = 0.001) and BMI (p = 0.007) than the low risk group.
It seems that although multiple pregnancy is a risk factor for preeclampsia, that this 
is due to the placental volume rather than possible vascular risk factors (including 
age) that are found in the other women identified as high-risk.
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Table 5. 6. Comparison of low risk and different high-risk groups in terms of selected factors and outcomes.
‘Low Risk’
(n = 40) ACU (n = 17)
‘High Risk’
ANC (n = 33) Multiple (n = 19)
Mean (±2s.d) Mean (±2s.d) Mean (±2s.d) P Mean (±2s.d) P
Age (y) 32.3 (10) 36.6 (8.8) 35.6 (6.6) 0.002* 33.9 (9.2) 0.16*
BMI (at booking) * 22.8 (7.6) 23.9 (7.7) 27.7 (12.2) 0.007* 23.6 (7.4) 0.84*
Booking BP
Systolic 105 (25.3) 111 (24.2) 0.118* 116 (29.8) 0.002* 109 (22.8) 0.21*
Diastolic 65 (18.0) 72 (18.5) 0.018* 72 (26.2) 0.01* 68 (15.4) 0.21*
MAP 92 (21.1) 98 (20.5) 0.05* 101 (27.8) 0.002* 95 (18.8) 0.17*
Gestation (Weeks) Median (Range) Median (Range) Median (Range) Median (Range)
Recruitment 11.9 (9.1-19.9) - - 13.6 (6.9-33.3) 17.9 (11.7-27.9)
Delivery 40.3 (36-42) 38 (23.6-41.6) 38.3 (28.7-41.4) 37.3 (27.3-38.9)
Delivery Type n (%) n (%) n (%) n (%)
NVD 17 (46) 5 (29) 12 (41) 2 (11)
Assisted Vaginal 8 (21) 4 (24) 4 (14) 3 (17)
Elective Caesarean 2 (5) 4 (24) 8 (28) 10 (55)
Emergency Caesarean 10 (28) 1 (6) 5 (17) 3 (17)
NK/Lost to f-u - 3 (17) - -
Outcome
I -  Preeclampsia 3 (7.5) 0 5 (15) 1 (5)
II -  PIH (no Proteinuria) 3 (7.5) 1 (4) 7 (21) 2 (10)
III -  PE on Chronic 0 0 1 (3) 0
IV -  No Hypertension 31 (77.5) 16 (64) 15 (45) 15 (75)
Lost to Follow Up** 3 (7.5) 8 (32)» 5 (15) 2 (10)
ACU = Assisted Conception Unit, ANC = Antenatal Clinic, BP = Blood Pressure, PE = Preeclampsia. MAP = Mean Arterial Blood Pressure. NK = Not known Outcomes as also 
defined in text o f chapter. I -  Preeclampsia, II - Pregnancy Induced Hypertension (no proteinuria), III - Preeclampsia superimposed on chronic hypertension, IV - No hypertension. 
P values by *Studenf s t-test *ACU subjects BMI recorded pre-pregnancy. Early pregnancy loss or delivery at other site. ** Early pregnancy loss
5.3.1 Raw ELISA Data
The longitudinal data are presented below grouped by hypertensive outcome, as 
defined in Chapter 3.3.5 (Table 3.3) and by recruitment group. Figure 5.1 shows low 
risk subjects, Figure 5.2 the high-risk and Figure 5.3 the multiple pregnancy subjects.
It can be seen that there are positive test results in the women with subsequent 
preeclampsia, sometimes from the second trimester (as early as 20 weeks, Figure 5.1 
A). This appears to be a different pattern in the low-risk subjects to the non- 
proteinuric hypertension (PUT) group. No positive results were seen in this group 
until late in the third trimester (Figure 5.1 B).
In the high-risk group, the majority of the subjects with preeclampsia had positive 
results before or at the time of clinical diagnosis. However, only two displayed 
positive results at an earlier stage in the pregnancy (Figure 5.2 A). Once again, in 
general the subjects with subsequent PIH did not display positive results (if at all) 
until shortly before delivery (Figure 5.2 B). This was the same as in the subject with 
preeclampsia superimposed on chronic hypertension (Figure 5.2 C).
In the single multiple pregnancy subject with preeclampsia, the ELISA only showed 
a positive result at the time of diagnosis of preeclampsia (Figure 5.3 A). The clinical 
team expedited delivery shortly afterwards. In the multiple pregnancy subjects with 
PIH (i.e. non-proteinuric) there were positive results for the ELISA several weeks 
before delivery, which is different to the low-risk and high-risk groups as above 
(Figure 5.3 B).
It is also possible that the small numbers in the study may explain the differences.
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Figure 5. 1. Low-risk subjects. Individual serial ELISA-assay plots for all subjects 
grouped by hypertensive pregnancy outcome and study number. ELISA values 
shown as a percentage of the plate positive control, as previously discussed. i  = 
Clinical diagnosis of preeclampsia. | = Delivery of PIH subjects. Dotted reference 
line shows cut off point for a ‘positive test’ (80% of plate positive control, ppc). PE 
= Preeclampsia. PIH = Non-proteinuric pregnancy induced hypertension
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Figure 5. 2. High-risk subjects. Individual serial ELISA-assay plots for all subjects 
grouped by hypertensive pregnancy outcome and study number. ELISA values 
shown as a percentage of the plate positive control, as previously discussed. -I = 
Clinical diagnosis of preeclampsia. Dotted reference line shows cut off point for a 
‘positive test’ (80% of plate positive control, ppc). PE = Preeclampsia. PIH = Non- 
proteinuric pregnancy induced hypertension
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Figure 5. 3. Multiple pregnancy subjects. Individual serial ELISA-assay plots for all 
subjects grouped by hypertensive pregnancy outcome. ELISA values shown as a 
percentage of the plate positive control, as previously discussed. i  = Clinical 
diagnosis of preeclampsia. Dotted reference line shows cut off point for a ‘positive 
test’ (80% of plate positive control, ppc). PE = Preeclampsia. PIH = Non-proteinuric 
pregnancy induced hypertension
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5.3.2 Grouped ELISA Data
The ELISA data were grouped by hypertensive outcome, as seen below. For the 
group of women who were high-risk at recruitment, when grouped by gestation of 
sample, and by each group of hypertensive outcome, there is a significantly higher 
ELISA result at booking (p = 0.03), at 30-34 weeks (p = 0.01) and at 35-41 weeks (p 
= 0.008) in those women with subsequent preeclampsia, compared to both normal at 
non-proteinuric (gestational) hypertension outcomes (Figure 5.4). No difference is 
seen at other gestations. No difference is seen between subjects with a normal 
outcome and those with non-proteinuric hypertension.
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***p = 0.008
Figure 5. 4. ELISA data for high-risk recruitment cohort, grouped by hypertensive 
outcome with gestation. Error bars represent ±SEM.
Looking at the grouped data for all recruitment cohorts, when grouped by gestation 
of sample, and by each group of hypertensive outcome, there is a significantly higher 
ELISA result at 30-34 weeks (p = 0.01) and at 35-41 weeks (p = 0.003) in those 
women with subsequent preeclampsia, compared to both normal at non-proteinuric 
hypertension outcomes (Figure 5.5). No difference is seen at other gestations.
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No difference is seen between subjects with a normal outcome and those with non- 
proteinuric (gestational) hypertension.
Figure 5. 5. ELISA data for all subjects, grouped by hypertensive outcome with 
gestation. Error bars represent ±SEM.
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5.3.3 The iPG-P ELISA as a Screening Test
The ELISA assay was analysed using 2 by 2 table analysis (Figure 5.7), where a 
‘positive’ result was taken as equal to or greater than 80% of the plate positive 
control, as described in Chapter 2. Likewise, a negative result was taken as less than 
80% of the plate positive control.
Due to study design, it was necessary to analyse individual samples for subjects 
grouped by gestational age at the time of the sample and by the hypertensive 
outcome. Overall results were poor and were also compromised by the small number 
of subjects.
Unfortunately, the small number of subjects with a preeclamptic or other (non- 
proteinuric) hypertensive outcome contributed to a very low sensitivity when the test 
was applied in the first trimester.
The assay performed best when predicting hypertensive outcome in women with a 
risk factor for preeclampsia. This may simply be due to the higher incidence of a 
hypertensive outcome in this group.
5.3.4 The ELISA Assay as a Diagnostic Test in Population vs. High 
Risk Women
Thus we have seen that from these data the ELISA is not particularly clinically 
useful as a screening test in the first or second trimester.
For samples taken near to the time of delivery, the test does seem to show consistent 
positivity in the preeclamptic subjects. However there is a risk, in labouring subjects 
of this becoming confused with the positive tests seen for non-hypertensive women, 
seen in Chapter 4.
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Table 5. 7. 2 By 2 Table analysis of IPG-P ELISA assay for groups of samples.
Specificity Sensitivity PPV NPV LR+ LR-
Population Sub-Group (%)________(%) ro/^  r0/
Single ELISA Assay at:
(a) Booking (<16 Weeks)
« « All Subjects
a |  Risk Factor for Preeclampsia
a  tg Low risk subjects only
*§ ?  (b) Second Trimester (16-28 Weeks)
$ Js All Subjects
Pm ° Risk Factor for Preeclampsia
Low risk subjects only
Single ELISA Assay at:
(a) Booking (<16 Weeks)
£ v All Subjects
« |  Risk Factor for Preeclampsia
*| 'I  Low risk subjects only
^  & (b) Second Trimester (16-28 Weeks)
a -5 
w w
n
62 91.1 0.0 0.0 89.5 0.0 1.1
27 100.0 0.0 0.0 88.9 0.0 1.0
33 83.3 0.0 0.0 89.3 0.0 1.2
74 80.3 50.0 23.5 93.0 2.5 0.6
40 82.9 40.0 25.0 90.6 2.3 0.7
32 75.9 66.7 22.2 95.7 2.8 0.4
62 93.9 15.4 40.0 80.7 2.5 0.9
27 100.0 0.0 0.0 74.1 0.0 1.0
33 89.3 40.0 40.0 89.3 3.7 0.3
All Subjects 74 84.2 47.1 47.1 84.2 3.0 0.6
Risk Factor for Preeclampsia 40 89.3 45.5 62.5 80.6 4.2 0.6
Low risk subjects only 32 76.9 50.0 33.3 87.0 2.2 0.7
LR+ = Likelihood Ratio for positive test, LR- = Likelihood ratio for negative test, NPV = Negative Predictive Value, PPV = Positive Predictive value
5.4 Conclusions/Discussion
Thus it is shown that as for the data from normal, non-hypertensive labour (seen in 
Chapter 4) there is a significant increase in the IPG-P ELISA signal in preeclamptic 
women. This is shown again in the single, paired urine samples (Chapter 6) and mirrors 
the increased urinary IPG-P bioactivity seen by Kunjara et al (Kunjara et al. 2000a). 
Examining the values for the subjects who developed preeclampsia, there appear to be 
two groups in terms of the ELISA positivity. Those that develop positive test results up 
to 15 weeks prior to the onset of clinical symptoms and those that develop test positivity 
around the time of clinical diagnosis. Numbers were too small to identify any difference 
in the clinical picture between these two groups. Additionally, a rise in the IPG-P 
ELISA signal can be seen at the time of labour in some of the samples. This parallels the 
data for the labouring urine samples discussed in Chapter 4.
It can be seen also that the ELISA does not stand alone as a screening test for 
preeclampsia. The specificity can be high, but the sensitivity is generally poor, and this 
would seem to be due to lack of ELISA positivity until the time of (or immediately 
before) the development of clinical preeclampsia in a proportion of the subjects. 
However, it might have application as one element of a two- or multiple-part test (such as 
doppler ultrasound, leptin, or nitric oxide) to improve overall sensitivity. Unfortunately, 
the minimally invasive design of this study prevented, for example, concurrent serum 
tests for other markers of preeclampsia.
The test may have some clinical use as a diagnostic assay, in combination with the 
clinical picture. This may be confused by test positivity at the time of labour in non­
hypertensive women.
5.4.1 Follow up Problems
Certain problems were experienced with the follow up of subjects recruited at the 
Assisted Conception Unit. As a non-NHS unit, referrals to the ACU were from a wide 
area. This was exacerbated particularly as the Unit has a good fecundity rate and is 
involved in pioneering technologies including pre-implantation genetic diagnosis (PGD). 
Table 5.8 below shows subsequent booking hospitals for those subjects with pregnancies
thongoing beyond the 20 week of gestation.
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Table 5. 8 . Booking hospitals for subjects recruited pre-pregnancy at the ACU
Within Greater London Area n
Barnet Hospital, Wellhouse Lane, Barnet, Herts 4
University College London Hospitals NHS Trust 3
Portland Hospital, Great Portland Street, London 1
Chelsea and Westminster Hospital, Fulham Road, London ^
Kingston Hospital, Kingston upon Thames *
Famborough Hospital, Orpington, Kent *
Outside Greater London Area
Darenth Valley Hospital, Dartford, Kent 1
East Surrey Hospital, Redhill, Surrey 1
Ashford Hospital, Ashford, Middlesex, TW15 1
West Hertfordshire Hospitals NHS Trust 1
East Hertfordshire Hospitals NHS Trust 1
Outside UK
Badhomburg, Germany 1
Understandably it was not practical to follow up these individuals as the protocol 
planned, due to manpower and time restrictions. In many cases, follow-up was limited to 
collection of delivery data and hypertensive pregnancy outcome code. In the event, none 
of these pregnancies resulted in an overt preeclamptic case (Table 5.6), despite the 
original aim of specifically recruiting higher risk cases. It was not possible to get further 
detailed data on certain aspects of labour care via telephone interviews with maternity 
staff (e.g. onset of labour data for four women, Table 5.5). As these did not affect primary 
outcome data (which were known), it was not felt appropriate in terms of time or 
financial resources to travel to distant maternity units and obtain ethical permission to 
examine case notes for these women.
5.4.2 Future Work
It is clear that the recruitment and numbers of preeclamptic cases were lower than hoped 
for and further studies are needed to increase these numbers.
Additionally, I would also hope to design a separate study to evaluate the test for women 
admitted with a hypertensive episode. That is, to properly assess its utility as a diagnostic 
assay in these cases -  a potentially clinically useful application.
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Chapter 6
IPGs in Established Preeclampsia
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6.1 Introduction
I have discussed in previous chapters how the polyclonal antibody based ELISA has been 
used as a urine assay for the prediction/diagnosis of preeclampsia in a varied group of 
women. The assay relies on detecting the presence of a P-type IPG in the urine of these 
women. The presence of this product in urine proves nothing, however, in terms of the 
pathophysiology of the disorder. It could be argued that the IPG may be produced 
systemically in the maternal blood, renal or other tissues and may not relate to the 
preeclampsia or to the pregnancy at all.
On the other hand, previous work has implicated the placenta as a source of the IPG. It 
has been observed that glycogen accumulates in higher quantities in the placenta in 
preeclampsia (Arkwright et al. 1993). Investigation with anti-IPG monoclonal antibody 
has shown that there are higher levels of P-type IPG in preeclamptic placenta compared 
to normal control placenta (Deborde et al 1999b). This seems to be localised in the 
microvillous brush border of the syncytiotrophoblast (Deborde et al 1999a). As noted in 
Chapter 1, there is also evidence that this syncytiotrophoblast is shed into the maternal 
circulation and it could be that the IPGs ‘hitch a lift’ as it were from the placental surface 
to the maternal system. Alternatively, the IPG release may be in parallel to this cellular 
shedding/apoptosis.
Nothing is known at this time about the presence of IPGs on the fetal side of the equation. 
It is possible that they are released on the fetal side of the placenta also. Amniotic fluid is 
largely composed of fetal urine from around 16 to 18 weeks of pregnancy onwards (In 
Williams Obstetrics: Cunningham et al 1997). Waste products from the fetal circulation 
such as urea, creatinine and uric acid tend to be concentrated here (though osmolality is 
lower than fetal urine) and so may IPGs be also.
6.2 Objectives
The objective of this study was to assess IPG levels in various compartments on the 
maternal and fetal side of the placenta to attempt to further localise the source of the IPG 
production. The measurement of the IPGs was to be carried out by using a combination 
of techniques. Firstly, the polyclonal-based ELISA and secondly a well-established ion-
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exchange column chromatography extraction followed by bioactivity assays of the 
extracted IPGs.
6.3 Design
A case-control study of women with active clinically diagnosed preeclampsia undergoing 
caesarean section before labour (cases) and non-hypertensive pregnant controls 
undergoing elective caesarean section was planned. Samples were to be taken at 
caesarean section. Initially, recruitment commenced at University College London 
Hospitals NHS Trust. The proposal was approved by the Joint UCL/UCLH Committees 
on the Ethics of Human Research. Recruitment was slower than expected, however, and 
it was decided to improve numbers by collaborating with a second institution. A British 
Council Higher Education Link existed between the Academic Departments of Obstetrics 
and Gynaecology at UCL and the Nelson R Mandela Medical School (University of 
Natal, Durban, South Africa). I contacted the head of department, Professor Moodley in 
Durban about recruitment. I arranged to travel to the University of Natal. The Medical 
School is attached to King Edward VIII Hospital, which has a large obstetric unit, with 
approximately 8000 deliveries per year. The research proposal was approved by the 
Research Ethics Committee at Nelson R Mandela Medical School prior to my trip in 
January-February 2002.
6.4 Subjects
All the data presented here is from recruitment at King Edward VIII Hospital, Durban, 
South Africa. Recruitment took place between 16th January and 8th February 2002. The 
study group included eleven women undergoing emergency caesarean section for 
clinically diagnosed preeclampsia or eclampsia (Table 6.1). Preeclampsia was defined by 
the criteria established by the International Society for the Study of Hypertension in 
Pregnancy (ISSHP) (Brown et al. 2001). Eleven normal, non-hypertensive pregnant 
control women were recruited in the same time period (Table 6.2). The subjects were 
matched for age and ethnicity with controls. It was obviously not possible to match for 
gestation, as preeclamptic subject requiring rapid delivery by caesarean would be of a 
less advanced gestation than controls requiring elective caesarean section. This problem 
has been encountered elsewhere (Chua et al. 1991).
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Table 6. 1. Characteristics of eleven patients with severe preeclampsia/eclampsia 
delivered by caesarean section
Patient Parity Gestation at delivery (weeks) Indication for delivery
1 0 39.6 Eclampsia
2 0 35.1 Preeclampsia, IUGR
3 6 36.0 HELLP, IUFD
4 2 31.0 Preeclampsia
5 0 31.0 Preeclampsia
6 2 32.6 Preeclampsia
7 1 37.0 Eclampsia
8 3 37.7 Preeclampsia
9 2 34.0 Hypertension, Raised Urate
10 1 36.4 Preeclampsia
11 2 30.7 Preeclampsia, Elevated liver 
enzymes
IUGR = Intra-uterine growth retardation; HELLP = Syndrome of haemolysis, elevated liver 
enzymes and low platelets; IUFD = Intra-uterine fetal death
Table 6. 2. Characteristics of eleven control patients with no hypertensive disease 
delivered by caesarean section
Patient Parity Gestation at delivery (weeks) Indication for delivery
1 0 39.0 Post Dates, Fetal 
Distress
2 1 38.0 Previous CS
3 2 37.7 Term Breech
4 3 39.0 Previous CS x3
5 2 39.9 Previous CS x2
6 2 37.0 Previous CS x2
7 2 39.4 Poor Obstetric history
8 2 37.9 Previous CS x2
9 2 39.3 Previous CS x2
10 3 40.0 Coded patient
11 3 37.0 Previous CS x3
CS = Caesarean Section
6.4.1 1nclusion Criteria
Subjects:
• Attended King Edward VIII Hospital, Durban for antenatal care
• Were diagnosed with preeclampsia as defined by ISSHP classification (see 
Chapter 1)
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• Underwent caesarean section before the onset of labour, as decided by the 
Obstetric Team on duty.
• Signed informed consent for the study
• Were willing to have the data of the pregnancy documented for study 
Controls:
• No evidence of raised blood pressure
• Undergoing caesarean section before the onset of labour for reasons other than 
preeclampsia
6.4.2 Exclusion Criteria
• Under 18 years of age at the time of recruitment
6.4.3 Informed Consent
Informed consent was an important part of the recruitment process, having obviously 
been a key part of the Ethics approval and the study involving invasive testing. The 
majority of patients attending King Edward VIII Hospital did not have English as a first 
language. Upon commencing the study, a copy of the patient information sheet translated 
into the Zulu language was prepared by staff with experience in this at Nelson Mandela 
Medical School. If the subjects did not understand English, this Zulu Information Sheet 
was used. The local Research Ethics Committee approved the Zulu version of the 
information sheet.
Following consent, details were taken of the current pregnancy and past obstetrics and 
medical history.
6.5 Methods
6.5.1 Sample Collection
All samples were taken by myself (Table 6.3). The samples taken at the time of the 
caesarean section were done so with effort to avoid risk to the mother and baby and 
prolongation of the procedure itself.
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Table 6.3 . Samples taken
Timing Sample Analysis
• Immediately Peripheral venous blood (5ml) Bioactivity assay
Prior to
Caesarean §
• At Caesarean Catheter urine specimen (30ml) ELISA for P-IPG
Section Amniotic fluid (5ml) ELISA for P-IPG
Umbilical Venous Blood (5ml) Bioactivity assay
Umbilical Arterial Blood (5ml) Bioactivity assay
§ Yi7:+u:., in  —
Uterine venous blood (5ml) Bioactivity assay
Urine This was collected as a catheter sample at the time of caesarean section and 
stored at -20°C initially.
Peripheral Venous Blood
This was collected at the time of or within thirty minutes prior to the 
caesarean. It was collected by syringe as a 5ml sample and transferred to a 
plain (unheparinised) tube.
Amniotic Fluid
At the time of caesarean section, a 5ml sample was aspirated with a sterile 
plastic syringe under direct vision after opening of the uterus and immediately 
after rupture of the membranes at the time of the operation. Care was taken to 
avoid contamination of the amniotic fluid with maternal blood. It had 
previously been planned to collect the fluid prior to membrane rupture, using a 
green needle to puncture the membranes and thereby avoid contamination 
with other fluids. However, the Ethics Committee decided that this would 
incur increased risk for the fetus and thus approval was given only for the 
samples to be taken without a needle on the syringe. Therefore this 
necessitated the samples to be taken after membrane rupture.
Cord Blood
Two 5ml samples were taken from the umbilical cord (one from the umbilical 
artery & and one from the vein) following delivery of infant and before or 
immediately after (within 5 minutes of) the separation of the placenta.
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Uterine Vein Blood
The sampling procedure is based on the method described by Johansen and 
Redman (Johansen et al. 1999). At the time of caesarean section, after the 
peritoneum was opened but before the incision was made in the uterus, a 
sample of 5ml blood was taken with a 21-gauge (green) needle from one of 
the broad ligament veins. Any small risk of haematoma formation was 
minimised by pressure on the vein after taking the sample. Additionally, 
uterine contraction following delivery minimised further blood loss. No 
excess blood loss or haematoma formation was observed during the conduct 
of the study.
6.5.2 Sample Processing
All samples were collected using a plain syringe and transferred to plain Vacutainer tubes 
(Beckton-Dickinson, Oxford, England) and processed within 3 hours of sampling time. 
Blood samples were spun in an Eppendorf 5804R centrifuge (Eppendorf, Hamburg, 
Germany) for 5 minutes at 5000rpm («4200g) at room temperature. Serum was then 
removed and stored at -20°C at the King Edward VIII Hospital until transport to the UK 
for analysis. Sample tubes were taken on dry ice via overnight air flight and delivered to 
University College London. Total transit time was 24 hours and samples remained at or 
below -20°C at all times. Samples then remained frozen at University College London 
until analysis.
6.5.3 Materials and Lab Analysis
These are as described in Chapter 2 -  Lab Methods.
6.5.4 Statistical Analysis
For matched samples, unpaired t-test analysis was carried out with a standard statistical 
and graphing package (Origin 5.0, Microcal Software Inc, Northampton, MA, USA).
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6.6 Results
The mean maternal age for the preeclampsia/eclampsia (study) and control groups was 
not significantly different (28.1 y and 27.8 y respectively). The mean gestation for the 
study group was 34.6 weeks and mean birthweight was 1905g. For the control group, 
these were 38.6 weeks and 302lg respectively.
Urine and Amniotic Fluid
Urine was not available for one of the normal subjects. Amniotic fluid was not obtained 
from four of the preeclamptic subjects due to reduced amniotic fluid volume at the time 
of sample collection or contamination with blood. Overall ELISA values (expressed 
relative to a standard urine sample) for all samples were significantly higher in amniotic 
fluid (mean = 693 units, where 1 unit is equivalent to 1% of the signal with the standard 
sample) compared to urine (mean = 175 units, p < 0.00001). For the matched urine and 
amniotic fluid pairs, values were significantly higher for the preeclampsia/eclampsia 
group compared to the control group (Table 6.4 and Figure 6.1, p = 0.002 and 0.01 
respectively).
Table 6. 4. IPG-P ELISA values for urine and amniotic fluid from normal and 
preeclamptic women.
Normal Preeclampsia
Mean (SEM) 
Median (range)
(n=10)
30 (7.7) 
18 (6-78)
Urine
(n=ll) 
308 (77.6) 
168 (90-752)
0.002*
Mean (SEM) 
Median (range)
AF
(n=ll)
555 (43.0) 911
529 (337-828) 1012
(n=7)
(134.6)
(370-1536)
0.0T
< 0.001* 0.001
AF = Amniotic Fluid. P-values for means by unpaired Student’s t-test.
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There was also a correlation between amniotic fluid and urine ELISA values for the 
normal group (r = 0.70, p = 0.02), but this was not apparent in the preeclamptic group, 
(Figures 6.2a and b).
The maternal platelet count was inversely correlated to amniotic fluid ELISA values (p = 
0.01) in the preeclamptic subjects (Figure 6.3a). No correlation was seen between 
maternal urinary ELISA and platelet levels (Figure 6.3b) or with other measured clinical 
parameters (gestation, maternal age, birthweight, serum urate or mean arterial blood 
pressure; data not shown).
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Figure 6. 1. ELISA values for matched urine and amniotic fluid sample pairs sample 
pairs for preeclampsia/eclampsia and control groups. Results expressed as ELISA 
values relative to a standard urine sample.
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Figure 6 . 2. Graph of ELISA values from maternal urine (shown on log10 scale) 
and amniotic fluid samples (expressed relative to a standard urine sample) for 
normal (a) and preeclamptic (b) women. Error bars represent SEM. Upper and 
lower 95% confidence intervals shown for fig 2a.
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Figure 6 . 3. Correlation between maternal platelet levels and amniotic fluid (a) 
and urine (b) IPG-P levels for preeclamptic subjects. Linear fit with upper and 
lower 95% confidence intervals
Serum
Total IPG-P bioactivity levels in the uterine vein were lower in the preeclamptic 
group than in the non-preeclamptic women (p = 0.01, Figure 6.4). No difference was 
seen between the groups for samples from peripheral vein, or umbilical vessels. 
Umbilical venous levels were not different from those in the umbilical artery. In the 
preeclamptic group, the IPG-P bioactivity was higher in the umbilical artery when 
compared with the uterine vein (p = 0.02) and showed a similar trend for the 
peripheral vein (p=0.056). This trend was also seen for the umbilical vein compared 
with the uterine vein (p=0.065) and the peripheral vein (p=0.08). These differences 
were not seen for the non-preeclamptic group. There was a strong correlation 
between uterine vein and peripheral vein levels in the preeclamptic group (r2 = 0.88) 
but not in the control group (r2 = 0.41, Figure 6.5). An inverse correlation was also 
seen between maternal platelet count and bioactive IPG-P in uterine and peripheral 
vein in the preeclamptic women (Figure 6.6, c & d). This was not seen for the 
umbilical serum samples (Figure 6.6, a & b). No correlation was seen with gestation 
for either preeclamptic or normal IPG-P levels for any of the values (data not 
shown).
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Figure 6 . 4. Total serum IPG-P bioactivity for preeclampsia/eclampsia and 
control groups from different sample sites identified in Fig 3 Expressed as 
units of activity per ml of serum (where 1 unit of IPG PDH activity is the 
amount required to increase the basal rate by 50%). Error bars represent 
SEM. Non-significant differences not shown. Sample site numbers 
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Figure 6 . 5. Correlation between uterine vein (UVB) and peripheral vein (PVB) 
IPG-P levels in (a) normal and (b) preeclamptic subjects. Expressed as units of 
activity per ml of serum (where 1 unit of IPG PDH activity is the amount 
required to increase the basal rate by 50%).
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(c) uterine vein and (d) peripheral vein. Linear fit with upper and lower 95% 
confidence intervals.
130
6.7 Conclusions/Discussion
To my knowledge, these are the first data investigating total serum IPG-P in 
preeclampsia. Previous authors have noted that IPG-P bioactivity is increased in the 
urine of preeclamptic women (Kunjara et al. 2000a) and also that inadequate release 
of IPG-P may be associated with insulin resistance (Shashkin et al. 1997). 
Furthermore, IPG-P in amniotic fluid has not been investigated to our knowledge. 
Amniotic fluid in the third trimester of pregnancy is largely composed of fetal urine 
and lung secretions and thus could show parallels with the maternal urine 
composition.
It appears from these data that in the normal women there is equilibrium between the 
maternal and fetal sides of the placenta. No difference is seen between any of the 
measured IPG-P bioactivity levels in the normal women and the ELISA shows 
correlation between the amniotic fluid and maternal urine. In the preeclamptic 
women, it appears that this equilibrium has been disrupted. There is no correlation 
between the amniotic fluid and maternal urine and additionally, the fetal serum levels 
of bioactive IPG-P are higher than in the mother. We hypothesise that this is due to 
release of the IPG-P from the placenta, supported by the raised urinary IPG-P 
bioactivity seen by other authors in preeclampsia (Kunjara et al. 2000a). 
Alternatively, secretion from the maternal kidney is a possibility, though secretion 
and immediate excretion would make less biological sense.
The inverse correlation of the amniotic fluid (ELISA) levels and maternal serum 
(bioactivity) levels with maternal platelets in preeclampsia (Figure 6.3a) provide 
further evidence that the IPG-P may in some way be involved in the pathophysiology 
of preeclampsia. Platelet count is well established as a reliable clinical marker of 
disease severity and forms a component of the HELLP syndrome, a severe form of 
preeclampsia. This data mirrors the inverse relationship between urinaiy IPG-P 
bioactivity and platelet count, which has been shown previously (Kunjara et al. 
2000a).
Previous work would suggest a placental source of the IPG-P production, with 
release into maternal and fetal circulations. However, the higher levels of 
measurable IPG-P in serum on the fetal side of the placenta in preeclampsia, and an
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absence of any difference in umbilical arterial and venous levels might indicate 
several possibilities. Firstly, a potential fetal production source with breakdown of 
placental transport to mother. Neither umbilical arterial nor venous serum levels 
reached statistical significance in terms of being higher in preeclampsia than in 
normal subjects and therefore no backlog on the fetal side seems to be occurring. 
However, amniotic fluid ELISA signals were much higher in preeclamptic women, 
suggesting sequestration in this compartment. Alternatively there may a placental 
production source with release of an abnormal, lipidic form of IPG-P (a GPI) into the 
maternal circulation. This form would not be detected by the conventional extraction 
and bioassay procedures.
The significantly higher levels in urine from the preeclamptic women compared with 
the normal group indicate the potential for use of the ELISA as diagnostic assay. In 
the preeclamptic state it is possible that an abnormal form of IPG-P, as yet to be 
identified, may be causing high ELISA positivity but not being measured in the 
serum by the conventional assay we used here. Alternatively, we recognise that a 
renal source of IPG-P production may exist. However, it is key that the two tests are 
in fact measuring IPG-P in different ways. The bio-extraction relies on interaction 
with the anion exchange column whereas the ELISA assay may be selectively 
binding an abnormal form of IPG to the gelatin phase of the plate.
This leaves the possibility that a sub-fraction or an unidentified, abnormal IPG-P 
form is part of the pathophysiology of preeclampsia. In this case, the amount of IPG- 
P measurable by the conventional bioassay may exclude the abnormal, lipidic form. 
The bioactive half-life of IPG-P, either in conventional or an undescribed form is not 
known at this time.
It is possible that IPG levels do not differ in the serum between the normal and 
preeclamptic state and that a difference is seen in the urine and amniotic fluid due to 
concentration/sequestration in these fluid compartments. Alternatively, increased 
renal clearance may be occurring, alongside increased placental production. 
Previous work has indicated that the IPG release is on the maternal side of the 
trophoblast(Deborde et al 1999b; Deborde et al 1999a) and it is thus interesting to 
speculate on the source of the IPG on the fetal side of the placenta. In preeclampsia,
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the umbilical arterial IPG-P levels are higher than in the maternal uterine vein, and 
probably the uterine artery; likewise the umbilical venous levels show a similar 
trend. It would be desirable to study larger numbers of patients to reinforce these 
data seen here.
We have previously demonstrated elevated urinary IPG-P in non-hypertensive 
labouring women (Paine et al. 2003). An earlier study had indicated the possibility 
of a common causal link between labour and preeclampsia (Adamsons and Wallach 
1989) related to declining oxygen tension within the trophoblast. It is possible that 
this causes abnormal release or metabolism of IPG-P, which may then be involved in 
the pathophysiology and could explain why we have found similar urinary IPG-P 
values in preeclampsia and labour.
6.7.1 Amniotic Fluid IPG-P
Amniotic fluid (AF) seems to be a rich source of IPG-P, though we do not yet have 
data on bioactivity levels.
There are altered amniotic fluid metal levels in preeclampsia in the third trimester, 
for example raised magnesium levels (Kolasa et al. 1983) and depressed zinc and 
calcium levels (Dawson et al. 1999). The data for this comes from a series of 29 
preeclamptic and 101 normal pregnancies. No published data exists regarding 
manganese levels in amniotic fluid in normal and preeclamptic pregnancy. In light 
of the published structure of IPG-P (Lamer et al. 2003), which confirms the presence 
of complexed Mn2+, it would be of interest to examine this in the future. Considering 
the suggested structure of IPG-A, containing complexed zinc, it would be valuable to 
perform IPG-A bioactivity assays on the normal and preeclamptic amniotic fluid. 
Time limitations prevented this being done as part of this project.
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Chapter 7
Conclusions, Discussion and 
Further Research
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7.1 Summary and Conclusions
7.1.1 Longitudinal data
It has been shown from the longitudinal studies that the ELISA is a qualitative test 
with a large spread. It is not a quantitative assay and its value is in the detection of a 
rapid rise or a high value, which will ring alarm bells for the clinician. Subtle 
differences and low values can be ignored. When expressed as a percentage of a 
standard positive control, a cut-off of 80% (as established by Rodaris, See Chapter 
2.1.4) seems to be a useful point for a ‘positive’ versus ‘negative’ value. In terms of 
monitoring IPG-P levels over the full pregnancy, the polyclonal-based ELISA is not 
a useful screening tool. However, it may be useful as a diagnostic tool for clinical 
usage.
Potential Clinical Usage of a Diagnostic Assay for Preeclampsia
There are several key problems facing clinicians in the management of preeclamptic 
patients where the presence of a diagnostic assay would be clinically useful.
1. Missed Diagnoses
Patients with underlying pre-pregnancy pathologies, including 
hypertension and renal dysfunction often mask the emergence of 
preeclampsia and patients may go undiagnosed with all of the attendant 
risks to mother and fetus. Preeclampsia is frequently then a retrospective 
diagnosis.
2. Mis-diagnosis
Patients with transient hypertension, often detected at the antenatal clinic 
visit, are admitted, in many cases, almost immediately to hospital. 
Preeclampsia symptoms may develop within hours and it is essential that 
these patients be closely monitored. Often, however, the rise in blood 
pressure is the result of a non-associated event and hospital beds are 
filled needlessly because of the absence of a definitive test. This may be 
particularly useful in patients with pre-existing risk factors for 
preeclampsia.
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3. Management of the Preeclamptic
Patients with a confirmed clinical diagnosis of preeclampsia present a 
difficult management conundrum for clinicians. With the absence of any 
effective therapy, patient management involves blood pressure control 
and seizure prevention, cardiotocography and ultrasound assessment of 
the fetus as described earlier.
For the grouped data, there is a significant increase in the ELISA signal in 
preeclampsia (Figure 5.4). However, in some of the individual cases, no rise was 
seen in the ELISA prior to the onset of preeclampsia. Similarly, a high proportion of 
false positive results were seen in subjects without a hypertensive episode in the 
pregnancy. For this reason, I propose that the ELISA would be more clinically 
effective as a discriminatory or diagnostic tool in women with a hypertensive episode 
than as a screening tool in the first or second trimester.
7.1.2 Urinary IPGs in Labour and the Postnatal Period
I have shown in Chapter 4 that urinary IPG-P is significantly raised in labour in non- 
preeclamptic women (Paine et al. 2003, Appendix 5). It was also mentioned that 
despite this rapid rise and the removal of the placental source they persist into the 
circulation during the postpartum period for a considerable period (Kunjara et al. 
2000a). It is possible that these raised levels in labouring women compared to non­
labour may indicate a role in the onset or progress of labour.
A previous study has indicated the possibility of a common causal link between 
labour and preeclampsia (Adamsons and Wallach 1989) related to declining oxygen 
tension within the trophoblast. It is possible that this causes abnormal metabolism or 
release of an abnormal IPG form, which may then be involved in the 
pathophysiology and could explain why we have found similar urinary IPG values in 
preeclampsia and labour.
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Potential Clinical Usage of a Diagnostic Assay for Labour 
1. Diagnosis of Early Labour at Term
Such an assay would be useful for women admitted in possible early 
labour. Frequently, other currently used parameters -  cardiotocography, 
clinical assessment of the cervix and pH testing for the presence of 
amniotic fluid — provide an equivocal result.
2. Diagnosis of Premature Labour
Women admitted with abdominal discomfort or pain when not at term in 
the pregnancy may be submitted to invasive speculum examination 
(which may indeed provide a falsely reassuring negative result) and are 
often needlessly admitted or wrongly discharged. A definitive diagnostic 
assay would eliminate much clinical uncertainty, risk to fetal and 
maternal health, and unnecessary expense.
Further Research
Due to the nature of the study design, the study carried out was unable to define IPG- 
P levels in early labour except in a small number of subjects undergoing induction of 
labour, which cannot be extrapolated to spontaneous labour. Further work needs to 
be carried out to obtain regular, timed urine samples leading up to labour. 
Additionally, more invasive studies could be designed to obtain regular urine 
samples from catheterised women in labour at more frequent intervals
7.1.3 IPGs in Established Preeclampsia
When analysing and comparing data from Established preeclampsia samples it must 
be stressed that the IPG-ELISA is likely to be measuring a different, high molecular 
weight form of IPG-P. The bio-extraction relies on interaction with the anion 
exchange column whereas the ELISA assay is likely to be selectively binding an 
abnormal form of IPG (possibly with a lipidic group attached) to the gelatin phase of 
the plate.
The data in Chapter 6 show that the overall IPG-ELISA values (expressed relative to 
a standard urine sample) for all samples were significantly higher in amniotic fluid
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compared to urine. This suggests a build-up on fetal side of the placenta, possibly 
due to the re-circulation of fetal urine within the amniotic cavity or production within 
the fetal kidney. For the matched urine and amniotic fluid pairs, values were 
significantly higher for the preeclampsia/eclampsia group compared to the control 
group.
Amniotic Fluid and Urine
There was a positive correlation between amniotic fluid and urine IPG-ELISA values 
for the normal group, but this was not apparent in the preeclamptic group. This may 
be due to the disruption of the equilibrium (normally found in a healthy pregnancy) 
during or after the onset of the preeclamptic disease process.
Platelet count was inversely correlated to amniotic fluid IPG-ELISA values in 
preeclamptic women, but no correlation was seen with other measured clinical 
parameters (gestation, maternal age, birth weight, serum urate or mean arterial blood 
pressure) or between maternal urinary IPG-ELISA and platelet levels. An inverse 
correlation was also seen between maternal platelet count and bioactive IPG-P in 
uterine and peripheral vein in the preeclamptic women. This indicates that the IPG-P 
may be involved in the pathophysiology of preeclampsia. Platelet count is well 
established as a reliable clinical marker of disease severity (Redman et al. 1978) and 
forms a component of the HELLP syndrome, a severe form of preeclampsia. These 
data mirror the inverse relationship between urinary IPG-P bioactivity and platelet 
count that has been shown by Kunjara (Kunjara et al. 2000a).
Serum
Total IPG-P bioactivity levels in the uterine vein were lower in the preeclamptic 
group than in the non-preeclamptic women but no difference was seen between the 
groups for samples from peripheral vein, or umbilical vessels. Umbilical venous 
levels were not different from those in the umbilical artery. In the preeclamptic 
group, the IPG-P bioactivity was higher in the umbilical artery, and probably the 
umbilical vein when compared with the uterine vein and the same trend was seen 
when compared with the peripheral vein. These differences were not seen for the 
non-preeclamptic group.
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There was a strong correlation between uterine vein and peripheral vein serum IPG-P 
levels in the preeclamptic group but not in the control group.
No correlation was seen with gestation for either preeclamptic or normal IPG-P 
levels for any of the values.
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Figure 7. 1. Proposed equilibrium of IPG-P in non-preeclamptic women
The data would indicate equilibrium (Figure 7.1) in the normal women between the 
maternal and fetal sides of the placenta. No difference is seen between any of the 
measured IPG-P bioactivity levels in the normal women and the ELISA shows 
correlation between the amniotic fluid and maternal urine.
In the preeclamptic women, it appears that this equilibrium has been disrupted. 
Amniotic fluid and urine levels do not correlate and additionally, serum levels of 
bioactive IPG-P are higher on the fetal than the maternal side of the placenta. This 
may be due to active secretion of the IPG-P from the maternal kidney. This does not 
seem to occur in the fetal kidney due either to fetal immaturity or the fact that the 
amniotic sac is a closed compartment.
Previous work would suggest a placental source of the IPG-P production (Deborde et 
al. 1999b), with release into both maternal and fetal circulations (Kunjara et al. 
2000a). However, the higher levels of measurable IPG-P in serum on the fetal side 
of the placenta in preeclampsia (Deborde et al. 1999a), and an absence of any 
difference in umbilical arterial and venous levels from this data might indicate an 
alternative situation. Firstly, a potential fetal production source with breakdown of 
placental transport to mother. Umbilical serum and amniotic fluid levels were 
significantly higher in preeclampsia than in normal and therefore a backlog on the 
fetal side may be occurring. Given these findings there may a placental production
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source with release of an abnormal, form of IPG-P (Figure 7.2) into the maternal 
circulation. This form would not be detected by the conventional extraction and 
bioassay procedures.
The significantly higher ELISA positivity in urine from the preeclamptic women 
compared with the normal group re-emphasises the potential for use of the ELISA as 
diagnostic assay. In the preeclamptic state an abnormal form of IPG-P, as yet to be 
identified, may be causing high ELISA positivity but not being measured in the 
serum by the conventional assay we used here. Alternatively, a renal source of IPG- 
P production may exist.
This leaves the possibility that a sub-fraction or an unidentified, abnormal form of 
IPG-P is part of the pathophysiology of preeclampsia. In this situation, the amount 
of IPG-P measurable by the conventional bioassay may exclude an abnormal, lipidic 
form.
It is possible that IPG levels do not differ in the serum between the normal and 
preeclamptic state and that a difference is seen in the urine and amniotic fluid due to 
concentration/sequestration in these fluid compartments. Alternatively, increased 
renal clearance may be occurring, alongside increased production. Previous work 
has indicated that the IPG release is on the maternal side of the trophoblast(Deborde 
et al 1999b; Deborde et al 1999a) and it is thus interesting to speculate on the source 
of the IPG on the fetal side of the placenta. Amniotic fluid seems to be a rich source 
of IPG-P. It would be desirable to study larger numbers of patients to reinforce the 
data seen here.
7.2 Future Work
7.2.1 Labour Studies
Further studies need to be designed to obtain frequent urine samples for the days 
immediately preceding labour. Design would involve more effort for the subjects 
due to the constraints of freezing samples within 4 hours of collection and their 
subsequent transport. Additionally, more invasive studies could be designed to obtain
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regular urine samples from catheterised women in labour at more frequent intervals. 
This would require consent by the subjects for urinary catheterisation and the 
consequent increased risk of urinary tract infection and urinary retention (post­
catheter removal). This may represent an ethical barrier to such a study. Women 
with clinically indicated catheterisation in labour tend to be those with prolonged or 
obstructed labour -  an abnormal sub-group and not necessarily representative.
The data I have presented here show parallels between preeclamptic pregnancy urine 
samples and non-preeclamptic labouring urine samples. Some early retrospective 
data have been shown to demonstrate that preeclamptic women are more easily 
induced into labour than non-preeclamptics (Bailey and Walton 2003). The effect 
was most marked at gestations below 37 weeks and in multiparous women. The 
authors do not state the method of induction used. Could this facilitation of 
induction of labour be related to elevated IPG-P levels? Conversely, Ferrazzani et al 
in a prospective study of a smaller series showed lower successful cervical ripening 
in the preeclamptic group compared to normals (Ferrazzani et al. 2003). The study 
design in this work was set to examine only non-preeclamptic women in labour and 
as such there is no comparable data. It would be valuable to include collection of 
delivery outcome data in a future prospective study collecting urine samples for 
ELISA in a larger cohort of preeclamptic and normal subjects requiring labour 
induction.
7.2.2 Preeclampsia
Ideally, more frequent and/or more regularly spaced samples should be collected to 
make the preeclamptic data set more robust and suitable for multiple regression 
analysis. It would be desirable to increase the numbers for the cross-sectional study 
looking at serum levels to elucidate any so far unseen differences in IPG-P within 
and between the preeclamptic and normal states. Furthermore, work on the IPG-A 
bioassay, which was not possible within the time frame of this MD would be ideal.
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Appendix 1: Comments on the IPG-ELISA
As stated previously, the polyclonal-based ELISA used here is effective due to a 
physical property of the IPG-P (possibly an abnormal, lipidic form) combining with 
the gelatin phase of the plate. The greatly raised positivity of the ELISA with 
preeclamptic urine and amniotic fluid samples indicates much higher levels of IPG-P 
in these compartments and/or an altered binding property of the IPG-P. It is possible 
that the IPG-P molecules may form micelles in the urine and amniotic fluid due to an 
amphiphilic property, (Figure A 1.1).
Figure Al. 1. Schematic representation of GPI micelle showing hypothetical 
abnormal lipidic form.
Glycan Moiety 
Inositol
Phosphate
Previous data does support the evidence of raised IPG-P bioactivity in maternal urine 
in preeclampsia (Kunjara et al. 2000a).
The IPG-P polyclonal ELISA assay was provided by kindness of Rodaris 
Pharmaceuticals Ltd (Oxford, UK). At the outset of the research, it was presented as 
a reliable assay for the diagnosis and possibly the prediction of preeclampsia. The 
company provided data of the inoculation protocol that was used to make the 
polyclonal. The IPG-P polyclonal antigen used as the immunogen in the preparation, 
was purified by the then-best purification procedure from the urine of a single 
woman with severe pre-eclampsia. However, no specific data were provided on the
i
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A1.2 Protein Content of Urine Samples
As an adjunct to the above investigation, protein values for the non-labour and labour 
samples from non-preeclamptic subjects in the study discussed in Chapter 4 were 
plotted against ELISA signal values. These can be seen in figure A 1.3 below. It is 
noted that a possible correlation exists, although the r-squared values are low (0.37 
for labour and 0.54 for non-labour samples respectively). Therefore the option of 
expressing the ELISA values per unit of protein should be considered.
P ro te in  c o n te n t  (O D 565) v s  ELISA R e s u lt
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Figure Al. 3. Plot of urine protein content in pg/ml against ELISA value for non­
labour and labour samples with respective trend lines and r-squared values.
A1.3 Proteinuria and Microalbuminuria
Proteinuria can be a common finding in normal, non-preeclamptic pregnancy, due to 
increased filtration rate and morphological and/or functional changes in the 
glomerular capillary. However proteinuria also correlates with increasing perinatal 
mortality (Ferrazzani et al. 1990).
i
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Results
See Figure A 1.2 below.
Figure A l. 2. Western Blot of urine samples with polyclonal ELISA serum. Protein 
standard (left-hand lane) (Sigma, Poole, Dorset, UK) plus urine samples in 
corresponding lanes.
205 000
116 000 
97 400
29 000
I----------------Urine Samples -
Sid 1 2 3 4 1 2
66 ODD
45000
The above film reveals that the polyclonal serum showed reactivity with the full 
spectrum of proteins present in the preeclamptic sample, including human serum 
albumin (HSA, Mr = 68,000). This might indicate that the original stock solution 
used as the inoculate to prepare the serum was non-pure IPG-P. Consequently, the 
ELISA may then be detecting protein as well as IPG-P. However, it must be 
remembered that the Western gel will only detect proteins (and not 
carbohydrates/lipids).
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purity of the IPG-P antigen and the antigen itself has never been fully characterised.
I speculated that the ELISA polyclonal antibody might be detecting other elements in 
the urine and amniotic fluid. Proteinuria is part of the definition of preeclampsia 
(Brown et al. 2001) and the extract was prepared from the urine of a preeclamptic 
woman (although clinical data of this index subject was not available from the 
company at the time).
A1.1 Western Blot of Urine Samples with Polyclonal Serum 
Method
See Chapter 2 -  Lab Methods 
Selection of Urine Samples
Due to limitations of equipment available at the time of the experiment (the number 
of lanes that could be created with the comb for the gel) 4 urine samples could be 
assayed. I randomly selected two urine samples from women with non-hypertensive 
pregnancy outcome (the subject identities of which were not known to me at the 
time), one with a positive ELISA result, and one negative. One sample was selected 
from a woman with clinically diagnosed preeclampsia and one sample from a subject 
with hypertension but no proteinuria on dipstick. All samples had previously been 
assayed using the ELISA assay and protein assay as described above. The samples 
and results of these two assays are summarised in table Al .1 below:
Table Al. 1. Samples selected for Western Blot
Sample Unique Clinical ELISA Result Protein Assay
Number Pregnancy
Outcome
(OD 450) (pg/ml at OD 
565)
321 Preeclampsia 313 630
© 432 Non-proteinurichypertension 212 82
© 262 Normal 208 367
© 264 Normal 14 228
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Abnormal protein excretion in pregnancy is usually defined as >300mg in 24 hours 
but it is not clear from where this figure is derived. Early work involved small study 
groups or mixed normal and hypertensive subjects.
Importantly, microalbuminuria is distinct from total proteinuria and albumin 
accounts for a small fraction of urinary protein (less than 12%) (Higby et al. 1994) 
This may be significant as the protein used bovine serum albumin as the standard.
Twenty-four hour urine collection for total protein is the gold standard. Higby et al 
published values for proteinuria in normal pregnancy in a group of 270 women 
(Higby et al. 1994). The mean protein excretion in 24 hours was 116.9 mg, upper 
95% confidence limit 259.4 mg. The mean albumin excretion in 24 hours was 11.8 
mg, upper 95% confidence limit 28.7 mg. Both protein and albumin excretion 
increased after 20 weeks of gestation and albumin accounts for a small fraction of 
total urinary protein excretion. A small series indicated that total protein and 
albumin excretion has a circadian rhythm (Koopman et al. 1985). More recently 
however, it has been suggested that a single urine sample is as accurate as a twenty- 
four hour collection in estimating protein excretion (Zuijderhoudt et al. 1989; Waugh 
et al. 2004).
A1.4 Detection of Microalbuminuria
Various published techniques have been used to detect microalbuminuria in a clinical 
setting (Table A 1.2)
Table Al. 2. Methods for assessing microalbuminuria compared with IPG-P ELISA
Method Used Cut-off for 
Positive Test
Sensitivity
%
Specificity
%
PPV
%
NPV
%
Micral Test1 20 pg/ml 68 92 56 94
Radio ImmunoAssay2 11 pg/ml 50 82 26 93
Immunochemical3 61 87 61 87
IPG-P ELISA
General Population 80% PPC* 42 88 31 92
High-Risk Population 80% PPC* 42 94 61 88
'(Das et al. 1996);2 (Rodriguez et al. 1988); 3 (Irgens-Moller et al. 1986)
*PPC = Percent of Plate Positive Control
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Das et al showed in a small group of low-risk women that detection of 
microalbuminuria of greater than 20pg/ml might be useful as a screening test for 
preeclampsia (Das et al. 1996). However, the study group had a very high incidence 
of preeclampsia (14.6%), which would tend to increase the sensitivity of the assay.
Misiani et al (Misiani et al. 1991) showed level of daytime urinary albumin secretion 
was significantly lower than in the post-partum period or non-pregnant controls, 
possibly due to lower serum albumin levels in pregnancy. They showed that 
secretion increased in women with subsequent preeclampsia from the 28th week 
onwards and on average 9 weeks before the clinical onset of the disorder. Another 
group has shown an increase in urinary albumin secretion in normal pregnancy and 
no significant difference in those subsequently developing preeclampsia (Konstantin- 
Hansen et al. 1992).
Figure A 1.4 shows the relationship of gestation vs. protein content for all samples 
from subjects with a non-preeclamptic pregnancy outcome. Preeclamptic subjects 
have been removed, as this would inevitably bias the set, as they will by definition 
have increased proteinuria after 28 weeks. The graph shows a wide variation in 
protein content
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Figure A l. 4. Graph of Gestation vs. Protein Content for all non-preeclamptic 
subjects.
• * • • (R)There are commercially available proteinuria tests such as Albustix (Bayer 
Diagnostics) and the more sensitive (and more expensive) Micral Test II ® (Roche 
Diagnostics).
A1.5 Caveats Regarding the Polyclonal Serum
Given the above comments and that the polyclonal-based ELISA signal correlates to 
some degree with proteinuria, it is possible that certain problems exist regarding its 
original preparation.
Firstly, low molecular weight compounds (<3000 MW) are not very antigenic unless 
they are complexed with proteins. The IPG extract was not complexed in this way 
and was used as a raw material for the preparation of the serum. Secondly, the 
correlation with protein content is seen in the urine samples from normal women 
(and not just in preeclamptics). This does not mean that the ELISA is exclusively 
picking up protein however. Finally, the Western blot is seen to be picking up every
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band of protein in the blot that is found in the preeclamptic (PE) urine (and not the 
one band that is not in the PE urine i.e. albumin). It must be remembered that of 
course gels only pick up protein.
Polyclonal Heated Samples
It is an interesting feature of the polyclonal protocol used that the heating of the urine 
samples alters (in the majority of cases) the ELISA signal. There are two obvious 
possibilities, related to the binding of the substrate to the ELISA blocked plate well. 
Either that the heating denatures protein in the urine sample, which then facilitates 
the capture by the gelatin phase, or that the heating causes release of bound IPG 
which then becomes detectable by the ELISA system.
Figure A l. 5. Possible mechanisms for ELISA microtitre well capture following 
heating, showing (a) denatured protein (b) bound IPG enabling protein binding 
(possibly with reconfiguration) and (c) heating causing release of free IPG which 
binds to gelatin phase.
Blocked microtitre 
well
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Appendix 2 -  Patient Information Sheet (CSP-MAP-001)
Patient Information Sheet Confidential
Study title:
A prospective observational cohort study to determine the role of inositol phosphoglycans in the onset 
of pre-eclampsia in a population of women
You are invited to take part in some research at this hospital to look at pre-eclampsia. You may have 
heard of this condition, which results in high blood pressure during pregnancy and can affect up to 5% 
of all women during their pregnancy. At this time, the cause of pre-eclampsia is not known and there 
is no treatment except to deliver the baby. A new urine test is being developed to diagnose pre­
eclampsia and we are doing a study to see what happens to this test in early pregnancy.
There are no additional procedures that involve any risk to your baby, which would not be performed 
already as part of antenatal care. All we ask is that you provide several urine samples for us 
throughout the pregnancy. Also, as part of your normal blood tests, we would ask to take small 
samples at the same time. If you have an amniocentesis, we would like to take a small amount (a few 
mis) extra of the fluid. After your baby is delivered, we would like to take a sample of cord blood and 
also part or the entire placenta. If you have a caesarean section, we would also like to take a small 
sample of the fluid from around the baby. This would be done before the membranes are broken, 
under direct vision so as not to harm the baby. Also, if you have a caesarean section, we would take a 
small blood sample from the vein from the womb with a very fine needle. There is a veiy small risk of 
bruising during this, which would be minimised by pressing on the vein.
You do not have to take part in this study if you do not want to. If you decide to take part you may 
withdraw at any time without having to give a reason. Your decision whether to take part will not 
affect your care and management in any way. An interpreter can be used if English is not a first 
language.
If you take part in this study your results would be treated in confidence. All documents collected by 
the researchers would be identified by a number and would not have your name on them. All such 
records and your right to them would be protected in accordance with European data protection 
legislation.
You are encouraged to request any further information about the study and you can contact:
Dr Malcolm Pain or (if Dr Paine is absent) Professor Rodeck
Clinical Research Fellow Department of Obstetrics & Gynaecology
Department of Obstetrics and Gynaecology University College Hospital
University College Hospital Telephone: 
86-96 Chenies Mews
London WC1
Aircall  
All proposals for research using human subjects are reviewed by an Ethics committee before they can 
proceed. This proposal was reviewed by the Joint UCL/UCLH Committees on the Ethics of Human 
Research.
UCL Hospitals is an NHS Trust incorporating the Eastman Dental Hospital, Elizabeth Garrett Anderson Hospital,
Hospital for Tropical Diseases, The Middlesex Hospital, National Hospital for Neurology & Neurosurgery and
University College London Hospitals
NHS Trust
Dr M A Paine
Elizabeth Garrett Anderson Hospital 
Huntley Street 
London WC1E 6DH
Appendix 3 -  Patient Information Sheet (CSP-MAP-004)
Patient Information Sheet Confidential
Study title:
An observational cohort study to determine the role of inositol phosphoglycans (P-IPG) in the 
onset of labour.
You are invited to take part in some research at this hospital to look at a new group of messenger 
compounds called Inositol Phosphoglycans or 'IPG's. These have been found in many parts of the 
body. They are involved in the way different cells in the body send messages to each other. Some 
previous work that has been done has shown that they may be increased in urine as part of the normal 
process of labour. We want to find out if this is true.
Taking part in the study would involve firstly answering some simple questions about your pregnancy 
and medical history and giving one urine sample in the antenatal clinic. Secondly, we would ask for 
several samples of urine during your labour. We will not interfere with your labour or delivery in any 
other way. There will be no procedures that will involve any risk to you or your baby.
You do not have to take part in this study if you do not want to. If you decide to take part you may 
withdraw from the study at any moment without having to give a reason. Your decision whether 
to take part will not affect your care and management in any way. An interpreter can be used if 
English is not a first language.
If you take part in this study your results would be treated in confidence. All documents collected by 
the researchers would be identified by a number and would not have your name on them. All such 
records and your right to them would be protected in accordance with European data protection 
legislation.
You are encouraged to request any further information about the study and you can contact:
Dr Malcolm Paine
Clinical Research Fellow
Department of Obstetrics and Gynaecology
University College Hospital
86-96 Chenies Mews
London WC1
All proposals for research using human subjects are reviewed by an Ethics committee before they can 
proceed. This proposal was reviewed by the Joint UCL/UCLH Committees on the Ethics of Human 
Research. Version 2
UCL Hospitals is an NHS Trust incorporating the Eastman Dental Hospital, Elizabeth Garrett Anderson Hospital,
Hospital for Tropical Diseases, The Middlesex Hospital, National Hospital for Neurology & Neurosurgery and
University College London Hospitals
NHS Trust
Dr M A Paine
Elizabeth Garrett Anderson Hospital 
Huntley Street 
London WC1E 6DH
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Appendix 4 -  Patient Information Sheet (CSP-MAP-005)
Study title:
A case-control study to determine levels of Inositol Phosphoglycans (IPGs) in pre-eclampsia.
You are invited to take part in some research at this hospital to look at pre-eclampsia. You may have 
heard of this condition, which results in high blood pressure during pregnancy and can affect up to 
5% of all women during their pregnancy. At this time, the cause of pre-eclampsia is not known and 
there is no treatment except to deliver the baby. We have shown that IPGs are raised in pre-eclampsia 
in urine and this study is looking at where the levels are highest in order to discover more about the 
cause of pre-eclampsia. We are recruiting women with pre-eclampsia and also women with normal 
pregnancies for comparison.
The obstetric team has decided that the best way to deliver your baby (or babies) is by caesarean 
section. We would like to take some samples before and during the procedure. This should not 
prolong the operation significantly and there is no risk to your baby. The samples will be:
• Before the Procedure:
A urine specimen and a saliva sample 
A blood sample just before the operation.
• During the Caesarean Section:
1.A small sample of blood from the vein of the womb, taken with a fine needle before the 
delivery of the babies. There is a small risk of bruising from this, which will be minimised 
by pressing on the vein after taking the sample.
2. A sample of fluid from around the baby (or babies), taken before the membranes are ruptured. 
This will be taken under direct vision, so that we can see that we will not harm the baby.
3. Part of the placenta and some blood from the umbilical cord - after the delivery.
Finally, we would like to take a daily urine sample for three days after your operation.
You do not have to take part in this study if you do not want to. If you decide to take part you may 
withdraw at any time without having to give a reason. Your decision whether to take part will not 
affect your care and management in any way. An interpreter can be used if English is not a first 
language.
If you take part in this study your results would be treated in confidence. All documents collected by 
the researchers would be identified by a number and would not have your name on them. All such 
records and your right to them would be protected in accordance with European data protection 
legislation.
You are encouraged to request any further information about the study and you can contact:
Dr Malcolm Paine 
Clinical Research Fellow
Department of Obstetrics and Gynaecology Aircall 0800 679402
University College Hospital Number 'UCH 443'
86-96 Chenies Mews 
London WC1
All proposals for research using human subjects are reviewed by an Ethics committee before they can 
proceed. This proposal was reviewed by the Joint UCL/UCLH Committees on the Ethics of Human 
Research. Version 2
Patient Information Sheet Confidential
UCL Hospitals is an NHS Trust incorporating the Eastman Dental Hospital, Elizabeth Garrett Anderson Hospital,
Hospital for Tropical Diseases, The Middlesex Hospital, National Hospital for Neurology & Neurosurgery and
University College London Hospitals
NHS Trust
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Elizabeth Garrett Anderson Hospital 
Huntley Street 
London WC1E 6DH
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Appendix 5 -  Consent Form
Consent Form Confidential
Study Title:
Insert Study Title Here
Please ask the patient to complete the following:
Have you read the Patient Information Sheet?
Have you had an opportunity to ask questions and discuss the study? 
Have you received satisfactory answers to all your questions?
Have you received enough information about the study?
To whom have you spoken?...........................................................
Do you understand that you are free to withdraw from the study:
At any time?
Without having to give a reason for withdrawing?
And without affecting your future medical care? Yes / No
Do you agree to take part in this study? Yes / No
Signed.................................................................. Date.............................
(Name in Block Letters)......................................................................................
Signed (Researcher)...............................................  Date..............................
Please circle 
as necessary 
Yes / No 
Yes / No 
Yes / No 
Yes / No
L
CL UCL Hospitals is an NHS Trust incorporating the Eastman Dental Hospital, Elizabeth Garrett Anderson Hospital,Hospital for Tropical Diseases, The Middlesex Hospital, National Hospital for Neurology & Neurosurgery and
